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Abstract 
 
Latest epidemiological data suggests 1.5 billion adults worldwide are either 
overweight or obese. With increasing weight and obesity, adipocytes increase 
in size. The enlargement of adipocytes has been associated with low grade 
chronic inflammation via elevated adipokine secretion. Previous 
epidemiological studies in humans and experimental studies in animals have 
shown that during different periods of pregnancy (gestation) the offspring that 
are born to maternal nutritional manipulation are more susceptible to 
developing metabolic diseases in later adult life. Therefore, the aim of this 
thesis was to investigate the role of maternal nutritional manipulation on 
adipose tissue depots and in particular the consequences the effect on markers 
of adipokine secretion.  
 
Studies were conducted on both large and small animals (i.e. sheep and rats). 
Sheep studies focused on mid to late and late gestation periods of maternal 
nutritional restriction. Rat studies concentrated on long term fructose feeding 
during pregnancy and its effect on both the mother and offspring. Gene 
expression analysis identified an up-regulation in inflammatory related genes in 
pericardial and subcutaneous adipose tissue in the sheep studies. This was also 
seen in the rat studies with protein and gene expression displaying an up-
regulation of inflammatory and metabolic related genes and proteins.  
 
4 
 
The main conclusion of my thesis is that after following maternal nutrient 
restriction, females appear to be much more sensitive to inflammatory and 
metabolic adaptations compared to males, possibly due to sex hormones 
playing a role. Whilst fructose feeding during pregnancy concluded the 
possibility of homeorhesis playing a protective role against potentially 
detrimental inflammatory pathways being activated in the mothers, the 
offspring however displayed signs of low level chronic inflammation in the 
retroperitoneal depot from early infancy to later adult life.  
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Chapter 1 - Introduction 
1.1 Obesity 
 Obesity is often described as an atypical or disproportionate 
accumulation of fat. The accumulation of fat leads to an increased risk of 
metabolic diseases and impairment of health1 2. The World Health Organisation 
(WHO) measures obesity based on a body mass index (BMI). BMI is the 
PHDVXUH RI DQ DGXOW¶V ZHLJKW LQ UHODWLon to their height. More specifically 
weight in kilograms divided by the square of height in metres1.  
BMI Index Equations:  
 
 
SI (International System of Units) ܤܯܫ ൌ ሺ݇݃ሻଶሺ݉ଶሻ 
United States of America Units ܤܯܫ ൌ ሺ݈ܾሻ ൈ  ? ? ?ଶሺ݅݊ଶሻ  
 
An example measurement (based on SI units) would be an adult weighing 65kg 
with a height of 1.70m and a BMI of 22.5. 
ܤܯܫ ൌ ሺ݇݃ሻଶሺ݉ଶሻ ൌ ܤܯܫ ൌ  ? ? ?Ǥ ?ଶ 
BMI was devised between 1830 and 1850 by a Belgian polymath named 
Adolphe Quetelet3. BMI is used by the WHO to define overweight and obesity 
as it provides the most efficient large population measurement tool for both 
sexes and all ages of adults.  
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7KH:+2GHILQHV³REHVLW\´DVt ZKLOVW³RYHUZHLJKW´LVt 25 but  30 (See 
Table 1)4.  
BMI works for most adults but taller adults have been reported to have a BMI 
abnormally higher when compared to their actual body fat levels. This occurs 
as BMI is proportional to weight given a fixed height, body shape and density. 
Therefore, when BMI is calculated proportional to height for a fixed weight, 
body shape and density, BMI is inversely proportional to the square of the 
height.  Therefore, if you take all body dimensions and double them, weight 
will increase with the cube of the height. BMI should remain the same but 
instead doubles. This irregularity can be explained with the observation that 
taller people are not just scaled up short people, they tend to have leaner frames 
in ratio to their height5.  
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Table 1: International Classification of adult underweight, overweight and 
obesity according to BMI1 4 
Classification BMI(kg/m2) 
 Principal cut-off points 
Underweight <18.50 
     Severe thinness <16.00 
     Moderate thinness 16.00 - 16.99 
     Mild thinness 17.00 - 18.49 
Normal range 18.50 - 24.99 
Overweight  
     Pre-obese 25.00 - 29.99 
Obese  
          Obese class I 30.00 - 34-99 
          Obese class II 35.00 - 39.99 
          Obese class III  
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1.1.2 Worldwide Obesity 
The prevalence of obesity of worldwide is increasing at an alarming 
rate. There are an estimated 400 million obese adults with 1.6 billion adults 
being overweight1. Obesity across Europe has also seen a sharp rise, with 
FRXQWULHVVXFKDV&URDWLDKDYLQJLW¶VRIPHQREHVHDQG$OEDQLDKDV
of its females obese6. The United States is by far the fattest population in the 
Americas; within its population, 31% of adult males and 33% of adult females 
are obese6. Surveys carried out from 2006 ± 2007 in America showed the 
frequency of obesity had risen from 15% during 1976-1980 to 32.9% during 
the 2003-2004 survey (See Figure 1.1 and 1.2)7.  
Obesity is not just confined to adults. Childhood obesity is also increasing at a 
startling rate. BMI is calculated differently for children, it is referred to as 
BMI-for-age. BMI values for children change depending on sex and age8. 
Unlike the adult version where a score is given, BMI-for-age values are plotted 
against a specific graph. BMI for children concentrates on certain percentile in 
which the child falls in. The BMI-for-age graph displays lines of specific 
percentiles, similar to that of weight and height charts for children8.   
BMI-for-age shows children being less than the 5th percentile are at risk of 
being underweight, 85th to the 95th percentile shows the child is at risk of being 
overweight. If the child is calculated to be greater than the 95th percentile then 
the child is overweight. A healthy child displays a result between the 15th and 
85th percentile8.  
One in ten children worldwide between the ages of 5-17 years old are 
overweight, a total of 155 million. Amongst these, 30-45 million children are 
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obese. The prevalence of overweight children under the age of 5 years old is 
3.3% or 17.6 million in developing countries. The prevalence of children who 
are overweight tripled between 1980 and 2000 in the United States alone1 9.  
 The worldwide rise in the prevalence of obesity is also seen in England 
as the Health Survey for England (HSE) presented data showing 38% of adults 
in England were overweight and 24% were classified as obese in 2006. The 
obesity rates in England are almost on a par with those seen in the United 
States. The HSE surveys in 2006 also showed that 29.7% of children aged 2 to 
15 were either obese or overweight10.  
 
Figure 1.1 - Percent of Obese (BMI > 30) in U.S. Adults in 19857 
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Figure 2.2 - Percent of Obese (BMI > 30) in U.S. Adults in 20067 
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1.2 Metabolic Syndrome 
Obesity has a profound impact on the human body and its metabolic 
system. Obesity increases the risk of health problems such as: 
x Hypertension 
x Insulin resistance and diabetes 
x Cardiovascular disease 
x Dyslipidemia 
x Osteoarthritis 
x Fatty liver disease 
As obesity increases the risk of health problems such as those listed above, it 
essentially becomes a central player in the metabolic syndrome11. The 
syndrome is seen as a collection of factors including hypertension, central 
adiposity, glucose intolerance, insulin resistance and dyslipidemia which leads 
to cardiovascular disease and/or diabetes11. Metabolic syndrome has seen an 
increase in prevalence worldwide which many have linked to the increasing 
frequency of obesity worldwide12. The metabolic syndrome is also known as 
syndrome X, metabolic syndrome X, Reaven's syndrome, insulin resistance 
syndrome or CHAOS (Australia). Each of these different syndromes is defined 
with varying symptoms and, therefore, the definition given by the WHO is 
most commonly used12.  
The WHO defines metabolic syndrome to have features such as high levels of 
blood glucose, increased blood triglycerides levels, decreased levels of HDL 
(high-density lipoprotein) cholesterol, increased blood pressure, and BMI over 
30. When a person is exhibiting three of more of the features listed above, they 
have metabolic syndrome13.  
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Fat accumulation around the abdomen has been clearly linked to insulin 
resistance and plays a central role in the development of metabolic syndrome. 
Insulin resistance is the situation where regular levels of insulin can no longer 
generate a standard insulin response from liver cells, fat and muscle14. Due to 
the impairment of action from the fat, liver and muscle cells begin to lose the 
ability to control the regulation of insulin resulting in raised insulin14.   
With insulin resistance playing a central role in metabolic syndrome, increased 
levels of plasma insulin and blood glucose are often seen as early indicators to 
a development of insulin resistance.  
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1.3 Adipose Tissue 
The primary role of adipose tissue is to store energy in the form of fat 
but it also insulates and protects the body15. Adipose tissue is composed from 
many types of cells including fibroblasts, macrophages and endothelial cells 
but the highest proportions of cells that occupy adipose tissue are adipocytes. 
Adipocytes are essentially fat cells. They give adipose tissue the ability to store 
fat and also utilise fat into energy when required16. These specialised locations 
DUHRIWHQUHIHUUHGWRDVµDGLSRVHGHSRWV¶ 
 
There are two types of adipose tissue: brown adipose tissue (BAT) and white 
adipose tissue (WAT) (Figure 1.3).  
 
White Adipose Tissue (Unilocular Cells): has a structure that consists of a 
large lipid droplet enclosed within a border of cytoplasm. Unlike brown 
adipose tissue, the nucleus of white adipocyte is flatten and situated on the edge 
of the cell17 18.  
Brown Adipose Tissue (Multilocular Cells): has a polygonal structure with 
smaller lipid droplets spread throughout the cell. Brown adipocyte has more 
cytoplasm with the nucleus being round and located away from the edge of the 
cell. BAT acquires its brown colour from the significant amount of 
mitochondria present17 18.  
Both BAT and WAT are able to store energy as triglycerides, the difference 
coming with white fat being able to release this energy in accordance to the 
requirements of the organism and brown fat transferring it as heat19. This 
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unique property gives BAT a decisive function in the regulation of body 
temperature, an important feature in hibernation, also in small and newborn 
mammals20. 
Originally studies concerning BAT were focused on non shivering 
thermogenesis and thermoregulatory responses with WAT studies mainly 
focused on energy metabolism20. This however began to change with 
researchers investigating BAT in diet-induced thermogenesis led them to focus 
on its role in assorted conditions related with changes of energy balance21, 22, 
23
.  
 Brown Adipose Tissue                            White Adipose Tissue 
 
Figure 3.3 - Stained microscopic images of brown (A) and white adipose tissue 
(B)24. 
Brown Adipose Tissue   
The main function of BAT is to generate heat in newborn infants and 
hibernating mammals. Body heat is produced and maintained via the 
mitochondria located within the BAT18.  
Chemiosmosis is a process that was first put forward by a British scientist, 
Peter Mitchell in 1961. The theory explains how ATP (adenosine triphosphate) 
A B 
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is synthesised in prokaryotes and eukaryotes. For eukaryotes, chemiosmosis 
occurs at the crystae (inner membrane of the mitochondria)25.  The theory of 
chemiosmosis suggests that ATP is produced via energy stored in the form of a 
proton-motive force or proton gradients across membranes.  
The process in which chemiosmosis occurs primarily involves two main 
components, the electron transport chain (ETC) and ATP Synthase. 
Chemiosmosis is coupled with oxidative phosphorylation26. In general, 
oxidative phosphorylation obtains electrons from NADH and FADH2 and 
merges them with O2. This energy that is released from these redox reactions 
allows for the production of ATP from ADP26.  
Brown adipose tissue has the unique ability to produce heat without the 
synthesis of ATP. Non-shivering thermogenesis is the main process for heat 
production for hibernating mammals and neonates27. Non-shivering 
thermogenesis is facilitated by UCP-1 (Uncoupling Protein-1). UCP-1 is an 
uncoupling protein located within the mitochondria of brown adipose tissue27.  
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UCP1  
UCP1 has the unique ability to supply a substitute route for protons to 
re-enter the matrix of mitochondria. This unorthodox pathway that is produced 
by UCP1 allows a short-cut for protons which are linked to the respiratory 
chain via the ATP synthase complex, this short-circuiting allows respiration to 
occur without ATP production. Therefore, heat is produced as respiration is 
allowed to be performed without ATP production (Figure 1.4) 
UCP1 is exclusive to brown fat as it offers a mechanism by which vast amounts 
of heat can be produced. Activation of UCP1 occurs through a pathway which 
liberates fatty acids in brown fat cells. The pathway begins with the 
sympathetic nervous system which releases norepinephrine at its terminals28 29. 
Beta-3 adrenergic receptors which are situated on plasma membranes interact 
with the release of norepinephrine. This, in turn, activates adenylyl cyclase, a 
lyase enzyme30. Adenylyl cyclase synthesises the transformation of ATP to 
cyclic AMP (cAMP). cAMP then begins a further chain of activation in which 
protein kinase A is activated, that then proceeds to phosphorylate 
triacylglycerol lipase and becomes activated. The function of triacylglycerol 
lipase is to transform triacylglycerols into free fatty acids. Free fatty acids 
therefore activate UCP130. During the end of thermogenesis, mitochondria 
oxidise the remaining free fatty acids. This is followed by the inactivation of 
UCP1 and, in turn, the brown fat cell restarts its regular energy-saving form30.  
To summarise, BAT is heavily integrated with the generation and allocation of 
heat. Brown adipocytes have the ability to store triglycerides, though they 
differ from those of WAT through their vast number of mitochondria30. 
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Mitochondria in BAT are distinctly different from those found in liver or 
muscle. Mitochondria present in liver or muscle use electrochemical potential 
gradients within the mitochondrial membrane to generate ATP. BAT expresses 
UCP1; UCP1 is the main catalysis behind energy being expressed as heat 
instead of ATP30.  
 
Figure 4.4 - UCP-1 Thermogenesis. The uncoupling protein UCP1 is a proton 
carrier characteristic of brown adipose tissue. UCP1 uncouples the respiratory 
chain of ATP production, converting the metabolic energy in heat. 
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1.4 White Adipose Tissue: 
WAT is one of the most predominant tissue available in the organism, 
its main features comprise of fuel storage along with protection of organs from 
damage and acting as a thermal insulator. WAT is allocated into numerous 
depots, positioned internally and subcutaneously31. White adipose tissue in 
non-overweight, healthy humans is responsible for 25% of body weight in 
women and 20% in men32. The cells contain one large fat droplet, which due to 
its size, causes the nucleus to be compressed into a thin rim at the border. The 
cells also have receptors for growth hormones, norepinephrine, insulin, and 
glucocorticods32. 
One of the main functions of white adipose tissue is its ability to be used as a 
store of energy. WAT has the ability to accumulate excess dietary fat in the 
form of triglycerides and also release free fatty acids (FFAs) during moments 
of energy demand or starvation33. Lipolysis is defined as the breakdown of 
lipids and the hydrolysis of triglycerides into FFAs (FFAs are further degraded 
into acetyl units through beta oxidation).   
WAT was simply known as a fuel storage depot until the discovery of leptin34. 
This gave the adipose tissue the recognition of an endocrine organ and fuelled 
sustained research into the role of adipose tissue which resulted in it being seen 
as an endocrine organ that was involved in many metabolic and physiological 
processes. 
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1.4.1 Adipose depots 
In the development of insulin resistance, total adipose tissue plays an important 
role, however it is theorised that certain fat depots maybe more heavily 
associated to risk factors for disease than others. The key adipose depots of 
significance are located in the abdomen and are split into SAT (subcutaneous 
adipose tissue) and VAT (visceral adipose tissue) with visceral adipose tissue 
further divided into mesenteric (a deep underlying depot which surrounds the 
intestine) and omental.  
The allocation of VAT and SAT differs from person-to-person and is reliant on 
a variety of factors such as nutrition, age, sex, and the energy homeostasis of 
the adipose depots35. Even though many similarities exist, the differences 
between rodent and human adipose tissue should carry caution when deciding 
which depots to study and furthermore when extrapolating the findings 
between species36.  
 
1.4.2 Visceral fat 
Visceral fat depots (particularly omental and mesenteric adipose tissue) 
characterise a major risk factor for the development and progression of T2DM 
(Type 2 Diabetes Mellitus) and CVD (Cardiovascular disease). Studies have 
shown that while total or subcutaneous tissue mass does not correlate with the 
development insulin resistance, visceral adipose tissue displays a positive 
correlation35,37,38. It is well known and comprehensively confirmed that the 
adipocytes of visceral fat tissue are significantly more lipolytically active than 
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subcutaneous adipocytes, which contributes furthermore to the plasma free 
fatty acid levels35,39. In certain studies it was shown that diabetic obese 
individuals showed a significant downregulation of adiponectin and 
upregulation of leptin gene expression when comparing mesenteric VAT to 
SAT and omental VAT40.  
Studies in rat focusing on mitochondrial content between epididymal (VAT) 
and human inguinal (SAT) adipocytes, showed a higher content of 
mitochondrial present in rat epididymal (VAT) adipocytes, as metabolic 
activity in cells are dependent on mitochondrial presence, this furthermore adds 
to the evidence of VAT adipocytes integral to energy homeostasis41. Further 
studies in adipose tissue taken from obese patients undergoing bariatric 
surgery, displayed higher relative oxidative phosphorylation (OXPHOS) 
activity in omental VAT then SAT42. It has been shown that subjects with a 
polymorphism within the UCP1 promoter reducing UCP1 gene expression are 
more susceptible to a high BMI, more significantly due to abdominal obesity43. 
This therefore adds weight to the conclusion that the amount of mitochondrial 
uncoupling and energy efficiency may indeed have an effect on obesity in 
WAT, in addition to BAT. High lipolytic activity could also be contributed due 
to the higher expression level of beta-adrenergic receptors in VAT44. In 
addition, glucose uptake (insulin-stimulated) was discovered to be higher in 
VAT when compared to SAT45. This results in excess visceral fat increasing 
the amount of free fatty acid being distributed to the liver, which therefore 
leads to increased very low-density lipoprotein particles and hepatic glucose 
output and in tandem leading to impairing the hepatic insulin response33.  
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,QFUHDVHG33$5ȖP51$H[SUHVVLRQKDVEHHQVKRZQLQVWXGLHVLQYROYLQJREHVH
subjects45, additionally there was no difference in omental VAT and SAT 
tissues, and surprisingly 33$5Ȗ H[SUHVVLRQ LQ mesenteric VAT was 
significantly higher in obese diabetic patients40. This authenticates the 
involvement RI33$5Ȗ in mesenteric adipose tissue lipolysis.  
Studies in rodents have shown lipid synthesis to be higher in internal adipose 
tissue compared to SAT46. Further studies investigating gene expression in rat 
retroperitoneal (rVAT), inguinal SAT (iSAT), and mesenteric VAT (mVAT) 
displayed that the larger sized cells in rVAT expressed a higher amount of 
33$5Ȗ, GLUT4, and Srebp1 mRNA expression compared iSAT and Mvat. 
The study was able to show overall that lipogenesis and lipolysis related genes 
combined with a low expression of fatty-acid oxidation related genes can give 
explanation to the high triglyceride turnover and therefore explain the differing 
behaviour of depots under physiological circumstances and its contribution in 
obesity-linked metabolic disorders47. The group was also able to show genes 
which were involved in lipid metabolism adjusted rapidly due to fasting in the 
internal rVAT depot in comparison to the SAT48.  
 
1.4.3 Subcutaneous fat 
As stated in the chapter above, VAT is known as the highly metabolically 
active depot with strong associations to insulin-resistance and progression of 
metabolic disorders, SAT, however, is known better for its short-term and long 
term storage capacity. Therefore, this depot is crucial for the accumulation of 
TG in phases of excess energy intake and also at times of starvation, exercise, 
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fasting, or starvation to supply the organism ZLWK))$¶VA suggested for the 
role of SAT is to play a buffer throughout the intake of dietary lipids. By 
playing a buffer SAT protects other tissues against lipotoxic effects48. 
SAT is anatomically divided by a stromal fascia (fascia superficialis) in 
humans, into deep subcutaneous adipose tissue (dSAT) and superficial 
subcutaneous adipose tissue (sSAT), both regions can be identified by their 
distinct histological characteristics. Studies have been able to show that sSAT 
is not linked to the risk of T2DM, whilst the depot sizes of dSAT have been 
significantly related to insulin-stimulated glucose utilization and also linked to 
fasting insulin levels along with total fat and VAT49,50. When observing obese 
patients, the relationship between dSAT and insulin resistance is seen strongly 
in male patients51,52. Studies researching expression and secretion of cytokines 
and hormones in lean patients, found dSAT to behave more like VAT than 
sSAT53. Further research in leption indicates that SAT seems to have an 
exclusive role in its secretion, due to SATs the correlation with plasma leptin 
levels, which is in contrast to plasma insulin levels who draw a parallel with 
inter abdominal fat54. Rat studies have also been able to show gender-linked 
YDULDQFH LQ 6$7 ZLWK 33$5Ȗ H[SUHVVLRQ EHing higher in males than in 
females55.  
 
1.4.4 Epicardial Fat 
The visceral fat layer situated around the heart is called the epicardial adipose 
tissue (EAT). This depot is believed to be important in the safeguarding of 
coronary arteries along with utilizing fatty acids as a source of energy for the 
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cardiac muscle. It has been suggested that the release of adrenomedullin and 
adiponectin may have a protecting effect on the heart during mechanical or 
metabolic situations56. 
Whilst being a protective force in certain situations, EAT has also been shown 
to act locally and influence the heart and vasculature via the secretion of pro-
inflammatory cytokines and possibly lead to the contribution of coronary 
atherosclerosis57,58,59. Studies relating to carotid artery stiffness and their 
relationship to the amount of EAT have been observed in obese patients with 
hypertension whilst a correlation with waist circumference showed no 
significant link60.  
 
1.5 Adipokines 
WAT adipocytes were seen to secrete many important hormones in 
addition to leptin, most importantly adiponectin. Leptin, adiponectin, 
plasminogen activator inhibitor type 1(PAI-1), tumour necrosis factor (TNF), 
resistin and many other proteins were notably termed as adipocytokines or 
most commonly called adipokines31. Adipokines have now totalled over 50 
different molecular proteins. The adipokines are very distinct in each of their 
structure and function which gives them a unique ability collectively to 
regulate processes such as lipid metabolism, vascular function, insulin 
resistance and glucose tolerance61. Adipokines are also directly linked to 
immunity and inflammatory processes in the body, many cytokines secreted 
within an immune response can also be produced by adipose tissue, suggesting 
a role for adipose tissue in immunity and inflammation61.  
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1.5.1 Leptin 
In 1994 Jeremy Friedman and his group from Rockefeller University 
published a paper which outlined a new gene in mice and humans, this gene 
was leptin34. Since then, leptin has been established as an essential element in 
energy homeostasis62. Leptin is produced by adipocytes in amounts relative to 
tissue mass62. It has a 167-amino acid structure and its gene, identified as Ob 
(Lep) gene (Ob meaning obese and Lep meaning leptin) is located on 
chromosome 1763. Leptin expresses its effects by binding to the transmembrane 
leptin receptor, named Ob-R64. In total there are 5 isoforms of the Ob-R 
receptor, the most well known is the Ob-Rb, that activates the Jak-Stat signal 
transduction pathway which in turn plays a vital role in the management of 
cellular reactions to growth factors and cytokines65-67.  
The hypothalamus is the most significant site of action for leptin68. The 
ventromedial nucleus region of the hypothalamus is where leptin binds69. This 
specific area of the brain is known for its control over appetite. Leptin helps in 
the regulation of energy intake as well the control of some neuroendocrine 
relationships. Studies in deficiency syndromes have shown that leptin has a 
strong association with insulin resistance34. Deficiency or mutation of the leptin 
ob/ob gene, in mice results in metabolic symptoms such as obesity, 
hyperphagia and diabetes70. When leptin deficient mice are administrated leptin 
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exogenously, these abnormalities are reversed, food intake is decreased and 
weight loss is observed, along with improved metabolic homeostasis70.  
Experiments with hyperglycemia and hyperinsulinemia in mice, leptin 
administrated at supra-physiological doses showed a reversal of these 
symptoms but there was no significant decrease in weight loss34 70. This shows 
that leptin has an individual effect on insulin resistance which is separate from 
its effects   on weight regulation.   
 
1.5.2 Tumour necrosis factor 
Tumour necrosis factor (TNF) is an adipokine that is secreted by the 
adipose tissue; TNF is also involved with the immune system71 72. There are 
WZRW\SHVRI71)DOSKDĮDQGEHWDȕ71)-ĮLVPRVWFRPPRQO\NQRZQIRU
cell apoptosis and regulation of immune cells. TNF-ĮLVDN'DSURWHLQWKDWLV
synthesised into a 51kDa trimer which derives its name from its pro-apoptotic 
properties in tumour cells73.  TNF-ĮLVFRPSULVHGRIa transmembrane protein 
with stable homotrimers74 75. As TNF-ĮLVHVVHQWLDOO\PHPEUDQHERXQGD71)-
ĮFRQYHUWLQJHQ]\Pe (TACE) releases TNF-ĮLQDVROXEOHIRUPYLDSURWHRO\WLF
cleavage76.  
Whilst adipose tissue synthesise a major proportion of TNF-Į the known 
producers of TNF- Į DUH PDFURSKDJHV73. Along with being involved with 
apoptosis, TNF-ĮDOVRVWLPXODWHVWKHVHFUHWLRQRIRWKHUDGLSRNLQHVVXFKDV,/-1, 
IL-6 and is involved in inflammation and immunity77. Within adipose tissue, 
TNF-Į KDV HIIHFWV RQ WKH OLYHU such as inducing insulin resistance by 
increasing serine-phosphorylation of insulin receptor substrate 1 (IRS-1)78. 
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This phosphorylation of IRS-1 leads to impaired insulin signalling79 80. TNF-Į
is highly expressed in visceral adipose tissue in comparison to subcutaneous 
adipose tissue81 82.  
TNF-Į KDV WZR UHFHSWRUV WKDW LW FDQ ELQG WR 71)-R1 and TNF-R283 84. Both 
receptors are present in adipose tissue, though TNF-R2 is more prevalent in the 
immune system83 84.  
When TNF-Į ELQGV WR HLWKHU 71)-R1 or TNF-R2 it leads to conformational 
changes in structure for the receptor85. The receptors form into a trimer shape 
into which fits TNF-ĮµVPRQRPHUVWUXFWXUH86. The changes in receptor structure 
in binding the ligand lead to an uncoupling of the SODD (silencer of death 
domains) inhibitory protein87 88. The uncoupling means the adaptor protein 
TRADD (TNFRSF1A-associated via death domain) is activated and begins 
binding to the death domain89 90. This binding leads to activation from one of 
three pathways. 
1. MAPK (Mitogen-activated protein kinase) pathway: JNK (C-Jun N-
terminal kinase) is activated in the MAPK pathway by TNF, the JNK 
group is involved in pro-apoptotic properties, cell proliferation and 
differentiation91. 
2. Death Signalling: With TRADD being activated it binds to FADD, this 
allows cysteine protease caspase-8 to be enrolled at a high 
concentrations. The high concentration of cysteine protease caspase-8 
leads to autoproteolytic activation and removing of effector caspases 
which in turn leads to cell apoptosis92.  
56 
 
3. NF-kB pathway: NF-N% ZKLFK LV XVXDOO\ LQKLELWHG E\ ,N%Į DQ
inhibitory protein) is phosphorylated by protein kinase IKK (IkB 
NLQDVH 7KH SKRVSKRU\ODWLRQ RI ,N%Į Ey IKK allows NF-kB to be 
released and translocate to the nucleus and oversee the transcription of 
cell survival, proliferation, anti-apoptotic and inflammatory responses87 
88
.  
71)ĮSOD\VDYLWDO UROH LQDGLSRVH WLVVXHE\VXSSUHVVLQJ WKHJHQHVFRQFHUQHG
with the consumption and storage of free fatty acids93 9471)ĮDOVRVXSSUHVVHV
genes implicated in the storage and uptake of glucose and adipogenesis95. 
71)Į KDV WKH DELOLW\ WR DOWHU WKH H[SUHVVLRQ RI other  adipokines such as 
adiponectin and IL-696.  
,Q WKH OLYHU 71)Į KDV EHHQ UHSRUWHG WR VXSSUHVV WKH H[SUHVVLRQ RI JHQHV
involved with fatty acid oxidation, metabolism and glucose uptake97. 71)ĮLV
involved with impaired insulin signalling through two separate paths.  
7KH ILUVW SDWK LQYROYHV 71)Į DFWLYDWLQJ VHULQH NLQDVHV ZKLFK OHDG WR DQ
increase in serine phosphorylation of insulin receptor substrates 1 and 2. The 
increased phosphorylation means that the substrates are unable to bind with 
insulin receptor kinases due to their inadequate state. Due to their inability to 
bind sufficiently to insulin receptor kinases, signalling is weakened78 98.   
The second path involves TNFĮ SOD\LQJ DQ LQGLUHFW UROH LQ LPSDLULQJ LQVXOLQ
VLJQDOOLQJ 71)Į LPSDLUV VLJQDOOLQJ E\ LQFUHDVLQJ VHUXP OHYHOV RI IUHH IDWW\
acids78 98.  
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1.5.3 IL-6 
Interleukin 6 (IL-6) is a cytokine that has the ability to produce a variety of 
effects spanning from inflammation to insulin resistance99. IL-6 has a strong 
relationship with insulin resistance and plasma levels of IL-6 are positively 
associated with obesity and insulin resistance62. Adipose tissue secretes 
approximately 25% of all IL-6 synthesised in the body, with a range of cell 
types such as fibroblasts, skeletal muscle, immune cells and endothelial cells 
also contributing to its production99. Visceral depots have been shown to 
secrete more IL-6 compared to subcutaneous depots100. The location of visceral 
depots allows them to secrete directly into the portal circulation, thereby 
allowing IL-6 to have stronger metabolic effect on the liver101.  
 IL-6 circulates between sizes of 22 to 27 kDa and binds to an IL-6 
transmembrane receptor resulting in a 2 protein complex forming, that complex 
binds to glycoprotein 130 (gp130) a transmembrane protein belonging to the 
cytokine receptor family. This three protein complex then permits signal 
transduction cascades62.  
Epidemiological studies have shown that subjects with type 2 diabetes have 
elevated levels of IL-6, which are significantly lowered in adipose tissue and 
serum following weight loss102-105. Genetic studies illustrate a strong 
relationship between IL-6 genetic polymorphism and insulin resistance106. A 
possible mechanism through which IL-6 may present hepatic insulin resistance 
is by inhibition of the insulin receptor signal transduction cascade. This 
inhibition can lead to an induction of suppressor of cytokine signalling-3 SOC-
3101.  
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A recent study of IL-6 administration however concluded that it does not 
inhibit glucose homeostasis in healthy subjects as levels were not elevated to 
those seen in disease states107. Along with human studies, studies carried out on 
IL-6 deficient mice showed obesity and glucose intolerance was not prevented 
through IL-6 administration108.  
Other possible effects of IL-6 include a decrease in the activity of lipoprotein 
lipase, thereby reducing the activity of triglyceride synthesis and then substrate 
availability. Secretion of adiponectin has also shown to be reduced by IL-6; 
this in turn leads to deterioration of insulin sensitivity109.  
 
1.5.4 Adiponectin 
Of all the adipokines expressed by adipose tissue, adiponectin is by far the 
most abundant with plasma protein levels averaging ~1 - 17ȝJPO110. 
Adiponectin is synthesised by adipose tissue and secreted into the blood. It was 
originally identified by four different research groups, used different techniques 
to clone and identify the gene and leading to a host of names such as Acrp30, 
AdipoQ, apM1 and GBP28 being published for the same protein111-114. Finally, 
adiponectin was chosen as name for the protein.  
$GLSRQHFWLQ¶V VWUXFWXUH FRQVLVWV Rf four individual regions made up of a 244 
amino acid polypeptide115. The four different regions all exhibit different 
properties, the first region is a short signal sequence region which allows the 
protein to secrete outside of the cell. The second region exhibits different 
properties depending on species116. The third region shows striking 
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resemblance to collagenous proteins and is often referred to as the collagen 
domain. The last region has been identified as the globular domain region (See 
Figure 1.5)116.  
 
 
 
 
Figure 5.5 ± Adiponectin regions. Adiponectin belongs to the complement 
factor C1q-like superfamily of proteins and is composed of an N-terminal 
signal sequence (SS), a variable domain, a collagen-like (tail) domain and a 
C1q-like globular domain near the C-terminus117. 
Adiponectin is present as a small globular form or in a full-length form. The 
dominant form is full-length adiponectin (fAd) and is present in nearly all 
plasma adiponectin116. The 3D structure of the globular domain of adiponectin 
VKRZV D YHU\ KLJK VLPLODULW\ WR WKDW RI 71)Į EXW WKHUH LV QR VLPLODULW\ LQ
sequence between the two118. Recent evidence has shown a low concentration 
of globular adiponectin (gAd) in plasma resulting from proteolytic cleavage119. 
A recent study added more evidence to this hypothesis by showing that 
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activated monocytes with/without neutrophils secrete leukocyte elastase, is 
responsible for the cleavage of adiponectin to form globular adiponectin 
fragments120. Further studies have shown gAd that is cleaved from the fAd 
contains a C-terminal; this subsequent C-terminal gives gAd the ability to 
manipulate metabolic changes in skeletal muscle119 121 122.  
The structure of adiponectin is vital to its understanding. Structural analysis of 
adiponectin helps to unlock the many pathways it regulates in the body. It 
produces a protein product of 30kDa that can lead to many complexes being 
formed such as trimeric complexes with low-molecular mass (LMW), 
hexamers with medium-molecular mass (MMW) and oligomers with high 
molecular mass (HMW) (Figure 1.6)123. Each different complex that is formed 
from the protein product exhibits different properties in various tissues124.  
 
 
 
 
 
 
 
Figure 6.6 ± Adiponectin complexes125. Adiponectin forms low-molecular 
weight (LMW) homotrimers and hexamers, and high-molecular weight (HMW) 
multimers of 12-18 monomers126,127. 
Trimer formation (LMW):  Trimers are formed through three monomers 
linking via their C-terminal globular domains. The trimer complex is then 
S-S 
S-S 
Trimer (LMW) Hexamer (MMW) Multimer (HMW) 
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secured into place by the triple helix structure of the three collagenous 
domains123 124.   
 
Hexamer formation (MMW): Hexamers are formed through two trimers 
coming together at the Cys39 residues. Trimers are structurally held into 
position by the use of disulphide bonds123 124.  
 
Multimer formation (HMW): HMW multimers are produced with multiple 
hexamers forming together with non-covalent interactions123 124. 
 
Adiponectin levels are negatively correlated with BMI and are 
especially low in obese subjects. This is not reflected with the circulating levels 
of other adipokines, which seem to have an inverse relationship with obesity110.  
Adiponectin influences many metabolic changes in the body. The two main 
processes with which adiponectin are associated with is glucose and lipid 
metabolism. With glucose metabolism, adiponectin affects gluconeogenesis 
and glucose uptake. Adiponectin has also shown to contribute towards 
increasing insulin sensitivity along with weight loss and a reduction in 
atherosclerotic formation128 129.  
Adiponectin has, therefore, been thought to be anti-diabetic, anti-
atherosclerotic and anti-inflammatory. Many of these properties can be 
attributed to its insulin sensitising effects130. Adiponectin activates the AMP 
kinase pathway and peroxisome-SUROLIHUDWRUDFWLYDWHG UHFHSWRU Ȗ 33$5Ȗ WR
exert its metabolic effects. The pathways are activated in the liver and skeletal 
62 
 
muscle resulting in fatty acid oxidation and reduction of triglyceride content in 
liver and skeletal muscle (Figure 1.7)131 132.  
 
 
 
Figure 7.7 ± Proposed molecular mechanisms of adiponectin116. The binding of 
adiponectin to its receptors provokes the activation of adenosine 
monophosphate AMPK and the activation of various signalling molecules, such 
as p38 mitogen-activated protein kinase MAPK, and PPAR. Activation of 
AMPK mediates pharmacological actions of adiponectin, including fatty acid 
oxidation, protein degradation, and glucose uptake. 
The presence of HMW, MMW and even LMW forms of circulating 
adiponectin have been detected in plasma, although the presence of gAd in the 
circulation is still debatable119 1337UDQVFULSWLRQIDFWRUVVXFKDV33$5Ȗ6WHURO-
regulatoryelement-binding protein (SREBP) and CCAAT/enhancer binding 
protein (C/EBP) have shown to regulate the adiponectin gene promoter134 135.   
 
63 
 
With diseases such as cardiovascular disease, metabolic syndrome, diabetes, 
lipodystrophy and insulin resistance all being associated with low levels of 
adiponectin, gender and ethnicity have now also been shown to effect 
adiponectin levels136-138.  
 
As stated before adiponectin does not positively correlate with increasing fat 
mass  and circulating adiponectin levels are notably lower in obese subjects in 
comparison to lean subjects, who have increased levels of adiponectin139-141. A 
possible mechanism to explain why adiponectin decreases as body fat mass 
rises is a possible feedback inhibitory system that  accounts for the increased 
concentrations of adipokines as a possible reason for body fat mass gain, these 
adipokines possess an inhibitory influence over adiponectin gene expression 
HJ71)ĮDQG,/-6)138.  
 
1.5.5 Adiponectin Receptors  
Adiponectin has two identified transmembrane receptors responsible for its 
possible mechanisms of action. These are a distant relation to the G-protein 
coupled transmembrane family142 143. AdipoR1 was first identified through 
screening for gAd in the skeletal muscle and AdipoR2 was identified due to its 
close homology to AdipoR1. Both receptors display a different preference for 
adiponectin type143. AdipoR1 is primarily expressed in skeletal muscle with a 
strong affinity to gAd and a low affinity to fAd. AdipoR2 is mainly expressed 
in the liver with transitional affinity to fAd and gAd142. AdipoR1 was first 
identified through screening for gAd in skeletal muscle and AdipoR2 was 
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identified due to its close homology to AdipoR1142 143. AdipoR1 and AdipoR2 
KDYHEHHQVKRZQWREHH[SUHVVHG LQSDQFUHDWLFȕ-cells, though further studies 
are required to confirm this144 145. Both receptors exert the effects of 
adipoQHFWLQRQIDWW\DFLGR[LGDWLRQ33$5ȖOLJDQGDFWLYLW\JOXFRVHXSWDNHDQG
¶$03.SDWKZD\142 146-148. 
Evidence supporting AdipoR1 and AdipoR2 for mediating fatty acid oxidation 
with globular and full-length adiponectin has been put forward through a study 
which uses siRNA (small interfering RNA) to suppress the expression of both 
receptors. This leads to a decrease in fatty acid oxidation from gAd and fAd in 
contrast to normal expression. The study highlighted that suppression of 
AdipoR1 and AdipoR2 that led to subsequent decreased levels of fatty acid 
oxidation leading to a conclusion that both receptors play a mediating effect on 
fatty acid oxidation142.  
 
AdipoR1 protein has been shown to be heavily conserved in a variety of 
species from yeast to man. The seven transmembrane structural fixture in 
particular is heavily conserved through different species.  The adiponectin 
receptors are known to play a role in the regulation of lipid metabolism which 
is mirrored with the yeast homolog YOL002c. Structural analysis of the 
receptors has revealed that the N terminal region was internal and the C 
terminal region external for both receptors. The structural geometry of 
AdipoR1 and AdipoR2 is reversed in all other existing G protein-coupled 
receptors142 149.  
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1.5.6 Monocyte Chemotactic Protein-1 (MCP-1) 
MCP-1 also known as Chemokine (C-C motif) ligand 2 (CCL2) or small 
inducible cytokine A2 is a protein which is encoded by the CCL2 gene in 
humans. MCP-1 is a small cytokine which is a part of the CC chemokines 
family. MCP-1 is a major player in the recruitment of memory T cells, 
monocytes and dendritic cells to the site of infection and tissue injury. MCP-1 
is secreted as a protein precursor which contains a signal peptide of 23 amino 
acids along with a mature signal peptide of 76 amino acids and has a molecular 
weight of ~13 kDa and is a monomeric polypeptide150. MCP-1 binds to 
membrane surface of CCR2 proteins which are highly expressed on activated T 
cell and monocytes surfaces. The receptor complexes of MCP1-CCR2 are 
initially occupied in attracting monocytes, natural killer cells and T-
lymphocytes to the sites of cellular injury or stress. Studies have shown MCP-1 
to up-regulate the expression of IL-6 in epithelial cells and amplification in the 
expression of TNF-ĮFRQFHQWUDWLRQZLWKLQFUHDVLQJ0&3-1 expression from in 
vitro models studies151. Studies investigating obesity and increased fat mass 
have displayed increased expression of MCP-1 subsequently leads to increased 
MCP-1 plasma concentrations151. Studies in obese mice specifically engineered 
for the over expression of MCP-1 gene have shown  amplified macrophage 
infiltration in adipose tissue along with an increase in hepatic triglyceride 
levels and insulin resistance, whilst MCP-1 knockout studies have shown 
decreased insulin resistance151.  
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1.5.7 Toll-like receptor (TLR) 
Toll-like receptor (TLR) is a major regulator of both adaptive and innate 
immune responses. TLR signalling is involved with the activation of the innate 
immune system through lipotoxicity. TLR has been shown to play a strong 
molecular link between hyperlipidemia, known for its clinical feature in obesity 
and the initiation of the innate immune system152. TRL-4 is widely expressed in 
a range of cells, especially macrophages and adipocytes and forms an important 
ligand complex when in contact with free fatty acids152. Once activated, TRL-4 
up-regulates the inflammatory expression in cytokines and stimulates insulin 
UHVLVWDQFH75/¶VDUHVHHQWRSOD\DPDMRUUROHLQRWKHUPHWDEROLFV\PSWRPVRI
obesity including hepatic steatosis and atherosclerosis153. TRL-4 has also been 
associated with macrophage infiltration and their expression levels exhibiting a 
positive correlation with the magnitude of increase in adipocyte hyperplasia 
and hypertrophy, therefore demonstrating a possible macrophage-related 
inflammatory response that may co-ordinate towards the development of 
obesity154. 
 
1.5.8 Interleukin-18 
Interleukin-18 (IL-18) is a pro-inflammatory cytokine that is generated by 
macrophages and various other cells, with its receptor belonging to the IL-1R 
and TRL super-family. IL-18 shares a homologous structure to IL-1 but is 
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expressed by both non-immune and immune cells155. Studies have shown over-
expression of IL-18 can lead to the development of severe pro-inflammatory 
disorders such as auto-immune diseases and inflammatory tissue damage156. 
Contrasting studies have shown IL-18 deficient mice exhibit obesity and 
insulin resistance in comparison to their wild type group and may exhibit a 
similar role to which IL-6 and TNF-Į GLVSOD\ LQ HQHUJ\ LQWDNH Dnd insulin 
sensitivity156.  
 
1.5.9 Fat mass and obesity associated gene (FTO) 
The FTO gene is located on chromosome 16 in humans with various variants of 
the gene showing correlation with obesity in humans. FTO is expressed in a 
wide range of tissues and in particular the hypothalamus, a region known for 
appetite regulation where its expression is highly concentrated157. Studies in 
mice have shown that FTO expression from the hypothalamus tissue is 
regulated by nutritional status, with starvation displaying a down-regulation in 
FTO expression158. These findings confirm the relationship between energy 
intake and FTO polymorphisms, leaving a possible suggestion that the product 
of the FTO gene is directly involved with energy balance regulation158. In 
addition the FTO gene is expressed in a wide range of tissues, including major 
tissues or organs that regulate energy metabolism and cardiovascular 
function158. The role that FTO plays in the regulation of these tissues and 
organs in their relationship to obesity and metabolic symptoms is still to be 
verified and remains unknown.  
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European epidemiological studies have identified variants of the FTO gene to 
be linked to obesity (allele SNPrs9939609). The study was able to conclude 
that carriers with one copy of the risk allele weighed 1.2kg more than people 
without any copies; subsequently carriers with two copies of the risk allele 
weighed approximately 3kg more and displayed a 1.67 fold higher risk of 
obesity159. FTO has also been show to be linked with an increased risk of type 
2 diabetes159. A study involving a combination of nutrient restriction (in utero) 
followed by juvenile obesity showed increased FTO gene expression in the 
hypothalamus, once again indicating its role in appetite control and obesity157. 
 
1.6 Endoplasmic reticulum stress pathways 
Organelle dysfunction is a promising concept used to explain the wide 
collection of maladaptive responses in an obese state. To be more specific, 
endoplasmic reticulum (ER) stress proceeded with the activation of unfolded 
protein response (UPR). During obesity, stressed adipocytes activate the UPR 
pathway to promote cell survival by increasing the recruitment of crucial ER 
chaperones, such as glucose-regulated protein 78 (GRP78) to the site of stress 
in order to aid the restoration of cellular homeostasis160. GRP78 also known as 
binding immunoglobulin protein (BiP) is an ER chaperone located at the lumen 
of the ER161. When unfolded proteins build up in the ER, resident chaperones 
such as GRP78 become occupied, releasing transmembrane ER proteins 
involved in generating the UPR. These transmembrane proteins (PERK ± PRK-
like ER kinase, Ire1, and ATF6 ± Activating transcription factor 6) span across 
the ER membrane, with their N-terminus situated in the lumen of the ER and 
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their C-terminus in the cytosol, thus supplying a bridge that connects these two 
compartments162.  Under normal conditions the N-terminus of the ER proteins 
is held together by GRP78, therefore preventing their activation. However 
when misfolded proteins accumulate, GRP78 is released from holding together 
Ire1, PERK, and ATF6. This release leads to an Ire1 and PERK 
oligomerization within the ER membrane. Oligomerized Ire1 binds with 
TRAF2 (TNF receptor-associated factor 2), signalling downstream kinases that 
activate NF-kB and c-Jun, resulting in expression of gene associated with host 
defence (inflammationary)163, 164. 
When the process fails to promote cell survival, the UPR pathway activates 
programmed cell death via the apoptosis pathway, through the activation of 
induction of the CHOP gene or through activation of the JNK pathway165 166.  
With the accumulation of increased adipose tissue leading to obesity, it is 
accompanied by adipocyte cell death which displays a distinct gathering of 
mast cells and macrophages in the swelling of adipose tissue during obesity167. 
These macrophages are seen to fuse and form a syncytium around the 
multinucleate giant cells (also referred to as crown-like structures), displaying a 
trademark of chronic inflammation168. 
 
1.7 Nutrient Restriction 
Growth of the fetus during their development in the mother is restricted 
by the amount of nutrients that are supplied via the placenta. When the nutrient 
supply rate does not meet requirements, development and growth rates are 
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altered. If the rate of nutrient supply is insufficient for long periods, the fetuses 
metabolic system makes alterations to compensate for the lack of nutrients169. 
Ultimately development of vital fetal organs and structure are often 
compensated for leaving the offspring to be born underweight and of a smaller 
size170.  
The Dutch Famine Study of 1944 (RU³Hongerwinter´RU Hunger Winter) is a 
study that can be used to understand the implications of nutrient restriction171. 
During the end of World War II, certain areas within the Netherlands were 
subjected to insufficient food supplies leading to a famine during the midst of 
winter171. Food rationing was implemented to compensate for the lack of food 
supply. The food rations for adults were restricted to between 400-800 calories 
a day, a quarter of recommended daily intake171. The famine took place in a 
well developed and modern country which meant the famine was well 
documented and allowed scientists to study the famine in great detail and 
measure the effects of famine upon pregnant woman and their offspring.   
A follow-up study to the Dutch famine of 1944 was completed by the AMC 
(Academic Medical Centre) in Amsterdam in collaboration with the University 
of Southampton. The study concluded that a significant amount of pregnant 
women dependent on their stage of pregnancy during the famine produced 
offspring who were underweight and smaller with greater susceptibility to 
metabolic diseases such as obesity, diabetes and mainly cardiovascular 
disease171-173.  
The study is used to support the fetal origins of disease hypothesis which 
supports long term programming from in utero events174. The hypothesis was 
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formed from observations made from low birth weight which Barker 
contributed to maternal nutrition. Barker hypothesised maternal nutrition is the 
key cause of long-term health consequences such as cardiovascular disease174 
175
. The Dutch Famine follow-XSRIDGXOWRIIVSULQJLVXVHGWRVXSSRUW%DUNHU¶V
hypothesis. The original idea of fetal programming was originally proposed by 
Lucas in 1991176.  
The fetal origin of disease hypothesis has received support from 
epidemiological literature177 178. The hypothesis was first introduced back in 
1992 by Hales and Barker who concluded that  females who have to withstand 
deprived nutritional conditions during pregnancy have the ability to change the 
development of the unborn infant in such a way that it will be adept to survive 
in surroundings with a lack of nutritional resources i.e. The Thrifty 
Phenotype179.  
The thrifty phenotype states babies who carry the thrifty phenotype and are 
born into a rich nutritional environment are more susceptible to obesity, 
diabetes, cardiovascular disease and other metabolic disorders. In contrast, 
babies which received a good nutritional intake during pregnancy and born into 
a rich nutritional environment will adapt better to the surroundings and 
therefore be less likely to encounter such problems180.  
 
1.7.1 Fetal nutritional programming of adult health and disease 
For the development and growth of the offspring, the intrauterine environment 
plays a critical role. The frequency of adult disease increases in infants who 
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have a suboptimal growth in utero181,182.  When looking at the effects of early 
OLIHQXWULWLRQRQJURZWKDQGGHYHORSPHQW³SURJUDPPLQJ´ZDVGHILQHGDV WKH
lasting consequences of a stimulus or insult during a sensitive period in early 
life183. 
Changes in fetal physiology can be permanently influenced by events that 
occur during gestation. The bulk of morphological features are present prior to 
the birth and this is the prime period for plasticity or adaptation. Subsequent 
adaptations to in utero insults may have long term adverse consequences in 
later OLIH7KHWKHRU\SURSRVHGE\WKH³IHWDORULJLQVRIDGXOWGLVHDVHK\SRWKHVLV´
is that fetal programming occurs when inadequate nutrition of the mother 
impairs fetal nutrient supply that leads to permanent physiological changes 
which can predispose to later cardiovascular disease, hypertension, impaired 
glucose tolerance and type 2 DM 181,182,184. 
Decreased glucose tolerance in adults has been linked to low birth weight. 
Decreased rates of fetal growth and impaired insulin-glucose metabolism have 
also been found in children and adolescents in several populations and in 
different countries172. A unique opportunity to study the fetal effects of severe 
maternal under nutrition during pregnancy in humans was provided by the 
Dutch famine, (late November 1944 to early May 1945)172. The official daily 
rations for the general population during this famine varied between 400 and 
800 Kcal (1680 and 3360 KJ). For those 702 participants whose prenatal and 
birth records could be assessed and who were born between Nov 1, 1943 and 
February 28, 1947 in Amsterdam were included for the purposes of this study. 
For participants who were exposed to famine in different stages of gestation, 
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their glucose and insulin responses to a standard oral glucose test were 
compared with those born after this period (i.e. Controls). These results 
suggested that decreased glucose tolerance in adults is linked to prenatal 
exposure to famine, especially during late gestation. The research also 
suggested that even if the effect on fetal growth is small, insufficient nutrition 
may lead to permanent changes in insulin-glucose metabolism172,185,171. 
It is now well recognised that either throughout or at specific stages of 
pregnancy, changes in the macronutrient or micronutrient composition of the 
maternal diet can have significant effects on the fetus171. 
 
1.7.2 Low ELUWKZHLJKWDQG³&DWFK-XSJURZWK´ 
,QGHYHORSHGFRXQWULHVWKHLQIDQWXQGHUJRHVDSHULRGRIDFFHOHUDWHG³FDWFK-up 
JURZWK´ JURZWK GXULQJ HDUO\ SRVWQDWDO OLIH ZKHQ LWV QXWULHQW VXSSO\ LV QR
longer constrained and where fetal growth restriction is generally the result of 
compromised placental nutrient transfer rather than a decreased intake of 
nutrients by the mother186. Being born into a plentiful postnatal environment is 
associated with higher accumulation of subcutaneous and visceral adipose 
tissue in a shorter period of time186, 187. 
Various studies have indicated that for infants with a small gestational age, fast 
post-QDWDO ³FDWFK-XS´ JURZWK PD\ KDYH D QHJDWLYH HIIHFW RQ ODWH PHWDEROLF
health. However, it is still not known at which point after birth the accelerated 
growth may be detrimental, with some studies indicating to the immediate early 
post-natal period188,189,190,191,192. Several other findings have also indicated that 
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accelerated growth in childhood further increases the risk193,194,195. The lack of 
correction of catch-up growth for low birth weight could be a possible 
confounder in many previous studies. What may be important is the shift from 
an adverse and sparse nutritional intra-uterine environment into one of 
potentially excess nutrition that small for gestational age (SGA) infants at the 
time of birth go through. What may facilitate a more efficient nutritional uptake 
and energy metabolism and thereby higher post-natal growth rate is the 
potential state of cellular nutrient restriction in SGA infants at the time of 
birth196. A positive relationship was shown between weight gain during the first 
two weeks of life and insulin resistance in adolescence irrespective of birth-
weight. This was discovered at age 13-16 years of preterm infants from a 
randomized intervention trial of neonatal nutrition192. Another study indicated 
that weight gain of term newborn infants from birth to six months was 
positively associated with metabolic risk at 17 years of age197.  
 
1.7.3 Effect of gender in nutrient restriction consequences 
Different aspects have demonstrated gender-specific differences in fetal growth 
and development following nutritional manipulation in utero. What has also 
been previously noted a gender specific regulation of the fetal and adult 
hypothalamic-pituitary-adrenal (HPA)198. A distinct sex-specific bias has been 
exhibited in responses to challenges that have been shown to incur 
developmental consequences198. An example of this is when only the adult 
female offspring are affected after maternal restraint stress in rats during late 
gestation (resulting in maternal HPA axis activation). Males appear largely 
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unaffected. Another increase response is found in adult females following 
prenatal alcohol exposure also but the males once again are not affected, HPA 
axis activity198. 
 
 
1.7.4 Immune response with Inflammation 
The body is comprised of a network of molecular pathways which respond to 
immunity in a variety of ways. The immune network has two such complex 
pathways199: 
1. Adaptive immune system (Immune memory pathway) 
2. Innate immune system (Non-specific pathway). 
These two systems protect the host organism against infection and are also vital 
in detecting differences between pathogens and host cells, in cases where both 
systems fail; auto-immune disease can transpire200. For instance, an antigen 
ZKLFK LQILOWUDWHV WKH H[WHUQDO EDUULHU DQG HQWHUV WKH KRVW¶V ERG\ WKH LPPXQH
response for both humoral and cell-mediated are stimulated. Upon reaching the 
antigen, phagocytic cells (macrophages, monocytes, dendritic cells or 
neutrophils) surround and ingest the antigen, followed by a phagocytic 
apoptosis of the antigen199. To help in the development of the immune system, 
specific immune cells such as antigen presenting cells (APC) and major 
histocompatibility (MHC) form complexes present themselves to the antigen 
and initiate an immune response. The complexes use the surface of the MHC to 
bind with the invading antigen, whilst circulating T-cells use their receptors to 
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communicate and stimulate the adaptive immune system to release cytotoxic T-
cells and B-cells201.  
In the case of injury or stress the cells affected secrete chemical signals known 
as chemokines, proteins and cytokines that provoke an inflammatory response 
to protect the surrounding cells and tissue. This chemical response causes 
immune cells, which are involved in biochemical complement cascades, to be 
activated by antibodies and breakdown the targeted cell202. The immune 
response from the host to such agonists is to regulate cell-adhesion molecule 
and oxidative stress factor expression, cytokine secretion and cell death203. In 
certain cases, inflammatory responses can be under or over reactive to the 
situation which can cause additional tissue damage because of certain pro- and 
anti-inflammatory mediators uncoupling204.  
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1.7.5 Obesity induced inflammation 
Obesity and hyperinsulinaemia are widely seen as established conditions that 
initiate the immune system to activate a chronic low level pro-inflammatory 
state. Excess or increased amounts of adipose tissue mass have shown to be 
positively correlated with the expression of pro-inflammatory gene, TNF-Į205. 
This is a gene more commonly associated with regulation of immune cells, cell 
signalling and recruitment of cytokines but through obesity studies, it has been 
shown to have a role in insulin resistance. TNF-Įis responsive to insulin and 
inhibits tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) 
thereby decreasing glucose intake205,78. This demonstrates the complexity of 
adipose tissue and inflammatory networks that underline the mechanisms 
obesity and insulin resistance.  
Concentrations of pro-inflammatory markers such as acute phase C-reactive 
protein (CRP) and other plasma cytokines have been shown to be correlated 
positively with increased adipose tissue mass206. This further reaffirms the 
relationship between obesity and inflammation. CRP is commonly associated 
with the development of cardiovascular disease (CVD) and is often used as a 
biomarker in assays for the early detection of CVD206. This also links the 
relationship between obesity and increased risks of morbidity through 
enhanced inflammation.  
As previously described, adipose tissue is known to secrete and synthesise a 
wide variety of molecular signals. In an obese pro-inflammatory state the most 
interesting are the immune-mediating adipokines with IL-6 and IL-10 showing 
increased expression and circulating plasma concentrations207,208,209. MCP-1 
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along with its receptor C-C motif receptor 2 (CCR2) have also shown increased 
expression in an obese condition151. Both IL-6 and MCP-1 are also understood 
to be involved in the contribution to the developing of insulin resistance208,151. 
There are a wide variety of mechanisms that could promote inflammation in 
DGLSRVH WLVVXH VXFK DV LQFUHDVHG 1()$¶V DGLSRNLQH VHFUHWLRQ DQG LQFUHDVLQJ
triglycerides concentrations ensuing from adipocyte hypertrophy and 
hyperplasia. Adipocyte hypertrophy is positively correlated with increased 
apoptosis and development of crown-like structure (CLS)168. CLS have been 
linked with increased macrophage recruitment and signalling210.  
The non-fat cell fraction of adipose tissue is hypothesised to be accountable for 
the majority of adipokine expression211. One of the main mechanisms 
hypothesised behind non-fat cell development in an obese state is through 
adipocyte enlargement caused by hypoxia and microcirculatory dysfunction212. 
Adipose tissue undergoing hypoxia leads to stimulation of vascular synthesis 
and up-regulation of vascular endothelial growth factor (VEGF) action, 
therefore increasing endothelial growth causing further macrophage and 
immune cell infiltration, leading to an inflammation feedback loop212.  
To conclude, recent studies have shown that well established metabolic protein 
hormones adiponectin and leptin, which not only influence the regulation of 
appetite via direct signalling on the hypothalamus, but also alter immune 
responses in an obese state displaying inflammation through indirect and direct 
pathways213,214 (see Fig 1.10). 
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1.7.6 Obesity and insulin resistance 
Insulin is a carbohydrate and lipid metabolism signalling hormone, produced 
by the pancreas and is central to balancing blood glucose levels immediately 
after a meal. Blood glucose levels are increased from eating which leads to the 
stimulation of insulin release from SDQFUHDWLF ȕFHOOV ,QVXOLQ LQ WXUQ FDXVHV
cells in the muscle, adipose tissue and the liver to uptake glucose from the 
blood. The glucose is then converted to glycogen and stored within these 
tissues. The mechanism in by which insulin operates is by suppressing hepatic 
gluconeogensis and by modulating entry and uptake of glucose through various 
glucose transporters, the major transporter being GLUT4215.  
One of the main responsibilities of insulin is to regulate the release of glucose 
into cells, supplying the cells with energy. Cells which have become insulin 
resistant cannot uptake in glucose, fatty acids or amino acids216. 
Insulin resistance (IR) can be defined as a physiological state to which cells 
fail to react to the normal behaviour of the hormone insulin. The body will 
produce insulin in a response to stimulus of increased glucose in the blood216. 
When the cells become resistant to insulin and are no longer able to use the 
hormone correctly, it leads to hyperglycemia. Ǻ-cells in the pancreas therefore 
increase their secretion of insulin, furthermore playing a role to 
hyperinsulinemia. This situation often remains unobserved and results in 
contributing to the conclusion of Type 2 Diabetes216.  
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Glucose uptake (and local storage of triglycerides and glucose as glycogen) is 
reduced in muscle and fat cells during insulin resistance, whilst insulin 
resistance in liver cells marks reduced glycogen synthesis and storage along 
with a breakdown to suppress production of glucose and release into the 
blood217 218. Insulin resistance is usually defined to as reduced glucose-
lowering effect of insulin, however many other roles of insulin are also 
affected. For example, fat cells are affected by a reduced uptake of circulating 
lipids and increased hydrolysis of stored triglycerides219,218. This leads to an 
increased recruitment of stored lipids in these cells leads to elevated free fatty 
acids in the blood plasma. These high plasma levels of insulin and glucose due 
to insulin resistance are key elements to the progression of metabolic 
syndrome220,218.  
During an obese state, the insulin sensing pathway is disrupted, a problem seen 
in all tissues sensitive to insulin. The sensing pathway is impaired due to a 
down-regulation of the GLUT4 gene in insulin responsive tissues215. A 
combination of impaired glucose storage and decreased stimulation of insulin 
regulated glucose transport leads to insulin resistance. This state can then 
further develop into hyperglycaemia and a possible development of type II 
diabetes.  
Obesity has been suggested to help in the progression of insulin resistance by 
playing a central role in the pathway to insulin resistance by reduction of 
binding to the insulin receptor, led by impaired phosphorylation of the insulin 
receptor and decreasing activity of tyrosine kinase in both adipose tissue and 
muscle215. Whilst many mechanisms are known for insulin resistance, obesity 
led insulin resistance are not fully known. Because of the complexity in 
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understanding all pathways stimulated by obesity it is hypothesised that the 
endocrine function of adipose tissue and increased levels of secretion of 
F\WRNLQHV 1()$¶V JO\Ferol and other various signalling markers from 
adipocytes in the obese state all promote insulin resistance221. 
Insulin resistance has been well established to show a positive correlation to 
increased visceral fat mass and BMI. Many epidemiological studies have also 
been able to display that subsequent weight loss coupled with a decreased in 
central adipose tissue depot mass actually reverses insulin resistance and 
improves sensitivity222. 
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1.8 Fructose  
The most common naturally occurring sweeteners in our daily diet are glucose, 
sucrose and fructose. Glucose and fructose are monosaccharides that are 
present in small quantities in fruits and honey. Sucrose is a disaccharide which 
has a structure that consists of one molecule of fructose connected to one 
PROHFXOH RI JOXFRVH WKURXJK DQ Į -4 glycoside bond and is found in 
significant amounts in sugarbeet and sugar cane223. 
A potential nutritional problem that has developed over the past few decades 
has been the gradual increase in fructose consumption in the daily diet and has 
tracked the increase in obesity incidence in developed countries 224. The 
widespread availability of fructose has increased in part due to its low cost and 
highly sweet taste, together with the introduction of high fructose corn syrup 
+)&6E\PDMRUEHYHUDJHFRPSDQLHVLQWKHHDUO\¶V225.  
 
1.8.1 Fructose Intake 
According to reports from the United States Department of Agriculture 
(USDA), sugar consumption per capita equalled to 90g/day in 1970226. At this 
time HFCS consumption was near enough to zero. As the production value of 
fructose decreased more beverage companies decided to implement the sugar 
as a cheaper equivalent to glucose, this coincided with the decrease in sucrose 
consumption.  
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1.8.2 Fructose Metabolism 
Fructose (C6H12O6) has the same chemical composition of glucose but is 
structured differently giving it unique abilities. When entering the gut, fructose 
is transported into the enterocyte via GLUT 5, a specific fructose transporter, 
located at the tip of the enterocyte. Unlike glucose metabolism, fructose does 
not require ATP hydrolysis and is therefore self-regulating of sodium 
absorption. After entry into the enterocyte, fructose is diffused into blood 
vessels through a GLUT2 transporter227,228. Studies in rodents have shown 
GLUT5 to be expressed relatively low until weaning but can be stimulated 
through fructose administration229. Ageing has also shown to be involved in 
fructose absorption; studies in aged rodents have exhibited decreased 
absorption rates in fructose and carbohydrates230.  
 
1.8.3 Hepatic Metabolism 
Once fructose is absorbed into the blood it is efficiently and quickly extracted 
by the liver (Figure 1.8). The glucose transporter GLUT2 is thought to be 
responsible for the transport of fructose into the liver231,232. The majority of 
fructose once extracted into the liver is quickly metabolised into fructose-1-
phosphate (P) by the highly specific enzyme fructokinase. Fructokinase has 
distinct properties such a low km (~0.5mM) and a high Vmax (suggested rate of 
~3µmol/min per gram of liver in human and rats)233,234,235. These unique 
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properties explain for the rapid rate of metabolism of fructose within liver 
cells.  
 
 
Figure 8.8 ± Fructose and glucose pathways. Fructose metabolism (grey 
arrows) differs from glucose (black arrows) due to 1) a nearly complete 
hepatic extraction and 2) different enzyme and reactions for its initial 
metabolic steps. Fructose taken up by the liver can be oxidized to CO2 and 
then converted into lactate and glucose; glucose and lactate are subsequently 
either released into the circulation for extrahepatic metabolism or converted 
into hepatic glycogen or fat. The massive uptake and phosphorylation of 
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fructose in the liver can lead to a large degradation of ATP to AMP and uric 
acid. 
 
Hepatic metabolism of glucose and fructose varies noticeably for many 
reasons. The first being, entry of glucose into the glycolytic pathway is 
regulated by glucokinase (also known as hexokinase IV). Glucokinase has a 
high Km for glucose unlike the high low km of fructokinase and therefore the 
rate of phosphorylation for glucose in the liver varies in relation to portal 
glucose concentration236. Conversion of glucose-6-P to fructose-6-P is 
catalysed by enzyme phosphofructokinase, the activity of this enzyme is 
moderated by citrate and ATP, therefore controlling the reaction based on the 
energy level of the cell237.  Overall the process of glucose being converted to 
pyruvate is regulated by insulin and the energy status of the cell. Insulin is 
involved in the stimulation of glucokinase gene expression and activation of 
glycolytic enzymes. In comparison to the conversion of fructose to triose-P, 
this process is self-governing and not dependent on insulin. Fructose 
conversion is also a quick process because of the low km of fructokinase and 
lack of a negative feedback of ATP or citrate. This process causes a temporary 
reduction in the amount of free phosphate and ATP presence in liver cells in 
reaction to fructose238,239.  
 
The remaining structure of fructose is the carbon atoms, which are processed 
into fatty acids within hepatocytes through a process known as de novo 
lipogenesis (DNL). The DNL pathway was first observed in rat in vivo studies 
and in rat hepatocytes where the administration of [14C] fructose displayed 14C 
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being taken up into liver lipids240,241,242.  Studies have shown stimulation of the 
hepatic DNL pathway through the administration of fructose or glucose-
fructose complexes in humans via the observing of infused 13C-labelled acetate 
in very low density lipoprotein (VLDL)243,244. DNL is performed in most cells 
but adipocytes and liver cells are predominantly well tailored for this process. 
Studies have shown that DNL in the liver has damaging effects which include 
the increasing of serum triglyceride and intrahepatic lipid (steatosis) levels, 
both of which lead to nonalcholic fatty liver disease and steatohepatitis245. 
Furthermore, increased hepatic DNL activity has been shown to be positively 
correlated with insulin resistance246.   
 
1.8.4 Long term effects of fructose 
The relationship between fructose intake and obesity has been somewhat 
controversial and is the subject of ongoing investigations247-249. To successfully 
evaluate the link between fructose consumption and obesity, the effect of 
fructose intake on total energy intake is a vital issue. Several studies have 
investigated the metabolic effects of replacing part of the carbohydrate diet 
with fructose for patients with type 2 diabetes mellitus as fructose metabolism 
does not require insulin secretion and has a low glycemic rise. These studies 
were able to demonstrate that fructose intake was related to a substantial 
increase in plasma triglyceride concentration and reduced levels of high-
density lipoprotein (HDL)-cholesterol250,251,252. Subsequent studies with 
animal models investigating the effects of diet supplemented with fructose or 
sucrose displayed that high-fructose/high-sucrose diets did exhibit harmful 
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cardiovascular and metabolic effects, such as insulin resistance, hyperuricemia, 
dyslipidemia, hypertension and weight gain253,248,249.  
 
 
1.8.5 Dyslipidemia and de novo lipogenesis 
Studies have been well established to display that ingesting a high-fructose diet 
for longer than 1 week leads to increased plasma total-VLDL-triglyceride 
concentrations and cholesterol in patients with type 2 diabetes, insulin 
resistance and even in healthy volunteers251,254,255. This abnormal amount of 
lipids in the blood is often referred to as dyslipidemia , with studies showing a 
sustained level elevated insulin levels can increase the risk of developing 
dyslipidemia256.  
 
 
Studies measuring plasma triglyceride kinetics in rats used high-glucose, -
sucrose and ±fructose diets concluded that both fructose and sucrose diets 
compared to the glucose diet lead to an increase in triglyceride production and 
a decrease in clearance of triglycerides257. Fructose is known to be highly 
lipogenic, as it supplies substantial quantities of hepatic triose-phosphate as 
precursors for fatty acid synthesis. it has been demonstrated in several studies 
that hepatic de novo synthesis was initiated following acute fructose intake and 
concluding that fructose also supplements to the production of both the 
glycerol and fatty-acyl components of VLDL-triglycerides258,259.  
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Various studies have contributed in supporting the role played by fructose-
induced hypertriglyceridemia in the stimulation of hepatic de novo lipogenesis. 
The two main observations that lend the most weight behind this process are 
the positive correlation demonstrated between partial hepatic de novo 
lipogenesis and fasting triglycerides in healthy patients fed an isocaloric, 
highsugar diet or a hypercaloric, high-fructose diet260,261. This study also 
illustrated that a 2-week infused diet with fish oil reduced fasting triglycerides 
and hepatic de novo lipogenesis in healthy patients previously overfed with 
fructose supplementation261.  
 
In support of the increase of fasting plasma triglycerides as described above, a 
postprandial rise was also observed in plasma triglycerides when acute fructose 
was administrated, this was explained by the weakened clearance of 
triglyceride-rich lipoprotein258, an effect also seen with chronic high fructose 
ingestion.  
 
Studies in overweight women have yielded results that show fructose 
involvement during a 10 week period studying postprandial triglyceride levels 
to be enhanced due to the intake of fructose sweetened beverages; these 
fluctuations in postprandial triglyceride levels are evident to impaired 
triglyceride clearance from fructose intake262.  This further reaffirms the theory 
that impaired triglyceride clearance leads to hyperlipidemia stimulated by 
high-fructose diets259.  
 
1.8.6 Fructose and the pathogenesis of metabolic diseases 
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In observation of the compelling evidence documented for the case that high 
fructose can stimulate in human and animal models a cascade of metabolic and 
cardiovascular changes it is justifiable to question whether fructose intake 
plays an important role in the development of metabolic disease within our 
populations 
1.8.7 Fructose and weight gain 
To evaluate the effect of fructose on body weight gain, various cross-sectional 
studies have been reviewed recently, most notably studies involving sugar-
sweetened beverages performed on children and adolescents263. Many of the 
studies involved did show a positive correlation between consumption of 
sugar-sweetened beverages and body weight264,265,266,267 but others failed to 
replicate these results268,269,270. Analysing these studies to produce a definite 
answer for the possible link between weight gain and fructose requires caution 
as many factors have to be taken into account, such as patterns of physical 
activity, patterns of feeding, socioeconomic status, education, etc.  
Studies involving meta-analyses investigating the relationship between body 
weight and consumption of sugar-sweetened beverages also produced 
contradictory results. Meta-analysis involving 88 studies detailed a significant 
positive correlation between weight gain and consumption of sugar-sweetened 
beverages271 whilst an alternative meta-analysis of 12 studies produced no 
correlation of weight gain272.  
Results from intervention studies produced the clearest relationship between 
sugar-sweetened beverages and weight gain. An intervention study involving 
HFCS-sweetened beverages and aspartame-sweetened beverages (an artificial 
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non-calorie, non-saccharide sweetener) concluded in considerable weight gain 
from the HFCS group only273. In a study examining overweight patients 
receiving either sugar-sweetened beverages or non-calorie sweetened 
beverages (observed as a control group) resulted in significant weight gain and 
energy intake from the sugar-sweetened beverage group whilst there was no 
weight change in the control group274. Equally in relation to increased weight 
gain with sugar-sweetened beverages, several studies mainly involving 
adolescents and children with a daily reduction of sugar-sweetened beverages 
resulted in a significant decrease in body weight and energy intake275,276,277.  
 
1.8.8 Fructose and cardiovascular issues 
The Framingham Heart Study investigating the link between sugar-sweetened 
beverage consumption and cardiovascular risk factors was studied in over 
6,000 subjects. The study was able to demonstrate that consumption of one or 
more sugar-sweetened beverage on a daily basis was significantly correlated 
with the occurrence of metabolic syndrome. The prevalence of metabolic 
syndrome for this study was characterised by three or more of the following 
symptoms: waist circumference of females (>35 inches) and males (40 inches), 
high triglyceride, blood pressure, fasting plasma glucose and low levels of 
HDL-cholesterol278. In addition, the study conducted a follow up of subjects 
who at the time of inclusion into the study did not exhibit metabolic syndrome 
but through consumption of one or more sugar-sweetened beverage on a daily 
basis resulted in an increased chance of developing metabolic syndrome278.  
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Studies conducted investigating cardiovascular risk over the past few decades 
KDYH EHHQ DEOH WR LGHQWLI\ VHYHUDO ³XQLTXH PDUNHUV´ DVVRFLDWHG ZLWK
cardiovascular disease. These include certain inflammatory cytokines or 
mediators such as TNF-Į ,/-6 and other various adipokines, who have been 
positively correlated with sucrose intake in association with increased 
cardiovascular risk279. 
1.9 Fructose and Inflammation 
Several studies in experimental animals have been able to demonstrate 
inflammation induced by fructose intake. For example, expression of the 
intracellular adhesion molecule (ICAM)-1, a leukocyte adhesion protein was 
shown to be induced in human aortic endothelial cells from fructose intake280. 
Concentrations of fructose that are normally achieved in daily human ingestion 
of a fructose-supplemented meal (1mM) has shown to rapidly induce both 
mRNA and protein expression of ICAM-1281.  During inflammation, ICAM-1 
is an adhesion molecule that allows the attachment of leukocytes to the 
endothelium and subsequently allows them to transmigrate into peripheral 
tissue. This cellular migration produces modifications of vascular permeability 
causing the transfer of solutes to peripheral tissues282.  
Studies have shown that the expression of MCP-1 in various cell types is also 
induced through fructose intake283,280. MCP-1 is seen as a key cytokine in the 
development of atherosclerosis and is involved in mediating an inflammatory 
response in symptoms related to metabolic syndrome.  
A possible mechanism behind inflammatory markers such as MCP-1, IL-6 
being induced by fructose intake can be explained through various factors such 
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as the development of dyslipidemia, insulin resistance, and excess uptake of 
IDWW\ DFLGV $GLSRVH WLVVXH¶V PDLQ SURSHUW\ LV WR SURFHVV H[FHVV IDWW\ DFLGV
supplemented by the diet and store them in the form of triglycerides. 
Triglycerides are later converted to energy during phases of starvation, the 
capacity for storing fat in adipose tissue is however limited. It is when these 
limits are breached that adipose tissue begins to malfunction in its capacity to 
regulate fat storage and acquire fatty acids which leads to elevated levels of 
fatty acids in circulation284. The increased fat mass from fructose intake leads 
to reduced adiponectin secretion in adipocytes and further stimulates the 
release of TNF-Į DQG ,/-6, due to the removal of any inhibitory controls138. 
These conditions lead to a possible elevated inflammatory response, in 
particular MCP-1, who as previously described, stimulates the recruitment of 
other monocytes and macrophages to the adipocyte of target285.  
 
1.9.1 Fructose and pregnancy 
Studies involving fructose intake during pregnancy have been scarce, though 
early studies using fructose based diets of 78% and 50% during different 
periods of pregnancy have shown changes in maternal 
hypertriglyceridemia286,287. These studies focused on high-fructose diets which 
are not common in human diet as fructose is consumed in lower concentrations 
because it is more widely used as a sweetener. Therefore a lower fructose 
concentration studies may yield different results, this was successfully 
researched in a study using 10% fructose during pregnancy and lactation288, 
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resulting in hyperinsulinemia during the weaning phase for the offspring and 
hyperglycemia and hyperinsulinemia for the mothers288.  
In addition studies examining fructose intake during pregnancy have shown 
that when given with an otherwise nutritionally balanced diet results in raised 
increased insulin and plasma glucose concentrations along with body fat 
content288. The magnitude of effect can however differ between stages of 
gestation with hypoglycaemia and hypertriglyceridemia occurring in early 
gestation compared with hypotriglyceridemia in late gestation287.  
A recent study was able to demonstrate the first findings of sex-specific effects 
on placental and offspring development induced by maternal fructose intake289. 
The study highlighted that fructose intake during pregnancy lead to maternal 
hyperinsulinemia and increased circulating plasma fructose and leptin levels 
exclusive to females. These changes were correlated with a reduction in 
placental weights in females also. No such changes were observes in male 
offspring leading to a sex-specific change during fetal development289.  
These studies underline the need for further investigation in the effects of 
fructose in gestation as molecular techniques along with the understanding of 
adipocyte biology have advanced. Furthermore studies researching the impact 
of fructose intake during pregnancy have not been studied extensively.   
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1.9.2 Main hypothesis and aims 
The introduction chapter above has reviewed the theories and ideas behind 
nutritional manipulation during different periods of gestation and how this 
leads to adipose tissue dysfunction and the possible consequences this has in 
the development of metabolic diseases later in adult life. This thesis will detail 
both large and small animal models, with the sheep study focusing on nutrient 
restriction during early to mid gestation and late gestation followed by 
differing post natal conditions. The small animal study (wistar rats) focuses on 
long term fructose feeding during pregnancy on mothers and their offspring.  
Current research on certain ectopic depots such as subcutaneous, 
retroperitoneal, epididymal, and pericardial adipose tissue is limited in their 
investigation relating to nutrient manipulation during pregnancy. Also with 
very little research focusing on fructose intake during pregnancy and its long 
term effects on the offspring has been studied, this study covers both a nutrient 
restricted environment and a nutrient rich environment during pregnancy, in 
two animal models.  
The principal hypothesis for this thesis was that the presence of nutrient 
manipulation with differing post-natal environments in ovine and rodent 
models, will promote an elevated inflammatory state, arbitrated by 
physiological alterations in ectopic adipose tissue depots.  
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Chapter 2 Ȃ Methods 
2.1 Study Protocols 
 During the first phase of the PhD all laboratory experiments conducted in 
England were performed in the, Academic Division of Child Health at the 
University of Nottingham. All experimental practices followed national 
legislation alongside the ethical approval of the University of Nottingham. For 
all animal research performed the approval of the Home Office was obtained 
and all procedures conducted on animals were subject to the terms of the 
Animal Act.  
The University of Nottingham administered a code of laboratory practice (the 
United Kingdom Control Substances Hazardous to Health, COSHH: SI No 
1657, 1988) under which all laboratory procedures were undertaken. All 
experimental equipment was supplied from Laboratory Supplies with all 
chemicals and reagents unless stated otherwise supplied from Sigma-Aldrich 
Company (Gillingham, UK). For all other suppliers and standard solutions 
consumed in the laboratory, details can be found under the Appendix section.  
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2.1.1 Sheep Study ± early-to-mid gestational nutrient restriction 
During the study all procedures carried out by Professor Michael Symonds and 
Dr. D. Gardner in accordance with the 1986 UK Animals Act of Scientific 
Procedure. Welsh mountain sheep were randomly allocated into one of three 
groups; nutrient restricted (NR-O), lean (L) and obese (O). During the 
experiment the Welsh mountain ewes were housed at the University of 
Nottingham Joint Animal Breeding Unit located at the Sutton Bonington 
Campus. All ewes selected for this experiment were of similar body 
composition and age; they were mated with Texel rams. To determine the fetal 
number present during pregnancy, ewes were scanned via ultrasound at 30 
days of pregnancy, only ewes displaying twins (n=26) during ultrasound were 
further selected to take part in the study. 
Pregnant ewes (n=12) allocated to the NR-O group were each fed 3.5MJ/day 
(50%) from days 30 to 80. Pregnant ewes in both C-O and L groups were 
given normal metabolic energy requirements of 7MJ/day (100%) with 7 sheep 
allocated to the O group (n=7) and 8 sheep to the L group (n=8). The metabolic 
energy requirements were restored back to 100% for all groups after 80 days of 
gestation to 12-13MJ/day. After birth, the offspring from all the groups were 
kept with their mothers for the lactation period of 10 weeks. Mothers were fed 
to requirements for lactation purposes.  
$FFHOHURPHWU\ µ$FWLZDWFK¶ /LQWRn Instrumentation, UK) was used to 
measure the physical activities of all the groups in periods of 30 seconds over a 
24 hour period. This procedure was carried out during the period of the 
stocking environment. The results from this showed a great fourfold rate in 
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physical activity of the L group in comparison to the O group. Other 
observational activities taken during the study was food intake, this 
measurement was taken daily during the hours of 0800 and 0900h (the time of 
animal feeding was also during this period).  
Strict guidelines were followed for the metabolic and nutritional requirements 
of the ewes during pregnancy. The guidelines were based on recommendations 
by the Agricultural and Food Research Council (1980). The daily nutritional 
dietary intake for the mothers was 1kg of loosely chopped hay and 200-500g of 
barley at an increasing fraction dependent on stage of pregnancy and 
nutritional group. All mothers were allowed unrestricted access to water with 
additional minerals and vitamins added into dietary intake throughout the 
pregnancy in accordance to guidelines stated above. 
To promote obesity, O and NR-O groups between the 4th and 12th months after 
birth were given ad libitium concentrated pellets and confined into a space of 
17 animals per 50m2 to restrict physical activity (stocking environment). A 
total of twenty-two sheep were born (10 male and 12 female) from the control 
fed mothers. They were grouped randomly into either Obese or Lean control 
groups as listed above. Groups were assigned regardless of gender as previous 
observations in 1 year old sheep displayed no differences in metabolic 
responses290. Furthermore the maternal nutrient restricted group was also 
comprised of twenty-two newborns with 18 females and 6 male sheep. At the 
time of euthanisation (12 months of age), the sheep were humanely euthanased 
with an electric shock. Tissue samples were collected and snap frozen into 
liquid nitrogen and kept at -80oC , including pericardial adipose tissue, until 
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further analysis was required. Before any tissues were kept for preservation, all 
samples dissected were weighed.  
 
Figure 9.1 ± Sheep Study: Early to mid gestational nutrient restriction model. 
O=Obese group (100% of normal energy requirement given from 0 day of 
gestation, physical activity was restricted from 3 to 12 months during post-
natal period to promote obesity). NR-O = Nutrient restricted-obese group 
(50% of normal energy requirements given from day 30 to 80 during gestation, 
physical activity was restricted from 3 to 12 months during post-natal period 
to promote obesity). L =  Lean group ((100% of normal energy requirement 
given from 0 day of gestation, physical activity was not restricted during post-
natal period)  
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2.2 Sheep study ± late gestational nutrient restriction 
This study had all animal procedures were performed under the guidelines and 
accordance with the UK Animals (Scientific Procedures) Act (1986) and the 
UK Home Office. The animal experimentation procedures were all completed 
by Professor M.E Symonds, Dr D. Gardner and Dr S. Sebert. All experimental 
practices followed national legislation alongside the ethical approval of the 
University of Nottingham. For all animal research performed the approval of 
the Home Office was obtained and all procedures conducted on animals were 
subject to the terms of the Animal Act.  
The University of Nottingham administered a code of laboratory practice (the 
United Kingdom Control Substances Hazardous to Health, COSHH: SI No 
1657, 1988) under which all laboratory procedures were undertaken. 
All experimental equipment was supplied from Laboratory Supplies with all 
chemicals and reagents unless stated otherwise supplied from Sigma-Aldrich 
Company (Gillingham, UK). For all other suppliers and standard solutions 
consumed in the laboratory, details can be found under the Appendix section. 
The experimental procedures performed in this study were performed under 
manufacturer or supplier instructions and where required the experiment was 
optimised by Dr S. Sebert, Dr L. Chan, Dr M. Hyatt, Dr D. Sharkey, Dr P. 
Fainberg, Dr I. Bloor and Mr M. Pope at the Academic Child Health 
department. 
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The Early Nutrition Programming Project 2007 (EARNEST, FP6, #FOOD-
CT-2005-007030) was the second sheep study was conducted. The aim of the 
present study was to determine the extent to which exposure to a nutrient 
restricted diet in late gestation with or without accelerated postnatal growth 
may influence the development of metabolic related issues such as obesity and 
diabetes in early adult life. 
 
The study was designed for experimental nutritional treatments at different 
developmental stages during pregnancy. Dietary and physical activity 
manipulation was performed at 3 different critical stages prenatal, lactation and 
post-natal development stages. During the prenatal stage mothers were fed 
either a high or low calorie diet during the late gestation period (110 days till 
term). The second stage was designed to examine the effect of being reared as 
a twin (i.e. with competition from a sibling for available food) or raised alone. 
The third stage of nutritional experimentation was post-weaning development 
which involved the offspring at 3 months of age being placed in environments 
of low and high physical activity till the age of 17 months of age. The 
environments of low and high activity were in place to nurture the 
development of obese and leans animals, respectively.  
 
The sheep selected for this study were Bluefaced Leicester cross Swaledale 
ewes, a total of forty twin bearing sheep were chosen of similar age and body 
weight. The ewes were bred and housed at the University of Nottingham Joint 
Animal Breeding Unit located at the Sutton Bonington Campus. As previously 
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described above, ewes selected on the basis of being confirmed they are twin 
bearing, this was confirmed via ultrasound (as described above).  
Forty pregnant ewes were divided equally into three groups for the first 
prenatal stage of experimental nutritional development. Ewes were randomly 
selected into either a nutritional restricted group (N), a fed to appetite group 
(A) or fed to requirements group (R). The N group had n=20 sheep, the A 
group had n=10 and the R also had n=10 sheep entering into their last 4-6 
weeks of pregnancy (late gestation). 
 
The nutritional restricted group (N) only received a recommended 60% of the 
normal daily nutritional daily energy requirement (0.46 MJ/kg0.75 body weight 
at 110 dGA and 0.72 MJ/kg body weight at 140 dGA). The fed to appetite 
group (A) received 150% of the recommended normal daily nutritional 
requirements (1.15 MJ/kg0.75 body weight at 110 dGA and 1.80 MJ/kg0.75 body 
weight at 140 dGA). The fed to requirements group (R) received 100% of the 
normal daily nutritional requirements (1.00 MJ/kg0.75 body weight at 110 dGA 
and 1.80 MJ/kg0.75 body weight at 140 dGA). The daily nutritional and energy 
requirements for the pregnant ewes were calculated on guidelines based on the 
ARFC manual (1993) of µ(QHUJ\DQG3URWHLQ5HTXLUHPHQWVRI5XPLQDQWV¶ 
Once the lambs were born for all three group (N: n=40, R: n=20 and A: n=20) 
they were raised during the lactation period as either twins or raised alone by 
their reVSHFWLYH PRWKHUV $OO RIIVSULQJ UDLVHG DV WZLQV ZHUH ODEHOHG DV µ6¶
6WDQGDUGJURZWKRIIVSULQJUDLVHGDORQHE\WKHLUPRWKHUZHUHODEHOHGDVµ$¶
(Accelerated growth with no competition). During the lactation period all 
mothers were fed to requirements.   
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The final stage was post-weaning; at this point the ewes were allocated into 
either a lean environment (L) or an obesogenic environment (O). These 
environments were set up to establish the development of obesity through the 
effect of physical activity. The obesogenic environment had a stocking rate of 
6 sheep per 19m2 whilst the lean environment had a stocking rate of 6 sheep 
per 1125m2. Nutritional requirements during post-weaning were the same for 
all sheep, they were fed high concentrate pellets (12.6 MJ/kg) (Manor Farm 
Feeds, Oakham, UK) and a mixture of hay (8.8 MJ/kg) which constituted to 
100% of the energy requirements recommended from the guidelines as 
instructed above. All sheep had their daily energy intake measured through 
food intake and refusal; all sheep diets also contained a balanced measurement 
of minerals and vitamins with sheep having unrestricted access to water.  
 
 As previously stated in the earlier nutritional intervention  study, physical 
activity of the sheep was measured using AccelHURPHWU\µ$FWLZDWFK¶/LQWRQ
Instrumentation, UK). Accelerometry was used to measure the physical 
activities of all the groups in periods of 30 seconds over a 24 hour period 
during their restricted or unrestricted physical activity stage. Collars placed 
around the necks of the sheep had probes placed over a 24 hour period, these 
probes recorded activity measurements at a rate of 32 times per second. The 
data collected from the probes was uploaded to a dedicated software 
programme (Actigraph, FL, USA) for analysis. The data showed a two to 
three-fold increase of activity between the obesogenic and lean environments.  
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Measurement of body weight were taken on a regular 3 day cycle, body weight 
was also measured at birth, throughout the first month of birth and on a weekly 
basis up to 3 months. All weight measurements were established with the use 
of weighing scales. Once the sheep reached 16 months of age both systolic and 
diastolic blood pressure readings were monitored along with a standard blood 
pressure reading taken whilst the animal was under sedation. 
Other measurements were also taken in conjunction with those listed above; 
they included fat mass, bone density and free fat mass. These measurements 
were taken via dual x-ray absorptiometry (DXA) once the sheep reached 8 
months and then finally at 16 months of age.  
DXA measurements were taken by fasting sheep overnight and later sedated 
with an intramuscular injection (mixture of ketamine and xylazine). The sheep 
were scanned in a Lunar DPX-L bone densitometer (Lunar, Florida, USA) for 
15 minutes each and after this procedure was completed, sheep were retuned 
back to their respective holding pens once fully recovered. For correct 
validation of the DXA scan performed on the sheep, a whole body chemical 
analysis was therefore performed on 14 half carcasses. All carcasses were 
dried and cut into more manageable pieces after the DXA scan. For fat 
percentage and nitrogen content analysis, 250g of dried tissue was 
homogenised for use in the Gerhardt Soxtherm fat analyser (Wolflabs, York, 
UK) and FlashEA1112 nitrogen analyser (Thermo Scientific, Massachusetts, 
USA). 
Nearing the conclusion of the study, all sheep underwent pre-mortem plasma 
sampling with various physiological evaluations. This was conducted 
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approximately 2 weeks prior to the end of the study where all sheep were 
located into individual holding pens for sampling and physiological tests. 
All sheep were humanely euthanized during the hours of 0900h and 1100h via 
electrical stunning followed by exsanguination. During the process of 
euthanisation all major organs and tissues were weighed (including adipose 
depots and glands). Specific tissues were sampled for histological analysis and 
therefore fixed in 10% formalin. The remaining tissues and organs were 
dissected and snap frozen into liquid nitrogen and stored at -80°C for further 
analysis.  
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Figure 10.2 - Sheep study: Late gestational nutrient restriction model. N = 
nutrient restricted (60% of normal energy requirements), R = fed to 
requirements (100% of normal energy requirements), A = fed to appetite 
(150% of normal energy requirements). During lactation, the N group were 
either raised as a singleton (-A = Accelerated growth raised without 
competition) or with a twin (-S =  Standard growth raised as a twin). Post 
weaning phase, all groups were raised in an obesogenic environment.  
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2.3 Canada Studies 
2.3.1 Rat Model 
The laboratory rat of choice for this study was the Wistar Rat (Rattus 
Norvegicus). The Wistar rat is a strain of albino rats which belong to the 
species of Rattus Norvegicus. The Wistar strain was first produced in 1906 at 
the Wistar Institute, Philadelphia, Pa, USA. The strain was the first model 
organism developed for extensive use in a medical research field during a 
period where only Mus musculus was widely used in laboratories. The original 
colony of Wistar rats was developed by Henry Donaldson, Milton J. 
Greenman, and Helen Dean King, currently more than half of all Wistar rats 
used in laboratories have descended from this original strain291. 
 
2.3.2 Fructose fed mothers study 2008 
Female Wistar rats (Charles Rivers, Montreal) were acclimated to the animal 
facility at the University of Alberta for one week with access to rat chow and 
regular drinking water ad libitum. Females were then mated to male Wistar rats 
overnight, with evidence of a vaginal sperm plug the following morning 
confirming gestational day (GD) zero.  At this point, females were randomized 
into one of two treatment groups: regular drinking water (CONTROL, n=17) 
or a 10% fructose solution in regular drinking water (FRUCTOSE, n-18), for 
the duration of the pregnancy.  Females were given standard rat chow (food, 
location) and their particular fluid ad libitum, with 24 hour food and fluid 
ingestion estimated on gestational days 7 and 14. These measurements were 
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made on individual rats, usually while their cage-partner was being mated. The 
animals were weighed on gestational days 0, 12, 19 and 20.  
Whole blood was collected from the tail vein of conscious rats under mild 
restraint before mating and on gestational days 12 and 19.  Blood samples were 
transferred to K2 EDTA microtainer tubes (BD, Franklin Lakes, NJ USA) and 
plasma was recovered following centrifugation (5 minutes, 2400 rpm, 
Eppendorf 5415 Microcentrifuge, Brinkmann Instruments, Westbury, NY) 
before being transferred to clean tubes, frozen and held at -20ºC until assayed 
for metabolites.  On gestational day 20, animals were weighed, humanely 
euthanized and a blood sample was obtained using cardiac puncture. Tissues, 
including the retroperitoneal adipose depots, were dissected, snap frozen into 
liquid nitrogen and held at -80°C until commencement of PCR analysis. Before 
commencement of all treatments and procedures, approval was obtained from 
the Animal Care and Use Committee in the Faculty of Agricultural, Life and 
Environmental Sciences at the University of Alberta, in accordance with 
standards established by the Canadian Council of Animal Care.  
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Figure 11.3 ± Rat Study: Fructose fed mothers model. FR group = Females 
fed 10% fructose water during pregnancy. CNTL group =  females fed water. 
Both groups were fed chow (ad libitum) from the onset of mating. 
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2.3.3 Blood Collection 
For collecting regular blood samples from rats we chose a safe and simple 
method called tail vein sampling. This method is suitable for most strains and 
easy to perform with competent individuals. The number of attempts at 
sampling blood from the rats was minimised to 2 for each rat with alternate 
sides of the rats tail used for needle punctures. The vein we targeted was the 
lateral tail vein, it is best approached approximately 1/3 from the tip of the tail 
and it runs towards to the base of the tail. As it easier to access closer to the 
ERWWRP RI WKH WDLO DV WKH VNLQ WKLFNHQV WRZDUGV WKH UDW¶V ERG\ 7KH YHLQ LV
clearly visible when the tail is rotated either anti-clockwise or clockwise.  
 
The procedure does require the warming of the rats prior to collecting blood 
from the tail. Heating the rat allows the blood vessels to dilate and therefore 
more visible for the injection to be placed, we used heat lamps with constant 
monitoring of the rats body temperature and behaviour. This procedure does 
have side effects on the rats such as dehydration (from salivation) and an 
increased metabolic rate which therefore could have an effect on the data 
collected from blood sampling.  
 
We constantly moved the heat lamp around the housing of the rat to ensure no 
hot spots were produced and a uniform heating environment was achieved. To 
ensure the rat was comfort and restrained at all times we used a sterile cloth 
provided by the University Animal Housing Facility to securely wrap the rat 
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into a cone like shape with the tail end sticking out of the wrap. Alcohol swabs 
were used to clean the rat tail and a sterile 20G ½ needle (Becton Dickinson) 
with a 2ml syringe (Becton Dickinson) was used to puncture the epithelium of 
the tail. Before inserting the needle into the tail, a negative pressure was 
created by pulling back on the plunger slightly, this allowed for a dead space 
for blood to pool before withdrawing more blood from the tail. Once blood 
1ml of blood had been collected, it was quickly transferred into a Microvette 
300 (Sarstedt); this stopped the blood from coagulating during the procedure, 
DOO PLFURYHWWH¶V ZHUH SODFHG RQ ZHW LFH RQFH EORRG KDG EHHQ VXFFHVVIXOO\
transferred from the needle. The rat was then calmly handled and its tail was 
cleaned with a warm swab and placed back into its original housing. This 
procedure is clearly easier to perform in younger rats as they tail skin is not 
harden as those of adult rats.  
 
2.3.4 Cardiac puncture 
During the euthanisation of rats cardiac puncture was performed on all rats. 
Cardiac puncture is a viable technique used to collect a large amount of blood. 
Depending on the age of the rat, 10-15 ml of blood was collected at time of 
euthanistation. All cardiac punctures are carried out before any other procedure 
is performed on the rat as the large amount of blood present in the heart can 
cause difficulties when dissecting tissues and extracting blood later in the 
procedure leads to coagulation of the blood. For all cardiac punctures a 23 ½ 
needle (Becton Dickinson), 5-10ml syringe (Becton Dickinson) and a 
Microvette 500 (Sarstedt) were used for collection. The rat is sprayed with 
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70% Ethanol along the chest and thorax whilst being laid on its back. The 
needle is inserted just below the diaphragm and angled to the left of the middle 
at a 10-30 degree angle. The needle is slowly inserted into the heart where a 
small bleb of blood will begin to collect in the syringe; slowly drawing back on 
the syringe will allow a large collection of blood to occur. All blood collected 
from euthanisation was placed on wet ice whilst other procedures occurred.  
 
2.3.5 Dissection 
 
Each rat underwent the same euthanasia procedure at the end of his or her 
respective term. Rats were given their final weighing at the time of 
euthanisation; euthanisation was carried out through a small dose of isoflurane 
soaked on a cotton ball. The ball was safely enclosed into a glass holding bowl 
with an airtight seal to ensure all flumes stayed in. This bowl was used to 
anaesthetise the rats before cervical dislocation. 
 
Restraining the rat on a flat surface and gripping the base tail with one hand 
and holding the head or the base of the neck with the other hand, and quickly 
pulling backward with the hand gripping the base tail performed cervical 
dislocation. To verify the dislocation was successful, a gap between the neck 
and spinal cord of 2-4mm can be felt. For larger adult rats a metal rod or 
wooden rod instrument were used to separate the spinal cord whilst gripping 
the tail, this required two or more people.  
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Once cervical dislocation was successful, cardiac puncture was performed as 
described above. To access all organs and tissues carefully, the rat was laid on 
its back against a non-slip surface; surgical scissors were used to cut shallowly 
and laterally above the urethral orifice and along both sides of the ribcage till a 
large flap of tissue is present. This flap can then be removed or pinned back to 
allow remove of organs and adipose tissues. Retroperitoneal, epidiymal and 
uterine adipose tissue depots were carefully removed from each subject along 
with vital organs such as the liver, heart, kidneys and pancreas. All tissues and 
organs were directly labelled and snap frozen into liquid nitrogen and later 
transported into an -80oC freezer.  
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2.4 ± Effect of Long Term Fructose Consumption 
All rats were housed within the University of Alberta, Animal Housing Facility 
and were Wistar rats (Charles River, Montreal). In total 8 female rats were 
supplied along with 4 male rats that were given 1 week to acclimatise to their 
new conditions and lower stress levels from the travel prior. Rats were caged 
in a Dynamic Containment Cage (DCC), which automatically monitored air 
pressure, air flow, filtering of allergens and carcinogenic and violate chemical 
agents, all bedding and cage washing occurred 3 times a week. They were all 
fed a chow diet (Purina 5001, USA) and given regular drinking water during 
their period of acclimatision. Female rats were then mated with males 
overnight; positive pregnancy was detected by the presence of a successful 
vagina plug or through the presence of sperm.  
The presence of sperm was carefully observed by inserting a plastic soft 
syringe (BD, Franklin Lakes, NJ USA LQWR WKH IHPDOH UDW¶V YDJLQD DQG
pipetting 0.1% saline solution (Fisher Scientific, USA) in and out. The next 
stage was viewing the saline solution under an optical microscope to view the 
presence of sperm. Sperm is positively identified as a small ball with a hooked 
tail protruding out.  
Once the female rat was identified as being pregnant, this was designated  as 
day zero, after which they  were randomly assigned into one of two treatment 
groups; regular drinking water (H2O CHOW, n=4) or a 10% fructose solution 
in regular drinking water (FR CHOW, n=4), for the duration of the pregnancy 
and weaning period. Both groups consumed standard chow and had free access 
to their food and respective drinking water throughout.  
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Females were weighed pre- and post-mating and during gestational days 0, 12, 
19 and 20. Food and water intake was estimated on gestational days 7 and 14 
on each individual rats, usually while their cage-partner was being mated.  
Once female rats reached day 19 of their pregnancy, they were caged 
separately to allow for a stress free birth and avoidance of the other female 
cannibalizing the pups once born. Whole blood was collected from the tail vein 
of conscious rats under mild restraint before mating and on gestational days 12 
and 19.  Blood samples were collected in EDTA tubes (BD, Franklin Lakes, 
NJ USA), centrifuged, the plasma was then recovered and stored at -20°C for 
later analysis of glucose and insulin concentrations.   
Females were housed in separate cages two days prior to parturition and were 
monitored twice daily to accurately count the amount of pups born to each 
mother. Due to the long term duration of the study, offspring numbers could 
not be predicted, as mothers could give birth from 1 to 12 pups. Offspring pups 
at 3 months; H2O CHOW n=9, FR CHOW n=7, at 6 months; H2O CHOW 
n=8, FR CHOW n=7, at 9 months; H2O CHOW n=7, FR CHOW n=6. 
Pups stayed with their mothers for 3 weeks (weaning phase) before being 
housed in pairs of the same sex away from their mother. Mothers were 
humanely euthanized after each of their respective weaning phases was 
completed. Pups that were born as runts were also humanely euthansed at the 
time of birth.  
Pups were randomly selected into 3, 6 and 9 month old groups, mothers that 
gave birth first had their pups selected for the 9 month group, followed by 6 
months and 3 months, this allowed for correct time management. All pups 
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were fed chow and regular drinking water throughout after weaning. Once 
each rat was of an adult size, it was decided whether they could co-habit the 
same cage if their size was becoming restrictive. All rats were weighed 
weekly, with monthly blood collection.  
On their final day rats were weighed, humanely euthanized and a blood sample 
was obtained using cardiac puncture.  Tissues, including the retroperitoneal 
adipose depots, were expediently dissected and immediately frozen in liquid 
nitrogen.  Tissues were stored at -80oC for further biological analysis. All 
experimental procedures and protocols were approved by the Animal Care and 
Use Committee in the Faculty of Agricultural, Life and Environmental 
Sciences at the University of Alberta, in accordance standards established by 
the Canadian Council of Animal Care.  
 
Figure 12.4 ± Rat Study: Effect of long term fructose consumption model. FR 
CHOW group were fed 10% fructose water during gestation and weaning 
while H20 CHOW group were fed water during gestation and weaning. 
Offspring for both groups fed only water and chow during post-natal period. 
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2.5 Standard PCR 
Polymerase chain reaction was first published in 1983 when Kary Mullis 
whilst working for Cetus invented a process which he called PCR, this 
technique went on to become the most widely used process for DNA 
amplification and earning Kary Mullis a Nobel Prize in 1993 (Chemistry)292. 
PCR bases itself on two oligonucleotide primers (that contain 5' and 3' 
sequences 20-30 nucleotides long); these primers flank the target DNA. 
Deoxynucleoside triphosphates (dNTPs) are also required as part of the 
process, magnesium chloride (MgCl2) is needed for the incorporation of dNTP, 
the final ingredient is the polymerase, Taq polymerase is the most commonly 
used due to high amplification ability in low concentrations293.  
PCR is broken up into three basic steps consisting of a denaturation of the 
DNA (90-94°C) followed by annealing of the primers (45-70°C) and finally 
extension by the polymerase (70-75°C). This cycle occurs 30-40 times to 
produce a sufficient yield of PCR products. Each cycle of PCR produces an 
exponential increase of DNA; common formula attributed to PCR is 2n, with n 
being the number of cycles assigned in the procedure294. 
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2.5.1 Hot Start PCR Procedure 
The programme used to synthesise DNA using standard PCR involves a three 
step process: 
Time Temperature Process 
4 minutes 105oC Initiation 
15 minutes 96oC Activation 
 
Time Temperature Process 
30 seconds 94oC Denaturation 
30 seconds 60oC Annealing 
60 seconds 72oC Extension 
7 minutes 72oC Extension 
 
Time Temperature Process 
Infinite 8oC Hold 
 
Standard PCR reactions were set up to a final volume of 20µl. The reaction 
involves 1µl of cDNA sample, 1µl of reverse primer (18s), 1µl of forward 
primer (18s), 10µl of PCR master mix (ABgene Ltd., Epson, UK) and 7µl of 
RNA free water (Ambion, Applied Biosystems, Warrington, UK). 
Standard PCR was used to amplify the adiponectin gene. In order to identify 
the gene product was adiponectin, Qiagen gel extraction kit (Qiagen Co., West 
6XVVH[8. ZDV SHUIRUPHG WR PDQXIDFWXUHU¶V LQVWUXFWLRQV 7KH H[WUDFWHG JHO
sample was sequenced and analysed through software called Chromas Lite 
(http://www.technelyium.com.au).  
  
30-45 Cycles 
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2.5.2 Gel Electrophoresis & DNA Extraction 
Products of PCR are analysed and identified by running the products through a 
gel matrix (polyacrylamide or agarose gel). The products move across the gel 
through electrophoresis. Electrophoresis allows for DNA fragments to move 
from a negative to a positive electrode, smaller fragments migrate quicker and 
larger fragments take longer to move, this allows for identification of PCR 
products from their fragment size295. 
For visualisation of the DNA fragment, it is essential to add an intercalating 
DNA dye to the gel before setting, most commonly used is ethidium bromide. 
Ethidium bromide emits fluorescence when exposed under ultra-violet light, 
therefore any DNA fragments present within the gel matrix is shown with a 
fluorescent band.  
To identify the correct size of each positive band present in the gel matrix, a 
DNA ladder is used to confirm the size of the bands. DNA ladders separate at 
regular base pair sizes to allow for unknown band sizes to be correctly 
calculated.  
Extraction of DNA fragments from the gel for further procedures can be safely 
achieved through the use of commercially available kits. The Qiagen QIAquick 
Spin kit uses DNA affinity columns and several washing steps to remove any 
contamination from the extraction. DNA suspended in the membranes columns 
can be eluted with the elution buffer supplied or nuclease-free water.  
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2.5.3 Gel Electrophoresis & DNA Extraction Procedure 
Gels were constituted to 2% of agarose gel grade (Invitrogen Life 
Technologies) by dissolving 2g of agarose gel powder into 50ml of 1xTAE 
buffer (diluted from a stock of 50x tris(hydroxymethyl)aminomethane base, 
EDTA buffer and acetic acid (Fisher Scientific). This solution was heated till 
clear and mixed with 5Pl of 10mg/ml ethidium bromide and then poured into a 
cast for setting. All PCR products were mixed with glycerol blue dye and 
placed next to a DNA ladder (100bp Blue eXtendec, Bioron, Ludwigshafen, 
Germany) in the cast gel. The gel was then run for ~1 hour at 100v using a 
BioRad PowerPac Basic (Hertfordshire, U.K). The gels were visualised using a 
UV trans-illuminator CCD camera (Fuji Film luminescent image analyser 
LAS-1000 v1.01). The bands that were emitting fluorescence were extracted 
out of the gel and purified using the QIAquick gel extraction kit (Qiagen). 
Gel bands that were extracted were weighed and dissolved into 2.0ml 
eppendorf tubes in 300Pl of GQ buffer per 100Pg of gel band extracted for 10 
minutes at 50oC. Once all the gel was dissolved, 100Pl of isopropanol (Fisher 
Scientific) was added per 100Pg of gel extracted and the mixture was vortexed. 
The solution was pipetted to a QIAquick spin column and centrifuged for 1 
minute at 10,000g, any filtrate solution carried over was discarded. A further 
500Pl of GQ was added to the column and centrifuged for 1 minute at 10,000g, 
this was to remove any leftover agarose, and all filtrate was discarded once 
again.  
700µl of PE buffer treated with ethanol was added to the column and left at 
room temperature for 5 minutes and then centrifuged for 1 minute at 10,000g 
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and any filtrate was discarded. The column was then transferred to a new 2ml 
eppendorf collection tube and centrifuged for 1 minute at 10,000g to allow for 
any residual PE buffer to be removed from the membrane. The column was 
then moved to a 1.5ml eppendorf tube, with the final step being the elution of 
DNA by pipetting 30µl of EB buffer (elution buffer) onto the column 
membrane and centrifuging for 1 minute at 10,000g.  
To calculate the concentration and authenticity of the DNA products extracted, 
they were analysed by using the NanoDrop®ND-1000. To verify the 
authenticity of the DNA products from new primers they were sent to the 
University of NottingKDP¶V &HQWUH IRU *HQHWLFV DQG *HQRPLFV 4XHHQ¶V
Medical Centre, Nottingham, UK) for DNA sequencing and results were cross-
referenced against the NCBI website online (National Centre for 
Biotechnology Information). All final DNA amplicons were aliquoted down to 
a diluted concentration of 1ng/µl and kept at -20oC until further use.  
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2.5.4 RNA extraction 
RNA extraction (Total Ribonucleic acid ± RNA) is a vital step in performing 
various molecular techniques such as RT-PCR, Q-PCR and Real-Time PCR. 
All PCR techniques require sensitive and non-contaminated samples therefore 
all steps before, during and after RNA extraction and purification must be 
performed vigilantly.  
RNA extraction from adipose tissue in all my studies were completed in the 
same principle method as described here. The technique used was a modified 
procedure of the one-step acid guanidinium thiocyanate-phenol-chloroform 
(TRI-Reagent solution ± Invitrogen) RNA isolation method via the use of an 
RNA extraction kit (Qiagen)296,297. Homogenisation of the tissue sample in the 
phenol-guanidinium thiocyanate monophasic solution causes inhibition and 
denaturing of RNase activity297. 
With the subsequent addition of chloroform into the solution leads to a creation 
of three phase layers. The organic phase situated at the bottom contains 
dissolved proteins and lipids. The interphase which is a thin layer in the middle 
contains dissolved DNA and the clear aqueous phase at the top is entirely 
constituted of dissolved RNA296,297. The aqueous phase is separated from the 
solution and further treated with ethanol; this washing treatment allows the 
51$ ȝJ to correctly bind to the membrane in the RNA centrifuge 
FROXPQ'HSHQGLQJRQ WKHPDQXIDFWXUHU¶V LQVWUXFWLRQVYDULRXVZDVKLQJ VWHSs 
are performed with guanidium salt-based buffers, these washing steps 
eliminates possible contaminants carried over from the phenol-guanidinium 
thiocyanate monophasic solution. The final wash is performed with nuclease-
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free water. Once the RNA is extracted, it has to be quantified to calculate the 
concentration of the sample by NanoDrop®ND-1000 (Nanodrop 
Technologies, Wilmington, USA) spectrophotometer to measure the 
absorbance of light at 260/280nm for RNA. Ultimately 260/280 ratio not only 
gives estimation for the RNA concentration but also purity of the RNA 
sample298,299. The ratio that is given for a pure RNA sample is between 1.8 and 
2.0299.  Before any sample was quantified on the Nanodrop, DNase I (Qiagen 
Co., West Sussex, UK) treatment was performed on each sample after RNA 
H[WUDFWLRQ'1DVH , WUHDWPHQWZDV FDUULHGRXW WRPDQXIDFWXUHU¶V LQVWUXFWLRQV
DNase works by cleaving to DNA and disrupting the phosphodiester bonds. 
This extra step was performed to eliminate any DNA left over from the final 
washes; this treatment also improves the final 260/280 ratio.  
 
2.5.5 RNA Extraction Procedure 
Samples from all studies based in Nottingham, U.K and Alberta, Canada were 
extracted using the RNeasy Plus Mini Kit (Qiagen, West Sussex, UK) with Tri 
Reagent (Sigma Chemical Co., Poole, UK). The procedure in Nottingham used 
100mg-150mg/ml of pericardial, subcutaneous or omental adipose tissue from 
each sample. For the procedure in Alberta, retroperitoneal and epididymal fat 
depots in rats were used (same tissue mg/ml as Nottingham) for each sample. 
Following PDQXIDFWXUHU¶V LQVWUXFWLRQV WKH SURFHVV XVHG PJPO of Tri 
Reagent for each sample homogenised with the Dipso-Mix (Medic Tools, 
Zurich, Switzerland) in Nottingham and the MP- FastPrep®-24 (MP 
Biomedicals LLC, OH, United States) in Alberta.  
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2.5.6 Nottingham Study 
Pericardial, subcutaneous and omental adipose tissue samples were 
homogenised at 3000rpm with the Dispo-Mix (Medic Tools, Zurich, 
Switzerland) homogeniser and then placed into a water bath for 2 minutes at a 
constant temperature of 37oC, this allows for lipid breakdown. Following this, 
the sample is centrifuged at 12,000g for 10 minutes at room temperature, 
allowing for any insoluble material to be removed. The supernatant following 
centrifugation is transferred to a fresh 2.0ml eppendorf tube. 0.2ml of 
chloroform (Fisher Scientific, Leicestershire, UK) was added to each sample; 
vortexed till the solution was thoroughly mixed and then left to stand at room 
temperature for 15 minutes. The mixture is then centrifuged at 12,000g for 15 
minutes at 4oC, following this centrifugation, the colourless upper aqueous 
solution which contains dissolved RNA is transferred to a fresh tube, this 
process is known as phase separation. Approximately 0.6ml of aqueous is 
pipetted into a gDNA Eliminator spin column (genomic deoxyribonucleic 
acid), centrifuged at 8,000g for 30 seconds at room temperature. The flow 
through from is saved and the column is discarded. The flow through is 
pipetted into a new 1.5ml eppendorf tube and 0.7ml of 70% ethanol added and 
vortexed for 15 seconds. 
The solution is then transferred into a RNeasy spin column and placed in a 2ml 
eppendorf collection tube, centrifuged at 8,000g for 15 seconds at room 
temperature. The flow through is discarded as all the RNA is engaged within 
the column membrane. 0.7ml of buffer RW1 is added to the column and 
centrifuged at 8,000g for 15 seconds at room temperature with the flow 
through being discarded. 0.5ml of buffer RPE is then added to the column and 
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centrifuged at 8,000g for 2 minutes at room temperature with the flow through 
being discarded. The column is then transferred to a clean 2ml eppendorf 
collection tube and centrifuged at 8,000g for 1 minute at room temperature 
with the flow through being discarded. This dry spin allows for any leftover 
buffer to be collected and removed from any downstream RNA applications. 
The column is finally moved to a sterile 1.5ml eppendorf collection tube for a 
final elution step with 30µl of RNAse free-water was added to the centre of the 
column and centrifuged at 8,000g for 1 minute. The final elution was repeated 
by taking the RNA and pippetting it back into the column and centrifuging 
again under the same conditions.  
For accurate measurements of RNA yield, the Nanodrop®ND-1000 (Nanodrop 
Technologies, Wilmington, USA) spectrophotometer was used. To avoid 
degradation of RNA299, the RNA stock solution was aliquoted into 10µl 
batches and further diluted into 1µ/µl batches for each sample. This allowed 
for efficient and simple use when conducting RT-PCR processing. All RNA 
samples were stored in a -80oC freezer.  
 
2.5.7 Alberta Study 
All the procedures outlined above were carried out to the same specification in 
Alberta, Canada, apart from the homogenisation. The MP- FastPrep®-24 (MP 
Biomedicals LLC, OH, United States) was used for homogenizing and lysing 
of all tissue instead of the Dipso-Mix (Medic Tools, Zurich, Switzerland).  
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2.6 Real Time PCR (real-time Polymerase Chain Reaction) 
With the introduction of Real-time PCR, many problems such as 
contamination are reduced. The time taken by Real-time PCR is considerably 
shortened when compared to block based PCR as Real-time PCR quantifies 
reaction products from each sample of every cycle300. 
Contamination is reduced as PCR tubes containing amplicons are not opened 
as gel electrophoresis is not required. Real-Time PCR generates quantitative 
results allowing standard curve generation, copy number calculation with a 
broad 107 fold range; all performed automatically300.  
In these studies, SYBR® Green was used. This is a fluorogenic dye which 
displays slight fluorescence whilst in solution but releases an intense 
fluorescent signal upon binding to double stranded DNA (including non-
specific amplification and primer-dimer complex. SYBR® Green is the 
cheaper alternative to the other chemistries but requires extensive optimisation.  
As fluorescence technology is used to detect and quantify the samples, the 
signal is in proportion to the amount of template present. As each cycle in the 
reaction occurs, the signal is exponentially increased. The signal becomes 
detectable once it crosses a set certain baseline, the cycle number at which the 
signal crosses the baseline is called the cycle threshold/crossing point (Ct/Cp). 
The software that analyses the Real-Time quantification calculations is 
Quansoft (Techne Inc., Burlington, USA).  
Currently, there are two main methods used to calculate the results from Real-
Time PCR; the comparative threshold method - Ct
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curve method; Quansoft uses a Ct method to calculate Real-Time PCR301. The 
slope that is produced by this method requires a range from -3.4 to -3.6 to 
prove a valid efficiency of 90%-100%. The slope is calculated using this 
formula: 
Eff = 10(-1/slope) ± 1 
Eff (amplification efficiency) is calculated by working out a standard curve 
based on Ct cycle values against the log of cDNA concentrations301.  
cDNA concentration calculations are performed during PCR reactions, as the 
PCR reactions exponentially increase the concentration of the reaction, the 
PCR data produces a sigmoid curve. The sigmoid curve exhibits a plateau after 
a certain concentration, the linear phase that is created allows for Ct values of 
each sample to be calculated. The calculation of DNA concentration in each 
sample is worked out by equating the standard curve of known standard 
concentrations.  
The standard curve is calculated through dilutions performed from known 
standard concentrations of the DNA. The DNA concentration is then diluted to 
1ng/µl. In order to perform a standard curve, further serial dilutions are made 
from 1X10-1 to 1x10-9.   
Analysis of Cp values also requires coefficient variance of each sample to be 
calculated. The coefficient variance allows us to evaluate the measure of 
precision from a set of Cp values.  All graphs and results are expressed in CEL 
(Comparative expression level). The CEL equation is as follows: 
127 
 
ǻ&p = (Cp of target gene ± Cp of 18s) 
Cp values were analysed for significance by performing a Kolmogorov-
Smirnov test to calculate whether the data was normally distributed. If the data 
is normally distributed, parametric tests such as a t-test can be carried out, non-
normally distributed data requires non-parametric tests such as Mann-Whitney.  
This method of calculation allows for quantification of gene expression by 
using a reference gene to compare against. A reference gene is often referred to 
a gene that has the ability to be expressed relatively highly across all cells in 
various conditions, this allows for the possibility of the target tissue to be 
normalised. This calculation is based on the assumption that the efficiency of 
the PCR experiment is 100%, therefore each cDNA strand is replicated 
perfectly for each cycle. Efficiency is verified through evaluating the standard 
curve produced, accepted ranges of efficiency are generally between 90-
105%302. 
With fluorescent PCR chemistries such as SYBR green, issues often occur 
with primer dimer formation. These formations are non-specific dye-DNA 
complexes which SYBR green also binds to along with double stranded DNA 
and emit fluorescence. Therefore it is essential to evaluate the PCR product 
qualitatively to confirm the actual sequence targeted has been amplified. This 
is verified by adding an additional step to the PCR procedure, at the end of the 
final cycle, a melt-curve is performed. The melt-curve allows for the recording 
of temperature at integral stages of increasing oC, as the temperature increases 
it leads to the denaturing of the PCR product, this in turn leads decreased 
fluorescent signal. The PCR product melting curve should produce a specific 
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peak at a certain temperature depending on the base and length of the 
sequence. A melt curve analysis which shows one temperature peak means no 
primer dimer or possible containment from DNA-complexes were present in 
the experiment.  
 
Figure 13.5 - Real-Time PCR 18s samples using the StepOne Plus Real Time 
PCR SysteP 7\SLFDO µVLJPRLGDO¶ FXUYH LQ 4-PCR, the fluorescence signal 
crosses the threshold and increases exponentially until it reaches a plateau.  
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Figure 14.6 - Melting curve using the StepOne Plus Real Time PCR System. A 
typical melt curve from Q-PCR, the single peak indicates the specificity of 
product amplified. 
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2.6.1 Primer Design  
Nottingham Study 
3ULPHUV IRU 71)Į OHSWLQ DQG LQVXOLQ UHFHSWRU ZHUH GHVLJQHG XVLQJ %HDFRQ
Designer 4.0 software (Premier Biosoft, Palo Alto, USA). Primers designed for 
adiponectin were created using Primer3 (Whitehead Institute for Biomedical 
Research, USA).   
In designing primers, the creation of primer dimers can restrict the efficiency 
of the PCR reaction.  By using such specific programmes, the probability of 
primer dimer formation is greatly decreased. Primers were designed on the 
mRNA sheep, pig and cow sequences obtained from the NCBI (National 
Centre for Biotechnology Information) online database. Primers designed had 
introns spliced out and extron boundaries crossed, this allows for a greater 
specificity to the gene of interest and avoids amplification of gDNA (genomic 
DNA). 
Along with minimal formation of primer dimer, primer design software also 
allows the user to determine the size of the amplicon. The optimum melting 
temperature for primers when used in a Real Time assay is approximately 
60oC. The final condition that should be taken into consideration is C 
(cytosine) and G (guanine) content, the C and G optimum percentage per 
primer is 50% but percentages from 30 ± 80% are acceptable.  
Primers used in my project met the criteria described above. Leptin, IL-6, 
TNFĮDQG ,QVXOLQ UHFHSWRUSULPHUVZHUe designed by Dr. Melanie Hyatt, 18s 
primers were designed by Dr. Sylvain Sebert, MCP-1; TRL-4 primers were 
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designed by Dr. Don Sharkey, all other primers used in this study were 
designed by myself. All primers were acquired from Sigma-Genosys (Sigma 
Chemical Co., St. Louis, USA) and were diluted to a 1:40 dilution from a stock 
VROXWLRQ RI ȝPROO XVLQJ RI 51$VH IUHH ZDWHU $PELRQ $SSOLHG
biosystems, Warrington, UK). 
 
Alberta Study 
All primers designed for the Alberta study were based on mRNA from Rattus 
Norvegicus sequences obtained from the NCBI (National Centre for 
Biotechnology Information) online database.  All primers were acquired from 
Sigma-Genosys (Sigma Chemical Co., St. Louis, USA) and were diluted to a 
GLOXWLRQ IURPD VWRFN VROXWLRQRIȝPROO XVLQJRI51$VH IUHH ZDWHU
(Ambion, Applied biosystems, Warrington, UK) as previously prepared in 
Nottingham study.  
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Table 2: List of primers used in the rat studies 
Name Sequence Accession Number 
18s Forward CGCGGTTCTATTTTGTTGGT NM_001142758 
18s Reverse AGTCGCCATCGTTTATGGTC 
FTO Forward GCTGTGCCGTTGTGCATGGC NM_001039713.1 
FTO Reverse GCCACGGCTGACCTGTCCAC 
Adiponectin Forward AATCCTGCCCAGTCATGAAG NM_144744.2 
Adiponectin Reverse TCTCCAGGAGTGCCATCTCT 
Leptin Forward GAGACCTCCTCCATCTGCTG NM_013076.3 
Leptin Reverse CTCAGCATTCAGGGCTAAGG 
NF-kB Forward AGGCCATTGAAGTGATCCAG XM_342346.4 
NF-kB Reverse CAGTGAGGGACTCCGAGAAG 
IL-18 Forward AATGCGGAGCATAAATGACC NM_019165.1 
IL-18 Reverse TAGGGTCACAGCCAGTCCTC 
TNF-Alpha Forward ACTCCCAGAAAAGCAAGCAA NM_012675.3 
TNF-Alpha Reverse CGAGCAGGAATGAGAAGAGG 
MCP-1 Forward ATGCAGTTAATGCCCCACTC NM_031530.1 
MCP-1 Reverse TTCCTTATTGGGGTCAGCAC 
GRP78 Forward TGCAGCAGGACATCAAGTTC NM_013083.2 
GRP78 Reverse CTGCATGGGTGACCTTCTTT 
IL-6 Forward CCGGAGAGGAGACTTCACAG NM_012589.1 
IL-6 Reverse ACAGTGCATCATCGCTGTTC 
CHOP Forward CCAGCAGAGGTCACAAGCAC  
CHOP Reverse CGCACTGACCACTCTGTTTC  
TLR4 Forward AGCTTTGGTCAGTTGGCTCT  
TLR4 Reverse CAGGATGACACCATTGAAGC  
IL-1B Forward CACCTCTCAAGCAGAGCACAG  
IL-1B Reverse GGGTTCCATGGTGAAGTCAAC  
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2.6.2 Reverse Transcription (RT-PCR) 
Reverse transcription is used to produce cDNA (complimentary DNA); that 
can then be used in Real-Time PCR to analyse the expression of selected 
genes. In order to produce cDNA, single stranded RNA is reverse transcribed 
to produce double stranded cDNA with the use of a reverse transcriptase 
enzyme and DNA primers.  
RT-PCR process works by random DNA primers annealing to the mRNA 
template to produce a complimentary sequence of the template mRNA with 
elongation and transcription occurring through a reverse transcriptase enzyme, 
this produces cDNA allowing for future PCR amplification. 
 
Figure 15.7 - RT-PCR process step by step. A random primer binds to single 
stranded mRNA and the sequence is elongated by a transcriptase enzyme to 
create cDNA. Template of double stranded cDNA is then amplified by classic 
PCR.  
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2.6.3 Reverse Transcription Procedure 
Reverse transcription is performed using Superscript II Reverse Transcriptase 
(Invitrogen Life Tecnhnologies, Paisley, UK). The programme used to perform 
the experiment is listed below. 
Steps Conditions 
Dilution Dilution of  samples to obtain a 
concentration from 1 to 5 µg/µl in 
RNASE free water 
Elongation Mix 1µl of P(d)N6 ( random primers from 
Amersham pharmacia) 
8µl of DEPC (diethylpyrocarbonate) 
water 
1µl of RNA from a stock solution 
volume of 1µg/1µl ± Total volume of 
10µl 
RNA elongation and random 
primer hybridization 
Incubation 10 minutes at 65oC in a 
thermocycler 
RNA elongation samples to be kept on ice 
RT master mix preparation DTT (Dithiothreitol) - 2µl 
5X Buffer - 4µl 
DnTP (Deoxyribonucleotide 
triphosphate) -2µl 
RNAse free water ± 2.5µl 
Superscript - 2µl 
10µl of master mix to be added to each 
RNA elongation sample 
Incubation 45 minutes at 42oC in thermocycler 
Samples are stored in a -20oC freezer 
 
Before the samples can be run with their gene of interest, the reverse 
transcriptase samples must be run along with their negative controls to check 
for possible genomic DNA expression. Negative samples are prepared as listed 
above but without Superscript II Reverse Transcriptase. All real time PCR 
experiments that were performed using cDNA samples were diluted from their 
concentrations obtained from reverse transcriptase to a 1:10 dilution.  
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2.6.4 Real-Time PCR Procedure 
Serial dilutions from 1 x 10-1 to 1 x 10-9 were made from the target cDNA 
template (1ng/µl) gene as a set of standards to be run for each Real-Time PCR 
experiment to calculate the efficiency of each experiment. The unknown 
samples were run alongside the standards for each experiment and gene 
analysis was calculated by using the housekeeping gene ribosomal 18s to 
normalise all the unknown cDNA samples present. 
Real Time PCR assays were carried out using the programme listed below: 
Step Temperature Time 
Denaturation 94oC 15 minutes 
 
Denaturation 94oC 10 seconds 
Annealing 60oC 30 seconds 
 
Melt Curve 75oC ± 90oC - 
Final Hold 4oC - 
 
All real time PCR assays were carried out using a total of 15µ for each sample 
reaction. The samples included 1.5µl each of forward and reverse primers, 
4.5µl of cDNA and 7.5µl of SYBR Green (Qiagen Co., West Sussex, UK). 
Each sample was run in duplicate on each plate of 96 wells. Controls included 
no template and no primer samples, also in duplicate. After each plate was 
successfully pipetted, plates were sealed using an Abgene plate sealer with 
individual thermal seals (Alpa Laboratories, Hampshire, UK) heat sealed onto 
each plate. Plates were then placed into the selected Real-Time PCR machine 
Quantica Q-PCR instrument (Techne) or the StepOne Plus Real Time PCR 
System (Applied Biosystems). 
45 Cycles 
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Real time PCR data analysis was carried out using Microsoft Excel (Microsoft 
Co., Redmond, USA), SPSS (SSPS Inc., Chicago, USA), Prism and Quansoft. 
Analysis of data from Quansoft can be easily exported into Microsoft Excel; 
Quansoft refers to Ct values as Cp (crossing points) values. 
 
2.7 Histology 
Histology is known as the study of sectioned tissues through anatomical 
microscopy which facilitates visualisation of the cellular structure and 
composition, further enhanced through numerous histological stains. To 
preserve degradation of the tissue, it is essential to chemically fix the whole 
tissue before any histological procedure can proceed. Chemically fixing a 
tissue is performed by firstly placing it in formaldehyde, this process 
permanently cross-links the proteins in the tissue allowing preservation of the 
tissue303. For successful fixing, it is vital for the tissue to be encased within a 
holding matrix to help maintain its cellular and structural composition, this 
also aids in sectioning the tissue for microscopic analysis. The holding matrix 
in which the tissue is held must have certain properties that allow the fixing 
chemicals to flood and saturate the tissue and allow the tissue to solidify 
without damaging or disturbing the structure. 
The most commonly used holding matrix for microscopy in histology is 
paraffin wax. Paraffin has hydrophobic properties which make it immiscible in 
water and therefore the tissue must undergo a dehydration step prior to 
embedding in the paraffin wax. The dehydration step is performed by 
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submerging the tissue in xylene (hydrophobic clearing chemical) and ethanol 
(dehydrating agent), the tissue is then ready to be sliced using a microtome. 
 
2.7.1 Histological tissue processing   
Subcutaneous and omental adipose tissues from each animal based in 
Nottingham and retroperitoneal and epididymal adipose tissues from each rat 
situated at Alberta were treated with 10% formalin (10% v/v formaldehyde in 
0.9 w/v sodium chloride/distilled water (Fisher Scientific) saline solution) for 
approximately 2-4 hours. Sections from each tissue sample were placed onto a 
Histosette II (Simport, Quebec, Canada) 30mm x 27mm x 5mm cassette and 
undergoes 6 steps of ethanol dehydration proceeded by 3 steps of ethanol-
clearing with xylene (Fisher Scientific). The next three steps involved 
submerging the tissue sample in paraffin wax at 60oC and leaving to solidify 
the tissue sample overnight, using the Shandon Excelsior tissue wax processer 
(Fisher Scientific) 
Sectioning the tissues was achieved by slicing each sample using a sledge 
microtome (Anglia Scientific, Cambridge, UK) at 5µm, 10 slides for each 
sample. The sectioned tissue was washed in 70% ethanol before being floated 
in water at 45oC, this allows for the sectioned wax tissue to stretch out via 
surface tension. The floating tissue sections were transferred onto Superfrost 
Plus slides (Menzel-Glaser Inc, Braunchweig, Germany) and left to dry on a 
heat rack for 15 minutes and placed into a drying oven for 24 hours at 37oC. 
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2.7.2 Haematoxylin and eosin staining 
Harris haematoxylin (also known as hematoxylin, C.I. 75290 or Natural Black 
1) is aluminium based salt dye used for staining tissue. In its oxidised form, 
haematoxylin forms haematein. Haematein produces coloured complexes with 
specific metal ions such as aluminium and iron salts, therefore Harris 
haematoxylin is a suitable dye for staining tissues to visualise cellular nuclei. 
Harris haematoxylin is a regressive dye and decreases in intensity and its 
distinct blue colour is washed off by a weak alkali304,305.  
A contrasting dye used to visualise tissue architecture neighbouring the nuclei 
is Eosin Yellowish. Eosin Yellowish is an acidic based dye (defined as 
eosinophilic), known for binding to basic structures such as muscle fibres, 
cytoplasm, and collagen304. Eosinophilic formations are differentiated and 
visualised through various washes with water. 
H&E (Haematoxylin and eosin) staining is a common method widely used in 
histology for examining structures of adipose tissue.  The presence of crown-
like structures and damage to adipocyte structure can be observed and 
measured through quantitative analysis210,167. 
 
2.7.3 H&E staining procedure 
A blinding process was implemented by assigning one slide per sample used 
via a random identifier; these slides were kept on a separate slide rack from 
other samples to ensure no bias. Slides underwent dewaxing by submersion 
into two xylene containers for 3 minutes each and then a further two stages of 
139 
 
submersion into 100% ethanol containers for rehydration followed by one 
stage of 70% ethanol submersion and a final stage of washing with distilled 
water.  
The slides were firstly stained in Harris haematoxylin container (VWR Ltd, 
Lutterworth, UK) for approximately 5 minutes and washed with tap water to 
remove any excess dye. To implement the regression phase of haematoxylin 
staining, the slides were submerged into an acid-alcohol mixture (1% 
concentration hydrochloric acid in 70% ethanol) for 5 seconds and then 
ZDVKHG ZLWK WDS ZDWHU DQG IXUWKHU VXEPHUJHG IRU  PLQXWH LQ D 6FRWW¶V WDS
water container (0.2% sodium bicarbonate and 20% magnesium sulphate 
distilled water solution). Slides were then rinsed in tap water and placed into a 
1% Eosin Yellowish stain trough (VWR Ltd, Lutterworth, UK) for 3 minutes 
and then rinsed in tap water to remove excess dye and allow for differentiation 
to occur of eosinophilic formations. The slides underwent a 2 stage 
dehydration phase by submerging them for 2 minutes in 100% ethanol 
container and then two 3 minutes submerging in xylene to remove any excess 
ethanol on the slides. The final step was to mount the slides with coverslips 
(VWR Ltd, Lutterworth, UK) using the DPX mounting solution (Fisher 
Scientific, Loughborough, UK) and then left to dry at room temperature 
overnight.  
 
2.7.4 Immunohistochemistry 
Albert H. Coons and his fellow colleagues were the first to successfully use a 
fluorescent dye to label antibodies in the identification of specific antigens in 
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tissue sections306,307. Immunohistochemistry (IHC) is a process known for 
identifying and localising the antigen of interest from a tissue section by the 
aid of a specific reagents and labelled antibody via antigen-antibody 
interactions that can be visualised through markers such as enzymes, 
fluorescent dyes, colloidal gold and radioactive elements and used either an 
direct or indirect staining method.  
The direct staining method involves only a one step approach which involves 
the labelled primary antibody binding directly to the specific antigen to 
generate a signal. While this method is fairly simple and quick, the sensitivity 
is much lower with direct staining as its signal amplification is lower. 
Indirect staining requires the use of an unlabelled primary antibody and a 
labelled secondary antibody, the primary antibody is the first layer that binds to 
the specific antigen and the secondary antibody then binds to the first antibody, 
this method has a much higher specificity in comparison to the direct staining 
method308.  The most widely used method for indirect IHC is a secondary 
antibody horseradish peroxidase (HRP) enzyme and when in the presence of 
3,3 diaminobenzidine (DAB) it produces a brown formation, a chromogenic 
mixture via catalytic conversion309. Before any antibody exposure can begin, it 
is vital all sectioned slides are dewaxed and rehydrated, a comparable process 
to the histological staining method, this permits all IHC reagents to access the 
sectioned tissue. As previously described, formalin fixation of tissues develops 
in cross-linking of proteins, which in turns results in masking any viable 
antigenic sites. In order to disrupt the protein cross-links, samples are required 
to undergo a heat-induced epitope retrieval (HIER) process310.  
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2.7.5 IHC procedure 
A blinding process was implemented by assigning one slide per sample used 
via a random identifier; these slides were kept on a separate slide rack from 
other samples to ensure no bias and placed onto the Leica BondMax IHC slide 
processor (Leica Microsystems) and run via a software program (Vision 
Biosystems Bond version 3.4A) using Bond polymer refine detection reagents 
(Leica Microsystems).  
Slides were treated with washes from xylene and ethanol for 1 minute each and 
then incubated at 95oC with epitope retrieval mixture. Slides were then treated 
at room temperature for 5 minutes with Peroxide Block. All slides excluding 
those for negative control were treated to 150µl of pre-optimised primary 
polyclonal anti-rabbit antibody (Abcam, Cambridge, UK) dilution (MCP-1 
1:500, Abcam, GRP-78 1:150, Abcam) for 30 minutes before being treated to 
150µl of HRP conjugated secondary anti-mouse and rabbit antibody polymer 
for 8 minutes. Slides were then treated with 3,3 DAB for 10 minutes until a 
brown precipitate has formed and then treated with Harris haematoxylin for 5 
minutes. At the end of each stage the slides were automatically washed with 
Bondwash buffer and distilled water. The final step was to mount the slides 
with coverslips (VWR Ltd, Lutterworth, UK) using the DPX mounting 
solution (Fisher Scientific, Loughborough, UK) and then left to dry at room 
temperature overnight. The samples processed in the blinded process were 
observed using a 10x magnification and photographed for image analysis at 10 
random areas. Volocity (Perkin Elmer, Cambridge, UK) imaging software was 
used to estimate positively stained cell percentage normalised against the total 
cell number present.  
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2.8 Bicinchoninic acid total protein determination 
The BCA assay method was used to calculate the total protein concentration 
from samples. The assay is based on a colourimetric reaction between BCA, 
proteins and copper sulphate311. The peptide bonds reduce Cu2+ to Cu1+ ions in 
proteins when incubated at a certain temperature. This activates the BCA 
reagent to form a chelation complex with the Cu1+ ions, which in turn results in 
a purple compound311. The colour change from the standard green to purple is 
equal to the proportion to the quantity of protein present in the selected sample, 
the wavelength at which absorbance is measured is at 526nm. The unknown 
concentrations are then quantified against the standard curve.  
 
2.8.1 BCA assay procedure 
50ml of reagent A which contains 2% sodium carbonate, 1% bicinchoninic 
acid, 0.4% sodium hydroxide and 0.16% sodium tartrate was constituted to a 
final volume with distilled water and 10% sodium bicarbonate. 50ml of reagent 
B (4% copper sulphate solution) is made to a final volume with distilled water. 
Reagent C was produced by mixing reagents A and B together at a ratio of 
100ml: 2ml, the solution was stored at 4oC until further use.  
Eight bovine serum albumin (BSA) concentrations were used to produce 
standards ranging from 1.0 to 0.00 mg/ml; the standards were created in 0.9% 
saline. 2.5µl from each unknown protein sample was diluted to a ratio of 1:20 
in 0.9% saline solution and constituted to a final volume of 50µl. For each 
standard, negative control and unknown sample, 10µl was pipetted into a 96-
143 
 
well microplate followed by 200µl of reagent C to each well, the plate was 
then incubated at 37oC for 30 minutes in an orbital shaker. This final step 
allowed for colour development from green to purple and for measurement at 
wavelength 526nm. Each sample was replicated in duplicate with an 
acceptable level of 5% coefficient of variance only; any samples that were 
outside this range were repeated. For each sample reading, a 20x multiplication 
factor was formulated onto the recorded absorbance results to account for the 
primary dilution factor of 1:20.  
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2.9 Electrochemiluminescence  
Electrochemiluminescence or electrogenerated chemiluminescence (ECL) is a 
novel approach to detecting antigens by generating luminescence via 
electrochemical reactions in mixtures. A highly exergonic reaction is produced 
with from electrochemically created intermediates in electrogenerated 
chemiluminescence, the reaction leads to an electronically heightened state of 
excitement which emits light312. The ECL excitation is a direct reaction lead by 
a redox reaction of electrogenerated species through a transfer of energetic 
electrons. This form of luminescence excitation is a type of 
chemiluminescence in which all or one of the reactants are generated 
electrochemically on the surface of electrodes313.  
 
The ECL method has proven to be a very resourceful technique in analytical 
applications in highly sensitive and precise methods. ECL has the distinct 
advantages of chemiluminescent analysis (no background optical signal) and 
effortlessness control of the reaction through application of an electrode 
potential. Varying the electrode potential leads to an enhanced selectivity of 
ECL by controlling the species which are oxidised/reduced on the electrode 
and which species engage in the ECL reaction314.  
ECL mechanism commonly uses Ruthenium complexes, in particular 
[Ru(bipy)3]Cl2 (this complex discharges a photon at ~620nm) which 
regenerates with TPA (Tripropylamine) in a liquid-solid or liquid mixture (See 
Figure 2.8).  
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ECL Features 
x 7KH SKRWRQ¶V HPLW OLJKW DW aQP WKHUHIRUH HUDGLFDWLQJ DQ\ LVVXHV
with colour quenching.  
x Background interference is minimal as the stimulation mechanism 
(electricity) leads to decoupling from the signal (light). 
x Numerous excitation cycles from each label leads to an amplification of 
the signal, increased sensitivity and enhanced light levels. 
x Carbon coated electrode surface allows for 10x greater binding ability 
compared to conventional polystyrene. 
  
Figure 16.8 - Electrochemiluminescence mechanism uses SULFO-TAG labels, 
which emit light upon electrochemical stimulation initiated at the electrode 
surfaces of MSD assay plates.   
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2.9.1 MSD Technology 
 
MSD is a detection process by which ECL technology uses SULFO-TAG 
labels, that when excited by electrochemical stimulation emits light. Labels 
such as the SULFO-TAG are stable, non-radioactive and allow for a variety of 
choice for specific coupling chemistries. The electrochemical stimulation is 
initiated upon the electrode surface of multi-spot and multi-array plates.  
MSD technology allows for quick and efficient method of analysing and 
measuring one or more proteins from a single small volume sample. MSD 
multi-array plates provide a platform for the construction of sandwich 
immunoassays. Uncoated plates are provided to the user, allowing the user to 
coat the assay with a capture antibody against a target protein specific to their 
experiment. 
The sample is then added to the plate and a working solution comprising of the 
labelled detection antibody (MSD SULFO-TAG label, an anti-target antibody 
tagged with the electrochemiluminescent) are incubated over a period of time. 
The target which is present in the sample then binds to the capture antibodies 
present on the electrode surface; the immunoassay sandwich is finally 
complete by recruiting the labelled detection antibody to the target (See figure 
below).  
A final MSD Read Buffer is added to the plate to allow for the correct 
chemical milieu for ECL to occur, the plate can then be loaded onto a MSD 
SECTOR for analysis. The SECTOR instrument is used to apply an electric 
voltage across the plate, which causes the electrode surface where the label 
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target is present to emit light. The SECTOR instrument processes the intensity 
of emitted light from the plate as a quantitative measure for the amount of 
target protein of interest in the sample.  
 
2.9.2 ECL ± MSD Multi-Array Procedure 
All instructions provided by MSD Technologies (Meso Scale Discovery, 
Maryland, USA) for the cytokine multi-plex plates were followed as 
suggested.  
 
2.9.3 Solution preparation 
Preparation of solutions to the correct dilution and concentration was vital 
before prepping the MSD plate. All chemical solutions were provided by MSD 
Technologies (Meso Scale Discovery, Maryland, USA).  The detection 
antibody solution was provided at 50X concentration, the final working 
concentration for the MSD plate should be 1X. For each plate used, 60µl of the 
stock solution (50X) was added to 2.94mL of Diluent 5, this brought the 
concentration to 1X. The read buffer which is added to the MSD plate at the 
end before reading in the SECTOR instrument is diluted to a working solution 
of 2X in deionized water. For each plate, 10mL of 4X read buffer was added to 
10mL of deionized water. The MSD plates supplied required no pre-wetting as 
they were already pre-coated with the antibodies of the specific analyte chosen. 
The plates were also subjected to stabilizing treatment to ensure the stability of 
the immobilised antibodies.  
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2.9.4 Calibrator and standard solutions 
All reagents were brought to room temperature with the stock solution of the 
calibrator allowed to thaw on ice. Calibrators are diluted in diluent 6, an 8-
point standard curve consisting of 2 replicates for each point were used. Each 
well requires 25µl of calibrator standard. The correct setup required for each 
plate requires a 4-fold serial dilution with diluent 6 alone for the 8th step, set up 
as the blank. 
Standard Concentration (pg/mL) Dilution Factor 
100X Stock 1,000,000  
STD-01 40,000 25 
STD-02 10,000 4 
STD-03 2500 4 
STD-04 625 4 
STD-05 156 4 
STD-06 39 4 
STD-07 9.8 4 
STD-08 0 n/a 
 
For preparation of the 8-point standard curve: 
 
1. To produce the highest point calibrator (STD-01), 10µl of the rat 
cytokine stock calibrator was added to 240µl of diluent 6 (dilution 
factor of 25)  
2. The next step is to transfer 50µl of the STD-01 into 150µl of diluent 6. 
Repeat this 4-fold serial dilution step for the next 5 additional times to 
produce 7 calibrators.  
3. The final STD-08 should be consisting of diluent 6 i.e. zero calibrator. 
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Assay protocol 
1. Dispense 25µl of diluent 6 into each well followed by sealing the plate 
with an adhesive plate seal and incubating for 30 minutes with vigorous 
shaking (300-1000rpm) at room temperature.  
2. Pipette 25µl of calibrator controls into the selected wells followed by 
25µl of sample into the remaining wells as planned. The plate is then 
sealed again and incubated for 2 hours with vigorous shaking (300-
1000rpm) at room temperature. 
3. Wash the plate 3 times with 200µl of PBS-T each time. After the wash, 
pipette 25µl of the 1X detection antibody solution into each well of the 
plate. Seal the plate with an adhesive plate seal and incubate for 2 hours 
with vigorous shaking (300-1000rpm) at room temperature.  
4. Wash the plate 3 times with 200µl of PBS-T each time. After the wash 
add 150µl of 2X read buffer to each well and insert the plate into the 
SECTOR Imager. Preload the plate template onto the computer and 
analyse the plate. The plate must be read immediately after the addition 
of the read buffer into all the wells.  
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2.9.5 Analysis of results   
All calibrator controls need to run in duplicate to produce a standard curve. 
The standard curve is modelled on using least squares fitting algorithms so that 
the signals processed from the samples of known levels of the analyte of 
interest can be used to calculate the concentration of the analyte in the sample. 
The assays have a wide range (3-4 logs), this allows for accurate quantitation 
in many samples without the need for dilution. The MSD analysis software 
supplied utilises a 4-parameter logistic model (or sigmoidal dose-response) and 
includes a 1/Y2 weighting function. The weighting function is crucial as it 
provides a better fit of data over a wide dynamic range, particularly at the low 
end of the standard curve (See Fig 2.4.4).  
 
Figure 17.9 ± Typical standard curve from an MSD plate. The blue dots 
indicate the standards used to generate the standard curve, red dots are 
samples plotted against the curve to calculate concentration based on signal. 
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2.9.6 Statistical analysis 
Before any statistical analysis could be performed, the coefficient of variance 
for very duplicate sample used in the experiments was calculated. This was 
calculated on software package Microsoft Office Excel 2007 (Microsoft 
Corporation, Berkshire, UK), a spreadsheet program. To support accept 
reproducibility of the selected assay, the coefficient of variance had to be 
FRQILUPHGOHVVWKDQ'DWDSRLQWV WKDW IHOOZLWKLQWKHFULWHULDRIZHUH
accepted for statistical analyses. All statistical analysis of data in all 
experiments was performed using Microsoft Excel 2007 and GraphPad Prism 
v5.01 (GraphPad Software, California, USA). All data points from experiments 
also underwent normality of distribution tests; the Kolmogorov-Smirnov 
normality test for parametric or non-parametric distribution was selected for 
this task. The Kolmogorov-6PLUQRYWHVWFRQFOXGHVS LVGHWHUPLQHGDV
normality. For analysis of variance with comparable groups, they were 
assessed with a number of tests such as one or two-ANOVA for parametric 
data, for non-parametric data Kruskal-Wallis one-way analysis. For multiple 
JURXS SRVW KRF 'XQQ¶V RU %RQIHUURQL FRUUHFWLRQ WHVWV ZHUH DSSOLHG *UDSKV
produced for all experiments were based on software package GraphPad Prism 
v5.01 (GraphPad Software, California, USA), to represent consistency within 
all data sets; the data was displayed as mean average ± standard error of the 
mean (SEM). To yield a statistically significant result and have reason to 
justify the rejection the null hypothesis the p value must be less than 0.05.  
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Chapter 3 Ȃ Early-to-mid 
gestational nutrient restriction 
3.1 Introduction and aims 
Pericardial adipose tissue is situated on the exterior of the parietal pericardium 
and is distinctly different in position and blood supply from epicardial adipose 
tissue315. Epicardial adipose tissue is located on the surface of the heart, with 
the ability to expand into the heart and integrate with the muscle fibers of the 
myocardium316. Studies reported in a recent review317 demonstrated that depots 
of pericardial, epicardial and myocardial fat were associated with excess body 
weight21, 22, however the association between the fat depots and various 
measurements of body composition still remain questionable317.  
The heart is covered by a layer called the pericardium. The pericardium is an 
unrestricting sac that wraps itself around the heart and the major blood vessels. 
Fat which is situated on the outer layer of the pericardium is called pericardial 
fat318. The pericardium is organised in two layers, the inner layer of visceral 
pericardium (or epicardium) and the outer layer of parietal pericardium that has 
a thicker structure and shapes itself to the chest cavity318. The epicardium lines 
the outer layer of the heart with a layer of flat mesothelial cells that are situated 
upon a fibrocollagenous support tissue and contains a variety of different cells 
along with large arteries and venous tributaries transporting blood to and from 
the heart wall319. Adipose tissue is surrounded by coronary arteries and veins 
which help expand the epicardium319. To prevent friction between the heart 
and the pericardium, there is a middle fluid layer which allows inhibited 
movement of the heart during its muscle contractions319. 
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3.2 Hypothesis 
This chapter therefore aims to investigate the extent to which alterations of 
pericardial adipose tissue inflammatory activity induced by prenatal nutrition 
could increase cardiovascular risk when it accompanies obesity may be critical 
to the understanding of the developmental origins of cardiovascular disease. 
My hypothesis therefore is that maternal nutrient restriction during the early to 
mid gestation period followed by juvenile obesity will results in a significant 
accumulation of fat mass and increased genetic inflammatory response as a 
result of this increased fat mass.  
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3.3 Material and methods 
A fully detailed description of all the methods used in this chapter can be 
found in Chapter 2. The experimental set-up and model used to describe and 
illustrate and the result in this chapter can be observed in Figure 3.1. All 
animal experimentations that were reported i.e. tissue weights, plasma 
measurements and animal dissections were performed and supervised by Dr. 
D. Gardner and Dr. S. Sebert. For any sample or analytical exceptions are 
described in the results section of the relevant chapter. All statistical tests 
conducted in this chapter are detailed in Chapter 2. 
 
 
 
Figure 18.1 ± Sheep Study: Early to mid gestational nutrient restriction model. 
O=Obese group, NR-O = Nutrient restricted-obese group, L = Lean group. 
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3.4 Results 
3.4.1 The effects of maternal nutrient restriction between early to mid-
gestation on pericardial fat mass 
Results showed there no difference in body weight at birth between both 
groups, this correlation continued until the time of dissection at 12 months of 
postnatal age. In addition there was a difference in pericardial fat mass 
(p<0.05; Fig 3.2) and pericardial % total fat (p<0.05; Fig 3.2.1) in sheep to 
subjected juvenile obesity.  
 
Figure 19.2 - Pericardial fat mass (g) measurements of obese group (O, n=8) 
and nutrient restricted group (NR-O, n=12). Values are in mean ± SEM; 
statistical differences are donated by *, where *=  p<0.05. Analyses of 
pericardial fat mass (g) between the groups were treated with unpaired t-tests. 
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Figure 20.2.1 ± Pericardial % total fat measurements of obese group (O, n=8) 
and nutrient restricted-obese group (NR-O, n=12). Values are in mean ± SEM; 
statistical differences are donated by *, where *=  p<0.05. Analyses of 
pericardial fat mass (g) between the groups were treated with unpaired t-tests. 
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3.4.2 Pericardial gene expression of pro-inflammatory markers 
interleukin-6 (IL-6) and interleukin 18 (IL-18) 
As expected the analysis of pericardial mRNA expression of illustrated IL-6 
(p<0.05) and IL-18 (p<0.05) identified a significant up regulation for the group 
subject to maternal nutrient restriction followed by juvenile obesity. 
 
 
 
 
 
 
 
 
 
 
Figure 21.2.2 ± Interleukin-6 (IL-6) and Interleukin 18 (IL-18) mRNA 
expression values of the obese group (O, n=8) and nutrient restricted-obese 
group (NR-O, n=12). Values are in mean ± SEM; statistical differences are 
donated by * =  p<0.05 (unpaired t-test). 
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3.4.3 Pericardial gene expression of 78 kDa glucose-regulated protein 
(GRP-78) and monocyte chemotactic protein-1 (MCP-1) 
As expected the analysis of pericardial mRNA expression of illustrated MCP-1 
(p<0.05) and GRP78 (p<0.05) identified a significant up regulation for the 
group subject to maternal nutrient restriction followed by juvenile obesity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 22.2.3 ± GRP-78 and MCP-1 mRNA expression values of the obese 
group (O, n=8) and nutrient restricted-obese group (NR-O, n=12). Values are 
in mean ± SEM; statistical differences are donated by * =  p<0.05 (unpaired t-
test). 
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3.4.4 Pericardial gene expression of metabolic and inflammatory markers 
After observing the difference in pericardial adipose tissue mass we decided to 
examine certain adiposity markers such as FTO, leptin and adiponectin. TNF-
alpha which is also known for its regulating and modifying influence on 
adiponectin and other cytokines was also investigated. There was no change 
exhibited by the gene listed in Table 3.1. Other pro-inflammatory markers such 
as TRL4 were also tested for gene expression change but they were showed no 
significant change between the groups. 
 
Table 3: Inflammatory and metabolic gene mRNA expression of O (obese 
group) and NR-O (nutrient-restricted obese group). Values are mean ±SEM. 
NS = no significant difference (unpaired t-test) 
Group O (n=7) NR-O (n=12) p value 
Adiponectin 1.69 ± 0.41 1.40 ± 0.43 ns 
FTO 1.38 ± 2.60 1.10 ± 1.30 ns 
Leptin 2.77 ± 0.86 4.55 ± 1.34 ns 
TNF-Į 0.10 ± 0.06 0.07 ± 0.03 ns 
TLR4 0.003 ± 0.05 0.003 ± 0.06 ns 
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3.5 Discussion 
Work previously carried out by the University of Nottingham Academic 
Division of Child Health on obese sheep, have developed models based on a 
amalgamation of maternal nutrition restriction followed by varying postnatal 
activity treatment157. The nutritional restriction stage was aimed at the in utero 
period of early to mid gestation (ovine organ- and embryogenesis period), 
gestational days 30-80 during pregnancy210. When analyzing the physiological 
adaptations of adipose tissue and renal function, the study was able to 
demonstrate that maternal nutrient restriction throughout this stage resulted in 
altered inflammatory and metabolic genetic-protein reaction in the kidney and 
perirenal adipose tissue depots for individuals in groups of lean, obese and 
nutrient restricted obese210,320. Furthermore the study highlighted that the 
nutrient restricted obese group demonstrated enhanced metabolic dysfunction 
that were distinguished by increased apoptosis, renal oxidative stress along 
with increased renal lipid deposition321.  
My study was able to supplement the evidence that maternal nutrition 
restriction in the early to mid gestation period leads to increased inflammatory 
expression of IL-6, IL-18, and macrophage related MCP-1 and ER stress 
related GRP78 chaperone genes in the maternal nutrient restricted obese group. 
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3.5.1 Fat mass accumulation following maternal nutrient restriction in 
juvenile obesity 
A recent study investigating the role of pericardial fat in relation to 
atherosclerotic processes in coronary arteries showed a direct correlation to 
pericardial fat independent of the measure of adiposity currently undertaken 
such as body mass index and waist circumference322. Data collected from 
cross-sectional studies have also shown pericardial fat (independent of body 
fat) correlated positively to coronary artery disease323 324.  
Studies based on autopsy results have shown epicardial fat not be positively 
correlated to subcutaneous abdominal fat325 but in vivo studies have 
demonstrated differences in correlations with differing strength317 326. Studies 
have shown visceral fat to be an independent marker of myocardial fat327 with 
strong relationships with pericardial fat328.  
In addition, studies involving myocardial, epicardial and pericardial fat depots 
have shown strong correlations with the components of metabolic syndrome 
such as type 2 diabetes mellitus327, increased triglycerides and hypertension324, 
raised fasting insulin and elevated waist circumference329 330. Studies 
investigating pericardial and epicardial fat have been able to conclude that 
excess fat may be a contributing factor in the pathogenesis of coronary heart 
disease317 324 325.  
Current research concludes that epicardial is biochemically different from 
pericardial fat330, studies involving measuring fat thickness through 
echocardiography demonstrated the differences in epicardial and pericardial326. 
With epicardial echocardiography Iacobellis et al, were able to predict visceral 
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adiposity326 329, metabolic syndrome331, heart morphology332 333, fasting 
glucose334, insulin resistance330, liver enzymes334 and sub-clinical 
atherosclerosis335. The body of evidence for epicardial fat as a predictor for 
such metabolic diseases is becoming more apparent, therefore more research 
and understanding must be gathered for pericardial fat.   
My study was able to demonstrate changes in fat mass accumulation in 
pericardial adipose tissue resulting from juvenile obesity in comparison to 
maternal nutrient restriction followed by juvenile obesity. When reviewing my 
original hypothesis, I stated that individuals who were exposed to early to mid 
gestational nutrient restriction followed by juvenile obesity would accumulate 
more fat mass. The original hypothesis was based on the assumption that early 
WRPLGJHVWDWLRQZRXOGGULYHWKHIHWXV LQWRD³FDWFKXSJURZWK´SKDVHGXULQJ
postnatal growth, a period of growth where food was not restricted.  
However this was not demonstrated in pericardial fat and a possible reason for 
this may be the development of pericardial adipose tissue during early to mid 
gestation was severely inhibited and its ability to store fat was largely 
decreased. This may give an explanation to the number of inflammatory 
markers that up-regulated in pericardial adipose tissue from this study.  
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3.5.2 Expression of inflammatory markers following maternal nutrient 
restriction in juvenile obesity 
My study was able to display an up-regulation in inflammatory markers such 
as MCP-1, IL-6, GRP78 and IL-18. The inflammatory process was 
independent of fat mass accumulation as the control group which showed a 
statistically significant increase in fat mass but did not show any change in 
gene expression. A possible reason for the increase of inflammatory markers in 
a fat depot with lowered fat mass could be the maternal nutrient restriction 
during early to mid gestation causing a metabolic and physiological change on 
the outcome of pericardial adipose tissue functioning. This dysregulation 
during the gestational period may attribute to the inflammatory response as 
during postnatal growth, the individuals were forced into juvenile obesity 
through being maintained within a restricted activity environment and fed ad 
libitum. It is thus possible that the fat mass was unable to be stored 
successfully in the pericardial adipose tissue leading to inflammatory reactions 
and cell apoptosis. 
  
3.6 Conclusion 
As previously described in the introduction chapter MCP-1 is known for its 
properties in macrophage recruitment to sites of cell stress. GRP-78 is an 
endoplasmic reticulum chaperone that is increased in expression during times 
of adipocyte stress, in order to promote cell survival it is activated by the UPR 
pathway to restore cellular homeostasis161. IL-18 is an inflammatory 
interleukin that is produced by macrophages336 and IL-6 is well established for 
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its effects during an inflammatory response99.  Therefore in conclusion, the 
study was able to demonstrate that pericardial adipose tissue inflammation can 
be changed by in utero nutritional manipulation.  
However metabolic, appetite regulating and body mass related genes such as 
FTO, leptin and adiponectin were not shown to statistically significant between 
the groups. Limitations such as basing this conclusion on gene expression 
alone should be taken on board. Further research involving protein expression 
on inflammatory markers should be investigated before a concrete conclusion 
is theorized. Furthermore additional depots such as epicardial adipose tissue 
could also be investigated to evaluate the full extent of maternal nutrition 
restriction on cardiac physiology and function.   
165 
 
Chapter 4 Ȃ Late gestational 
nutrient restriction 
4.1 Introduction and aims 
The correct amount and composition of nutritional intake is required during the 
rapid developmental periods for the fetus as well as to during their first years 
of life. The supply and demand for nutrient turnover in young infants and 
children when compared to adults is much higher due to the rapid rates of 
growth. Growth from pre to post natal life and into adolescence is outlined by 
specific developmental changes in multiple organ composition and function. A 
failure to supply the adequate nutritional needs during this phase is likely to 
lead to adverse consequences on metabolic development and growth.  
Therefore providing the correct nutritional needs at the earliest stage possible ± 
pregnancy, is essential. My previous chapter looked at inflammatory marker 
gene expression in pericardial adipose tissue and adaptations in its metabolism 
during nutrient restriction between early and mid-gestation followed by 
juvenile obesity. This chapter focuses on nutrient restriction in late gestation 
with or without accelerated postnatal growth in subcutaneous adipose tissue.  
As highlighted earlier, with overwhelming evidence that VAT mass correlates 
with the progression towards CVD and T2DM via the development of insulin 
resistance and with little evidence VXSSRUWLQJ6$7¶VLQYROYHPHQW35,37,38, 6$7¶V
suggested ability is to play a buffer or a sink to avidly absorb circulating FFAs 
and TGs in the postprandial period. However once this buffer reaches its 
capacity the cells lose their protective benefit and fat begins to accumulate 
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around tissues not suited for lipid storage337. Therefore I feel it is a depot that 
with current research can also play a vital role in the understanding of CVD 
and T2DM development49,338. 
This chapter details the changes that occur during the final stages of 
pregnancy, a period of when 70% of fetal growth occurs, and any changes of 
nutritional uptake during phase may have negative effects later in life.   
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4.2 Hypothesis 
My hypothesis was that fetal sheep exposed to a nutrient restricted diet in late 
gestation, that is followed by accelerated postnatal growth would exhibit 
increased gene expression of inflammatory and metabolic markers in 
subcutaneous adipose young adult offspring. 
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4.3 Materials and Methods 
A fully detailed description of all the methods used in this chapter can be 
found in Chapter 2. The experimental set-up and model used to describe and 
illustrate and the result in this chapter can be observed in Figure 4.1. All 
animal experimentations that were reported i.e. tissue weights, plasma 
measurements and animal dissections were performed and supervised by Dr. S. 
Sebert and Dr L Chan. For any sample or analytical exceptions are described in 
the results section of the relevant chapter. All statistical tests conducted in this 
chapter are detailed in Chapter 2. 
 
Figure 23.1 - Late gestational nutrient restriction model, N =  nutrient 
restricted (60% of normal energy requirements), R = fed to requirements 
(100% of normal energy requirements), A = fed to appetite (150% of normal 
energy requirements). During lactation, the N group were either raised as a 
singleton (-A = Accelerated growth raised without competition) or with a twin 
(-S =  Standard growth raised as a twin). Post weaning phase, all groups were 
raised in an obesogenic environment.   
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4.4 Results 
4.4.1 The effects of a nutrient restricted environment and their impact on 
body weight and fat mass accumulation   
Weight measurements taken at the time of birth showed a reduced birth weight 
following maternal nutrition restriction (Fig 4.1.1). Both NA and NS groups 
were grouped together for the data shown in Fig 4.1.1, as the NA was treated 
the same as NS during gestation.  
 
Figure 24.1.1 - Birth weight measured following late gestational maternal 
nutrition restriction. N = nutrient restricted (60% of normal energy 
requirements, n=16), R = fed to requirements (100% of normal energy 
requirements, n=9). Values are in mean ± SEM; statistical differences are 
donated by * =  p<0.05 (unpaired t-test). 
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Following the difference observed in birth weight, I decided to look at the 
gestation weight gain between the groups. It was observed that low birth 
weight offspring (NS) exhibited a reduced weight gain throughout late 
gestation and did not display any signs of accelerated postnatal growth (Fig 
4.1.2). Groups RA and NA weighed more at the end of lactation (90days) due 
to their groups being allowed to accelerate growth unlike NS (Fig 4.1.2).  
 
Figure 25.1.2 ± Early post-natal growth displayed in a time course from birth 
to the end of lactation (90 days) for the RA group (fed to 100% of energy 
requirements, raised without competition, n=9), NA group (fed to 60% of 
energy requirements, raised without competition, n=8), and the NS group (fed 
to 60% of energy requirements, raised with competition, n=8). Values are in 
mean ± SEM; there were no statistical differences between the groups (Two 
way - ANOVA). 
 
  
171 
 
Following weaning, all offspring from nutrient restricted mothers needed an 
extra 4 months before their overall weight was within range of the other 
groups. This could be largely explained as a result from the reduced weight 
gain pre-weaning (Fig 4.1.1). The NS group did however show a faster rate of 
weight gain during post-weaning but no offspring group that underwent 
maternal nutrition restriction gained more weight than the control group at the 
final weigh (Fig 4.1.3). This was similarly observed between all groups when 
comparing total fat mass (Fig 4.1.4). 
 
Figure 26.1.3 ± Graph of weight taken at 17 months of age. RA group (fed to 
100% of energy requirements, raised without competition, n=9), NA group 
(fed to 60% of energy requirements, raised without competition, n=8), and the 
NS group (fed to 60% of energy requirements, raised with competition, n=8). 
Values are in mean ± SEM; there were no statistical differences between the 
groups (ANOVA). 
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Figure 4.1.4 Graph of total fat mass % 
 
Figure 27.1.4 ± Graph of total fat mass % taken at 17 months of age, RA 
group (fed to 100% of energy requirements, raised without competition, n=9), 
NA group (fed to 60% of energy requirements, raised without competition, 
n=8), and the NS group (fed to 60% of energy requirements, raised with 
competition, n=8). Values are in mean ± SEM; there were no statistical 
differences between the groups (ANOVA). 
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4.4.2 Maternal gestational nutrition restriction effect on gene expression of 
metabolic and inflammatory markers from subcutaneous adipose tissue 
From the previous results in birth weight and post-weaning weight gain, the 
metabolic marker leptin, which is associated with appetite regulation, was first 
investigated followed by adiponectin that has been seen to have increased gene 
expression in lean subjects. There was no gene expression difference observed 
between groups in leptin and adiponectin (Table 4.1). There were also no 
statistically significant differences in gene expression when groups were 
analyzed for gender differences (Table 4).  
Table 4: mRNA gene expression values of inflammatory and metabolic 
markers on RA group (fed to 100% of energy requirements, n=9) compared to 
NA group (fed to 60% of energy requirements, n=8). Values are in mean ± 
SEM; NS = no significant difference, S =significance (p=<0.05) 
Group RA (n=9) NA (n=8) p value Gender 
Adiponectin 3.75e-004± 1.7e-004 8.2e-004± 2.6e-004 ns ns 
Leptin 0.29± 0.1 0.36± 0.1 ns ns 
IL-6 8.2e-004± 1.3e-004  7.7e-004± 1.4e004  ns S 
TNF-Į 8.8e-004± 2.5e-004 8.5e-004± 2.4e-004 ns ns 
MCP-1 6.0e-004± 2.3e-004 2.8e-004± 5.9e-004  ns ns 
TLR-4 9.2e-004± 2.0e-004 7.9e-004± 1.6e-004 ns ns 
IL-18 0.23 ± 0.1 0.06 ± 0.02  ns ns 
GRP-78 7.9e-004± 1.2e-004 9.2e-004± 1.4e-004 ns ns 
FTO  8.8e-004± 1.8e-004 5.6e-004± 4.0e-005 ns S 
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The gene expression of IL-6 when analysed in mixed gender settings did not 
demonstrate any statistical difference between the groups (Table 4.1). 
However, when the group was analysed by gender, the females exhibited an 
up-regulation of IL-6 expression when fed to requirement during the gestation 
period (Fig 4.1.5). There was no statistically significant difference found in 
between males.  
 
 
Figure 28.1.5 - An up-regulation of IL-6 mRNA expression values in females 
from RA group (fed to 100% of energy requirements, raised without 
competition, n=9) compared to NA group (fed to 60% of energy requirements, 
raised without competition, n=8). Values are in mean ± SEM; statistical 
differences are donated by * =  p<0.05 (unpaired t-test). 
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When analyzing the gene expression of TNF-Į DQG *53-78, there are no 
statistically significant differences between the groups or gender. Other 
inflammatory markers such as IL-18, IL-18 along with MCP-1 and TLR-4 also 
did not exhibit and statically significant differences between groups or gender 
(Table 4.1). 
However, the obesity gene related marker FTO did reveal differences gene 
expression and was statistically significant different when comparing between 
genders in groups but not mixed (Table 4.1). FTO showed an up-regulation of 
expression in the female groups only who were fed to requirement during the 
gestation period (Figure 4.1.6). 
 
 
Figure 29.1.6 - An up-regulation of FTO mRNA expression values in females 
from RA group (fed to 100% of energy requirements, raised without 
competition, n=9) compared to NA group (fed to 60% of energy requirements, 
raised without competition, n=8). Values are in mean ± SEM; statistical 
differences are donated by * =  p<0.05 (unpaired t-test). 
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4.4.3 The effects of postnatal accelerated growth on gene expression of 
inflammatory on subcutaneous adipose tissue 
There were also no statistically significant differences in gene expression when 
groups were compared for gender (Table 5).  
Table 5: mRNA gene expression values of inflammatory and metabolic 
markers on NS group (fed to 60% of energy requirements, n=8, raised with 
competition) compared to NA group (fed to 60% of energy requirements, n=9, 
raised without competition). Values are in mean ± SEM; NS = no significant 
difference, S =significance (p=<0.05, unpaired t-test) 
Group NA (n=9) NS (n=8) p value Gender 
Adiponectin 0.0018 ± 0.0009 0.0032 ± 0.001 ns S 
Leptin 0.00077 ± 0.00031 0.00055 ± 0.00019 ns ns 
IL-6 0.0048 ± 0.00093 0.0063 ± 0.0048 ns ns 
TNF-Į 1.2e-005 ± 3.0e-005 7.5e-006 ± 4.3e-005 ns ns 
MCP-1 3.7e-005 ± 2.3e-005 2.4e-005 ± 1.2e-005 ns ns 
TLR-4 0.00077 ± 0.00025 0.00035 ± 0.00023 ns ns 
IL-18 4.7e-005 ± 1.4e-005 2.1e-005 ± 6.2e-005 ns ns 
GRP-78 7.5e-005 ± 2.1e-005 2.4e-005 ± 5.5e-005 ns ns 
FTO 6.2e-005 ± 1.6e-005 7.5e-005 ± 2.1e-005 ns ns 
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When analyzing the gene expression of TNF-Į)72*53-78, no statistically 
significant differences were observed between groups or gender. Other 
inflammatory markers such as IL-18, IL-6 and macrophage recruiter such as 
MCP-1 and TLR-4 also did not exhibit any statically significant differences 
between groups or gender (Table 5).  
The most striking result from the postnatal accelerated growth phase was for 
gene expression of the anti-inflammatory marker adiponectin that was found to 
be raised significantly in females but not males. The female group displayed a 
standard growth postnatal had a significantly increased gene expression (Fig 
4.1.7). 
 
Figure 30.1.7 - An up-regulation of adiponectin mRNA expression values in 
females from NS group (fed to 60% of energy requirements, raised with 
competition, n=9) compared to NA group (fed to 60% of energy requirements, 
raised without competition, n=8). Values are in mean ± SEM; statistical 
differences are donated by * =  p<0.05 (unpaired t-test). 
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4.4.4 The effect of a maternal nutrient restricted environment during 
gestation followed by differing post-natal conditions on the development 
of adipose tissue 
Subcutaneous adipose tissue samples were taken from all three groups and 
histological analysis was performed as described in the methods chapter. For 
each group, a representative image is shown below. 
 
 
Figure 31.1.8 ± Representative of haematoxylin & eosin microscopic stained 
section of adipocytes from the RA group ((fed to 100% of energy requirements, 
raised without competition, n=9) at x40 magnification.  
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Figure 32.1.9 ± Representative of haematoxylin & eosin microscopic stained 
section of adipocytes from the NA group ((fed to 60% of energy requirements, 
raised without competition, n=8) at x40 magnification.  
 
 
 
Figure 33.2.0 ± Representative of haematoxylin & eosin microscopic stained 
section of adipocytes from the NS group ((fed to 60% of energy requirements, 
raised with competition, n=8) at x40 magnification.  
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The adipose tissue was analyzed microscopically with cell size of each group 
calculated (adipocyte area ȝP2). There was no statistically difference between 
the groups or when separated between gender groups (Fig 4.1.7 ± Fig 4.1.9).  
When observing the tissue samples under the microscope using 
immunochemistry, there was no visible evidence of any infiltrated nucleated 
cellular structures or the possible development of crown-like structures present 
around the adipocytes. This removed the possibility of performing any 
quantification for the measurement of macrophage infiltration.  
Table 6: Adipocyte area (µm2) of subcutaneous adipose tissue from NS group 
(fed to 60% of energy requirements, raised with competition, n=9), NA group 
(fed to 60% of energy requirements, raised without competition, n=8). RA 
group (fed to 100% of energy requirements, without competition, n=9). Values 
are in mean ± SEM; NS = no significant difference (ANOVA). 
Group NA (n=9) NS (n=8) RA (n=9) Gender 
Cell Size  
(Area µm2) 
142454 ± 27125 159329 ± 20673 151610 ± 24475 ns 
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4.4.5 Discussion 
The rapid development of infants during the first year of life and continued 
infant life, although at lower rates, from the age of twelve months up to 
adolescence requires distinctive nutritional requirements. When comparing this 
nutrient requirement for growth to adults, infant requirement levels are much 
higher due to the increasing metabolic and nutrient turnover. This is because of 
the accompanying developmental changes in organ composition and function, 
therefore a failure to sustain or provide these nutrients during this crucial stage 
is likely to have adverse effects on development as well as growth. In 
conclusion, requirement of this nutrimental demand, especially during early 
life, is therefore fundamental339.  
 
4.4.6 Nutrient restriction during late gestation and intra-uterine growth 
restriction 
The growth and development phase of the fetus is a specialized physiological 
process340.  It is well know that maternal nutrition restriction during pregnancy 
reduces the rate of fetal growth, and is termed intrauterine growth restriction 
(IUGR)341. Studies have shown negative adaptations on the development of 
organs and tissues associated from low birth weight due to IUGR341,342.  
Recent experimental studies have been able to demonstrate the evidence of 
maternal nutrient restriction on the fetal cardiovascular system as well possibly 
altering ovarian development in sheep343,344,345. These programmed alterations 
that are observed during maternal nutrient restriction may be the underlying 
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origin for metabolic diseases such as diabetes, hypertension, and 
cardiovascular disease in later adult life346.  
Energy homeostasis of an individual is generated partly from the pre, post-
natal and lactation stages of development347. From this aspect, it can be said 
that the last phase of gestation in both human and ovine models are significant 
in determining both birth weight and postnatal development.  
The present study highlights a distinct nutritional scenario in young adult 
offspring life, where a 40% reduction in maternal nutrition uptake during late 
gestation (110 days to term), is proceeded by an environment that challenges 
the potential for post-natal growth.  
These changes are predicted to be damaging and increase the risk for damaging 
metabolic outcomes at the time of birth and throughout adult life, resulting in a 
predisposition for the onset of metabolic diseases.  
4.4.7 Changes in inflammatory gene expression  
IL-6 is a cytokine that spans a wide range of metabolic effects from 
inflammation to insulin resistance99 with studies illustrating plasma levels 
positively correlating with obesity and insulin resistance62. It has been well 
established that approximately 25% of IL-6 secretion in the body is from 
adipose tissue99. Therefore during maternal nutrition restriction in late 
gestation, it would be more than likely that there would be detrimental effects 
on the development of adipose tissue, which could lead to the possible 
dysregulation of IL-6 secretion. However, in my study, IL-6 was not 
statistically different in groups experiencing such an environment during 
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gestation. Only when the groups are split by gender do you see an increase in 
the expression of IL-6 in females. More interestingly the group that was fed to 
requirement during gestation exhibited an increase in IL-6 expression, leading 
to the possible conclusion that nutrient restriction during late gestation may 
hinder the ability of adipose tissue to control secretion of IL-6 hence the 
increased levels.  
The FTO gene is a recent addition to the appetite regulation and obesity 
associated cascade of genes. A common variant of the FTO gene was found to 
show strong relationships with the body mass index and prevalence from a 
young age159.  FTO is expressed in a wide range of tissues and most 
importantly the hypothalamus, a region associated for its appetite regulation, 
where its expression is highly concentrated157.  
My study was able to demonstrate the increased expression of the FTO gene 
within the group born to mothers fed to requirements, but was only observed in 
females. It is important to gain more information on this gene and its possible 
effects in the offspring following maternal nutrient restriction. As a recent 
European cohort study based on the original paper linking FTO to obesity, 
have shown the FTO gene to be linked with the predisposition of subjects to 
diabetes as a consequence of body mass348.  
In conclusion, females born to mothers who were fed to requirements and then 
exhibited accelerated post-natal growth exhibited the greatest response in gene 
expression within their subcutaneous adipose tissue. This post-natal growth 
may therefore have a role in enhancing the gene expression of IL-6 and the 
FTO gene. The functional consequences remain to be elucidated. A possible 
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mechanism for the changes in gene expression being expressed only in females 
could be down to sex hormones. It could be suggested hormones such as 
oestrogen could play a role in this change compared to males. There are 
significant differences in fat distribution, adipose tissue and adipocyte function 
between women and men, which to a considerable extent, could result from 
gender differences in oestrogen receptor expression349. Oestrogen is a female 
hormone, which is produced largely by the ovaries, and during pregnancy, the 
placenta. Oestrogens are also produced by secondary sources such as the liver, 
breasts, adrenal glands, and fat cells in smaller amounts350.  Studies have been 
able to highlight that adipose tissue and adipocyte oestrogen receptor alpha 
(5Į cooperate in preserving adipose tissue function and protecting against 
inflammatory damage351,352. The studies also ZHQW RQ WR VXJJHVW WKDW (5Į
signalling is vital for the development of adipocyte hypertrophy and adipose 
tissue inflammation by concluding that higher expression of adipose tissue 
oestrogen receptors in females may be responsible for higher adipose tissue 
insulin sensitivity and lower susceptibility to inflammation compared to 
males349. By evaluating this current research and comparing the work carried 
out in this chapter, it could be suggested that the female hormone oestrogen 
may have played a role in the differences observed in IL-6, MCP-1, and 
adiponectin. However without work being carried out on protein expression, 
this remains only a possibility.  
Whether oestrogen played a role in gender differences observed between IL-6, 
MCP-1, and adiponectin gene expression remains to be answered. However, it 
is an avenue of research that should be investigated to fully understand the 
mechanisms behind male and female differences in adipose tissue function.    
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4.4.8 Accelerated post-natal growth and its effects on anti-inflammatory 
gene expression  
Early post-natal and intrauterine periods of growth have been recommended as 
possible windows for the increased risks of metabolic disease in later life176. 
Markers of nutrient restriction during pregnancy such as low birth and thinner 
size have been associated with such adverse outcomes as cardiovascular 
disease and metabolic syndrome in adults353,354,355,355 356. Rapid weight gain 
during the postnatal phase has shown a relationship with greater risk for 
hypertension357, obesity188, cardiovascular disease358 and insulin resistance193.  
From the survey of literature above it can be seen that these two windows of 
early life growth are closely related because growth-restricted infants that 
underwent nutrient restriction during pregnancy usually offset this by 
displaying quick growth (catch up) in their first year of life after birth197. 
Studies have concluded that it is not low birth weight but more likely postnatal 
development that contributes more to the development towards metabolic 
disease in later adult life188,183. Consequently, it has not yet been firmly 
established at which period during the postnatal window (early infancy or early 
childhood), that rapid weight gain is responsible for the development of long 
term metabolic risks. However, a recent Swedish cohort study investigated the 
longer term effects of weight gain during both early infancy and early 
childhood on fat mass at adolescent359. The study concluded that rapid weight 
gain during infancy was solely responsible for an increase in metabolic risk at 
17 years of age. The study was able to show that this change was independent 
from a number of factors such gestational age, current height, rapid weight 
gain in childhood, birth weight and maternal fat mass along with 
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socioeconomic status197. These findings are also in unison with studies in 
murine studies360 and infants born preterm361,362,362 all concluding that rapid 
weight gain during early postnatal life could lead to increased risk in long term 
metabolic health outcomes363.  
My study was able to show evidence that low birth weight following intra-
uterine restriction can lead to a possible predisposition to accelerated postnatal 
growth. A key component towards explaining this response is the possible 
availability of food at the point of lactation. This difference is seen when the 
offspring are nurtured as a singleton which meant there was no overriding 
competition for milk from a sibling corresponding to the same age. The study 
was able to observe that prospective harmful metabolic outcomes were 
influenced by the time after birth in which growth was enhanced in growth 
restricted offspring. This time of rapid postnatal growth was also illustrative of 
that observed in human newborn who were small for gestational age364.  
The evidence found in this study was also able to demonstrate that adiponectin 
had a higher gene expression in nutrient restricted females with a standard 
growth compared to those who underwent accelerated growth. Adiponectin is 
known for existing in low quantities in obese and overweight individuals, with 
protective properties against cardiovascular damage, inflammation and glucose 
intolerance110,128,365. My results suggests that if rapid weight gain (catch up 
growth) is not present, adiponectin expression is enhanced for these individuals 
leading to possible anti-inflammatory properties, irrespective of nutrient 
restriction in utero.  
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4.4.9 Adipose tissue deposition and physiology 
The study did not show any statistically significant differences in other 
metabolic or inflammatory genes that were hypothesised. A possible 
explanation for the limited effect seen in gene expression during nutrient 
restriction in late gestation could be that subcutaneous adipose tissue is less 
metabolically active when compared to more visceral adipose tissue such as 
the main depot in the perirenal-abdominal region. A recent study was able to 
demonstrate a significant inflammation response in perirenal fat, a depot of 
visceral adipose tissue in response to nutrient restricted juvenile obesity210.  
The ability to store lipids and convert them into energy in times of need for the 
body is seen as one of the main functions of adipocytes. When the detrimental 
metabolic effects of obesity take a accumulative effect on the body in the shape 
of intra-abdominal fat, it is reasoned that subcutaneous adipose tissue is no 
ORQJHU DEOH WR IXQFWLRQ FRUUHFWO\ DV WKH ³HQHUJ\ VLQN´366 for caloric excess 
resulting either surplus energy intake or decreased energy expenditure.  This 
ultimately leads to a phenomenon called ectopic fat deposition366, whereby fat 
is accumulated at undesired locations such as the liver, muscle, heart etc. An 
increase in intra-abdominal fat mass should therefore be taken as warning to 
fat being accumulated at locations that could ultimately have harmful 
consequences such as increasing cardiovascular disease and diabetes. 
However, my study was not able to illustrate this theory as total fat mass in all 
groups were not significantly different between groups. Therefore, as there was 
no difference in total fat mass it was not possible to accept the hypothesis that 
subcutaneous adipose tissue dysfunction leads to ectopic fat deposition.  
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4.5.0 Conclusion 
In conclusion, this study was able to demonstrate that subcutaneous adipose 
tissue gene expression after nutritional manipulation during late gestation 
exhibits only limited adaptations. However, statistically significant differences 
in gene expression were found in 3 different metabolic and inflammatory 
markers, IL-6, FTO, and adiponectin (female groups only). These were 
observed in subcutaneous adipose tissue even though total fat mass and final 
body weight showed no differences.  
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Chapter 5 Ȃ Fructose fed mothers 
5.1 Introduction and aims 
Previous chapters have looked at the effect of maternal nutrition restriction 
during mid or late gestation on the offspring and the resulting development of 
inflammation and adaptations in metabolism and adipose tissue. The focus of 
the following chapters is to investigate the dietary impact of fructose feeding in 
mothers during pregnancy. From the introduction chapter, it was identified that 
obesity and weight gain are related to fructose intake during pregnancy and its 
possible role in the development of hyperglycemia and hyperinsulinemia in the 
mothers288. Most studies involving fructose intake in pregnancy are centred on 
a high-fructose diet, this study would investigate a low fructose intake of 10%, 
a diet close to complimentary daily human intake.  
5.2 Hypothesis 
The focus of this study was to investigate the effect of fructose consumption 
during pregnancy and its effect on fat mass and inflammatory markers. Despite 
the large amounts of evidence of potential adverse effects of fructose 
consumption, there have not been enough studies extensively looking into 
fructose consumption during pregnancy and its potential role with 
inflammatory markers. My hypothesis is a fructose intake during pregnancy 
will result in elevated inflammatory markers and increased fat mass compared 
to the control group.  
 
 
190 
 
5.3 Methods and materials 
A fully detailed description of all the methods used in this chapter can be 
found in Chapter 2. The experimental set-up and model used to describe and 
illustrate and the result in this chapter can be observed in Figure 5.1. All 
animal experimentations that were reported i.e. tissue weights, plasma 
measurements and animal dissections were performed and supervised by Dr. 
R.Bell and Abha Hoedl. For any sample or analytical exceptions are described 
in the results section of the relevant chapter. All statistical tests conducted in 
this chapter are detailed in Chapter 2, normalization of the mRNA gene 
expression results were calculated against one reference gene (r18s).  
 
 
Figure 34.1 - Rat Study: Fructose fed mothers model. FR group = Females fed 
10% fructose water during pregnancy. CNTL group = females fed water. Both 
groups were fed chow (ad libitum) from the onset of mating. 
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5.4 Results 
5.4.1 The effect of fructose feeding during pregnancy on body weight 
At the start of the study body weights of female rats did not differ between diet 
groups.  Both groups gained weight during pregnancy and there was no 
significant difference in final body weights between groups throughout 
gestation or at gestational day 20, the final day of the study. Adipose tissue 
mass (retroperitoneal) was significantly greater in the FR group compared to 
the Control group on gestational day 20 (See Table 7, p<0.05) 
 
Figure 35.2 - Graph of weight taken at gestation day 20. FR group (n=18) =  
Females fed 10% fructose water during pregnancy. CNTL group (n=17) =  
females fed water during pregnancy. Both groups were fed chow (ad libitum) 
from the onset of mating. Values are in mean ± SEM; there were no statistical 
differences between the groups (Unpaired t-test). 
 
  
FR CNTL
0
100
200
300
400
500
B
od
y 
w
ei
gh
t (
gr
am
s)
192 
 
5.4.2 Measurement of food and water intake during pregnancy 
Overall, energy intake was significantly greater in the FR group compared to 
the Control group on the 2 days measured but did not differ significantly over 
time within each diet group. 
Table 7: Measurements food and water intake along with body weight and 
adipose weight of the FR group (fed 10% fructose water, n=18) and CNTL 
group (fed water, n=17), values are in mean ± SEM; statistical differences are 
donated by * =  p<0.05 (unpaired t-test). 
Characteristic FR (n=18) Control (n=17) 
Initial Body Weight (g) 259.9±6.7 259.5±6.7 
End Body Weight (g) 400.3±8.10 423.2±9.9 
Adipose Weight (g) 4.95±0.6* 3.20±0.4 
 
  
Total Food Intake (g) 
  
7 Day Intake 13.66±1.2 24.62±1.1* 
14 Day Intake 19.28±1.6 27.56±1.5* 
 
  
Total 10% Fructose/Water Intake (ml) 
  
Gestation Day 7 Intake 131.8±14.3* 33.2±3.5 
Gestation Day 14 Intake 127.2±11.8* 36.8±3.8 
 
  
Total Kcal Intake 
  
Gestation Day 7 Intake 97.8±9.7 81.25±3.6 
Gestation Day 14 Intake 114.4±10.0 91.0±5.0 
 
Total daily food intake was significantly lower on gestational days 7 and 14 in 
the FR group compared to the Control group (gestational day 7; p<0.0005, 
gestational day 14; p<0.0317).  Food intake increased as gestation progressed 
in the FR group (gestational day 14 vs. day 7; p<0.031); this however was not 
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observed in the Control group.  Rats in the FR group consumed significantly 
more fluid on gestational days 7 and 14 (gestational day 7; p<0.0001, 
gestational day 14; p<0.0001 respectively) compared with the Control group.  
Fluid intake was similar at each of these times within the diet groups.  Overall, 
energy intake was not significantly greater in the FR group compared to the 
Control group on the 2 days measured but did not differ significantly over time 
within each diet group. 
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5.4.3 The effect of fructose intake during pregnancy on expression of 
metabolic markers 
To determine the effect of fructose intake during pregnancy on gene expression 
of metabolic markers, mRNA gene expression analysis was performed on 
several key genes implicated in obesity regulated metabolic markers as 
previously discussed in the introduction chapter.  
5.4.4 Gene expression of metabolic markers 
Metabolic marker analysis showed a statistically significant up-regulation in 
leptin adipose tissue gene expression of fructose fed group compared to the 
control group (p<0.05). Figure 5.2.1 
 
Figure 36.2.1 - An up-regulation of leptin mRNA expression values of FR 
group (n=18) =  Females fed 10% fructose water during pregnancy compared 
to CNTL group (n=17) =  females fed water during pregnancy. Both groups 
were fed chow (ad libitum) from the onset of mating. Values are in mean ± 
SEM; statistical differences are donated by * =  p<0.05 (unpaired t-test). 
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FTO gene expression analysis showed the same significant trend where the 
fructose fed group showed a statistically significant up-regulation in 
comparison to the control group (p<0.05). Figure 5.2.2 
 
Figure 37.2.2 - An up-regulation of FTO mRNA expression values of FR group 
(n=18) =  Females fed 10% fructose water during pregnancy compared to 
CNTL group (n=17) =  females fed water during pregnancy. Both groups were 
fed chow (ad libitum) from the onset of mating. Values are in mean ± SEM; 
statistical differences are donated by * =  p<0.05 (unpaired t-test). 
 
  
196 
 
Adiponectin gene expression analysis showed the same significant trend where 
the fructose fed group showed a statistically significant up-regulation in 
comparison to the control group (p<0.05). Figure 5.2.3 
 
Figure 38.2.3 - An up-regulation of adiponectin mRNA expression values of 
CNTL group (n=17) =  females fed water during pregnancy compared to FR 
group (n=18) =  Females fed 10% fructose water during pregnancy. Both 
groups were fed chow (ad libitum) from the onset of mating. Values are in 
mean ± SEM; statistical differences are donated by * =  p<0.05 (unpaired t-
test). 
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5.4.5 The effect of fructose intake during pregnancy on expression of pro-
inflammatory markers 
To determine the adipose inflammatory genotype, mRNA gene expression 
analysis was performed on several key genes implicated in obesity regulated 
inflammatory markers as previously discussed in the introduction chapter. 
5.4.6 Gene expression of inflammatory markers 
Metabolic marker analysis showed a statistically significant up-regulation in 
NF-kB adipose tissue gene expression of fructose fed group compared to the 
control group (p<0.05). See Figure 5.2.4 
 
Figure 39.2.4 - An up-regulation of Nf-kB mRNA expression values of FR 
group (n=18) =  Females fed 10% fructose water during pregnancy compared 
to CNTL group (n=17) =  females fed water during pregnancy. Both groups 
were fed chow (ad libitum) from the onset of mating. Values are in mean ± 
SEM; statistical differences are donated by * =  p<0.05 (unpaired t-test). 
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IL-18 gene expression analysis showed the same significant trend where the 
fructose fed group showed a statistically significant up-regulation in 
comparison to the control group (p<0.05), please see figure 5.2.5 
 
Figure 40.2.5 - An up-regulation of IL-18 mRNA expression values of FR 
group (n=18) =  Females fed 10% fructose water during pregnancy compared 
to CNTL group (n=17) =  females fed water during pregnancy. Both groups 
were fed chow (ad libitum) from the onset of mating. Values are in mean ± 
SEM; statistical differences are donated by * =  p<0.05 (unpaired t-test). 
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No additional statistical differences were observed in gene expression of MCP-
1, IL-6 and GRP-78, see table 8 
Table 8: mRNA gene expression values of inflammatory and metabolic 
markers on FR group (fed 10% fructose water, n=18) compared to CNTL 
group (fed water, n=17,. Values are in mean ± SEM; NS = no significant 
difference between the groups (unpaired t-test).  
Group FR (n=18) CNTL (n=17) p value 
IL-6 3.5e-006 ±5.5e-007 2.3e-006 ± 3.4e-007 ns 
MCP-1 2.7e-007 ± 2.0e-007 9.9e-007 ± 3.0e-007 ns 
GRP-78 2.3e-006 ± 7.0e-007 4.4e-006 ± 1.0e-006 ns 
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5.4.7 Plasma triglyceride concentration  
Triglyceride concentrations measured over 4 time periods during pregnancy 
displayed significant differences. The results identified a significant increase 
(p<0.005) of plasma triglyceride concentrations in the fructose group 
compared to the control group on days 19 and 20, following an smaller 
significant increase at day 12 (p<0.05) Figure 5.2.6 
Figure 5.2.6 Triglyceride concentrations measured during pregnancy 
 
Figure 41.2.6 ± Representative of triglyceride concentrations measured during 
pregnancy for FR group (n=18) =  Females fed 10% fructose water during 
pregnancy compared to CNTL group (n=17) =  females fed water during 
pregnancy. Values are in mean ± SEM; statistical differences are donated by * 
=  p<0.05; *** = p<0.01(Two way ANOVA with repeated measures)  
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5.5 Discussion 
The main focus of our study was to investigate the effect of fructose intake 
during pregnancy and its effects on metabolite and inflammatory markers in 
the mother. Previous studies have consistently been able to show that fructose 
consumption in non-pregnant state results with increased fat mass and 
bodyweight changes along with an association to the development of metabolic 
syndrome. Our study was able to show that 10% fructose consumed during 
pregnancy produced a change in body composition with increased fat mass of 
the adipose depot (retroperitoneal) and significant changes in the mRNA 
expression of metabolic markers, inflammatory markers and triglyceride 
concentrations.  
However, overall bodyweight was not different through pregnancy between 
groups but an increase in adiposity with fructose consumption was observed 
despite no difference in total daily energy intake observed either. This increase 
in adiposity is confirmed with the increased retroperitoneal fat mass within the 
fructose group during pregnancy. Results show that food and water intake 
during gestation can be a possible mechanism behind the increased fat mass. 
The fructose fed rats show a 4 fold increase in water intake during gestation 
with their food intake being compensated with a 2 fold decrease compared to 
the control group. This decrease in food intake by the fructose group may be 
largely down to the sweet and addictive taste that fructose provides over plain 
water, due to the large consumption of fructose the rats regulate their energy 
intake with a decreased amount of food intake. Fructose is a sugar that 
bypasses the normal regulatory enzymatic processes that glucose undergoes, 
therefore allowing fructose to contribute directly to increasing amounts of 
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triglycerides observed through pregnancy. The increased plasma triglyceride 
concentrations are features that are associated with hypertriglyceridemia. 
Studies described in the introduction relating to high-fructose intake during 
pregnancy leading to maternal hypertriglyceridemia286,287 also correlate with 
triglyceride results shown here. However, our study was able to show 
hypertriglyceridemia during late gestation which was not present in previous 
fructose intake studies, displaying instead hypotriglyceridemia in late 
gestation287. An explanation for hypertriglyceridemia could be the increased 
fructose intake which leads to an activation of de novo lipogenesis by 
increasing the amount of lipids present in blood often referred to as 
dyslipidemia. My study was able to show that during pregnancy, a low intake 
of fructose was able to demonstrate elevated triglyceride concentrations, 
similar to those found in studies investigating high fructose intake251,254,255.  
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5.5.1 Homeorhesis 
During pregnancy the body switches from its normal control of metabolism, 
homeostasis, to homeorhesis367. This state allows for the body to accumulate 
weight gain or a long period of time without the normal response of metabolic 
stress. Homeorhesis is often referred to as ³FRRUdinated changes in metabolism 
RIERG\WLVVXHVQHFHVVDU\WRVXSSRUWDGRPLQDQWSK\VLRORJLFDOSURFHVV´WKHVH
processes include lactation, a period where the mother is in requirement for her 
multiple organs to send nutrients to the mammary gland for milk synthesis367 
368
.   
During pregnancy the homeorhesitic state allows for dramatic changes in 
metabolic and reproductive hormones such as leptin, estrogen, progesterone, 
cortisol, prolactin and placental lactogen369 370. These hormones play a vital 
role in simulating metabolic processes in the organs that regulate nutrient and 
energy supply to the fetus for development, furthermore these hormones also 
play a role in the initiation of lactation371 372.  
'XULQJ WKH RQVHW RI ODFWDWLRQ WKH IHPDOH¶V ERGy will co-ordinate various 
metabolic changes in multiple tissues via the endocrine system to allow for the 
increased requirement of nutritional intake whilst simultaneously balancing 
homeostasis in the animal373. These nutritional demands made during lactation 
are either supplemented through an increased dietary intake or drawn upon 
from stored nutrients in tissues374 375. During normal pregnancy there is an 
expected level of increased bodyweight weight with body composition 
therefore including an increase in body fat/adiposity376. With a supplemented 
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diet of fructose intake daily, this situation can lead to possible risk of obesity or 
excessive weight gain during pregnancy.  
5.5.2 Pregnancy and inflammation 
Various studies in experimental animals have been able to demonstrate 
inflammation induced by fructose intake280,281, in non-pregnant rodents.  As 
previously stated in the introduction chapter, studies have been able to show 
that expression of MCP-1 in a range of cell types can be induced through 
intake of fructose283,280. MCP-1 is seen as a key cytokine in the development of 
atherosclerosis and is involved in mediating an inflammatory response in 
symptoms related to metabolic syndrome. Studies investigating inflammatory 
markers in pregnancy have shown, MCP-1 was increased in pregnant women 
suffering from severe obesity377,378 and preeclampsia379.  
A suggested mechanism behind raised inflammatory markers such as MCP-1 
and IL-6 being stimulated during fructose intake can be accounted for through 
various factors such as the progression of dyslipidemia, insulin resistance, and 
excess uptake of fatty acids. The excess fat mass implicated from fructose 
intake causes an inhibitory effect by reducing adiponectin secretion in 
adipocytes and further increasing stimulation for the release of TNF-ĮDQG,/-
6, thereby removing any inhibitory controls138. These circumstances can 
possible lead to an elevated inflammatory response, specifically MCP-1, that 
as previously described, is known for stimulating and initiating the recruitment 
of other monocytes and macrophages to the stressed adipocytes285.  
However, in my study MCP-1 was not up-regulated in gene expression neither 
were other inflammatory cytokines such as IL-6 and GRP78. A recent study 
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investigating inflammatory marker MCP-1 in pregnancy exhibited a reduced 
concentration in pregnancy under normal conditions giving a possible 
explanation that the reduction of MCP-1 may be a possible pathway to inhibit 
the characteristics from insulin resistance and homeostatic inflammation380. 
Limited research in this field makes validation for this theory complicated as 
only one report to date has been able to explain a peripheral decrease in serum 
concentration of MCP-1 during pregnancy381.  The decrease in MCP-1 may be 
a possible adaptation known as homeorhesis which is described above, 
allowing a metabolic change in endocrine organs to prevent the activation of 
macrophages and monocytes in a pregnancy-induced insulin resistance. This, 
however, has only been represented in a study researching hypertensive rats, 
where the expression of MCP-1 was greatly increased in the kidney and 
decreased significantly soon after pregnancy, along with blood pressure382.  
My study did, however, reveal increased expression of NF-kB, IL-18, FTO and 
leptin in the fructose fed group along with a decreased expression of 
adiponectin in the control group. Studies in non-pregnant rats have showed that 
fructose feeding leads to increased expression of classical inflammatory 
pathways such as NF-kB383. NF-kB is a protein whose activity is constant 
because it induces the expression of various genes which protect the cells from 
conditions that could cause cell apoptosis384. Studies have shown that  during 
pregnancy NF-kB  activity is raised and is essential to multiple pro-labour 
pathways384. Therefore increased fat mass during pregnancy would lead to an 
inflammatory response from NF-kB ultimately leading to increased expression 
of genes that prevent cell apoptosis. Studies involving IL-18 during pregnancy 
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have also highlighted increased serum concentrations during all periods of 
pregnancy and further increased during labour385.  
Metabolic markers such as FTO and leptin showed that fructose intake during 
pregnancy lead to increased gene expression, both makers have been 
previously described as appetite regulators and FTO to be associated with body 
mass index and obesity. These markers show that not all pathways associated 
with the inflammation response are inhibited during pregnancy. Adiponectin 
expression levels decreasing during pregnancy do go to exhibit the effect of 
increased fat mass and circulating triglyceride concentrations on adipose tissue 
function, as the regular inhibitory pathway of TNF-ĮDQG,/-6 were not highly 
expressed in the fructose group138.  
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5.6 Conclusion 
My study showed that fructose intake during pregnancy can lead to increased 
significant fat mass along with increased expression of metabolic markers 
related to appetite and body mass index, as well decreasing the expression of 
adiponectin. As hypothesised early that inflammatory markers would be 
elevated in expression and an increase in fat mass would be observed, it is 
observed that only a small inflammatory response was negated from this study. 
The possible reason being a homeorhesis reaction during pregnancy allows the 
mother to increase in size and therefore stop the normal potentially detrimental 
inflammatory pathways being activated.  
A possible addition to the study to clarify the inflammatory response would be 
a third group that represented a non-pregnant fructose intake group; this would 
have been able to clarify fructose induced changes in comparison to pregnancy 
induced changes. A noteworthy explanation to the increased fat mass by 
fructose could be due to the increase in water content in tissue. As noted above 
in the results, fructose water intake was increased dramatically in FR groups. 
A limitation that can be observed in this study was the single adipose depot 
studied; a further study may include the epididymal depot. Other factors to take 
into account are most conclusions in this study are drawn upon from evidence 
solely based on gene expression. Further research is required on the extent this 
has on protein expression, only then can a clear range of possible pathways be 
explained. 
Whilst this study shows many inflammatory effects on the maternal adaptation 
of homeostasis during pregnancy along with a small inflammatory and 
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metabolic effect, it is crucial that more investigations are carried out to 
research into the possible harmful effects of low-fructose intake during 
pregnancy. As fructose intake increases in the western diet, it is vital to know 
the effects of this during pregnancy for the long term health of the mother.   
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Chapter 6 Ȃ Effect of long-term 
fructose consumption 
6.1 Introduction and aims 
The final study in my thesis is based on fructose feeding during pregnancy and 
its long term effects on the offspring. The previous study investigated in 
chapter 5 examined the effect of fructose feeding during pregnancy on the 
mothers only. We observed changes in triglyceride concentrations, 
inflammatory markers and metabolic markers as well as homeorhesis 
pregnancy. However the previous study had limitations on its scope with fetal 
and offspring development not being further examined. Therefore this study 
will look at the metabolic effect on the offspring that occurs from early to later 
life following fructose intake in pregnancy. It has been well known that 
nutritional manipulation during various periods of pregnancy in animal and 
human models have shown increased risk of adverse effects on the offspring in 
later adult life170. This study is the first to explore the effects of fructose 
feeding during pregnancy and its long term effects on the offspring.  
 
6.2 Hypothesis 
My hypothesis is that fructose intake during pregnancy will lead to an increase 
inflammatory responses during early postnatal growth along with increased fat 
mass in the fructose fed group compared to the control. This will be evident in 
both adipose tissue depots with increased triglyceride concentrations and 
insulin levels calumniating from fructose feeding in pregnancy.  
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6.3 Methods and materials 
A fully detailed description of all the methods used in this chapter can be 
found in Chapter 2. The experimental set-up and model used to describe and 
illustrate and the result in this chapter can be observed in Figure 6.1. All 
animal experimentations that were reported i.e. tissue weights, plasma 
measurements and animal dissections were performed and supervised by Dr. 
R.Bell and Abha Hoedl and myself. For any sample or analytical exceptions 
are described in the results section of the relevant chapter. All statistical tests 
conducted in this chapter are detailed in Chapter 2, normalization of the 
mRNA gene expression results were calculated against one reference gene 
(r18s) 
Figure 6.1 Long term fructose consumption study model  
 
Figure 42.1 - Rat Study: Effect of long term fructose consumption model. FR 
CHOW group were fed 10% fructose water during gestation and weaning 
while H20 CHOW group were fed water during gestation and weaning. 
Offspring for both groups FR CHOW (n=21) and H2O CHOW (n=24) fed only 
water and chow during post-natal period. 
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6.4 Results 
6.4.1 Long term body weight measurements and fat mass measure during 
fructose feeding in pregnancy in females 
There were no observational differences in birth weight between the groups 
however 3 month body weight displayed statistical difference in weight gain 
from birth (p value =0.0163) . Results presented no other significant change in 
relation to fat mass apart from a significant increase of reproductive fat at 3 
months in the fructose fed group (p value =  0.0036). See Table 9. 
Table 9: Measurements of body weight and adipose weight of the FR CHOW 
group (fed 10% fructose water, n=18) and H2O CHOW group (fed water, 
n=17) were taken during the study, values are in mean ± SEM; statistical 
differences are donated by * =  p<0.05 (unpaired t-test). 
Characteristic FR CHOW H2O CHOW 
Weaning Weight (g)  79.50 ± 3.2 (n=21) 75.30 ± 3.0 (n=24) 
3 Month Body Weight (g) 274.9 ± 6.3* (n=21) 251.9 ± 6.6 (n=24) 
6 Month Body Weight (g) 306.1 ± 9.2 (n=13) 304.7 ± 16.1 (n=15) 
9 Month Body Weight (g) 337.5 ± 23.6 (n=6) 327.0 ± 40.9 (n=7) 
 
  
3 Month Retroperitoneal Fat (g) 2.1 ± 0.2 (n=8) 2.5 ± 0.3 (n=9) 
6 Month Retroperitoneal Fat (g) 6.2 ± 0.5 (n=7) 5.5 ± 0.3 (n=8) 
9 Month Retroperitoneal Fat (g) 6.4 ± 1.0 (n=6) 3.8 ± 1.6 (n=7) 
   
3 Month Uterine Fat (g) 5.0 ± 0.4* (n=8) 3.3 ± 0.3 (n=9) 
6 Month Uterine Fat (g) 5.5 ± 0.1 (n=7) 6.0 ± 0.5 (n=8) 
9 Month Uterine Fat (g) 7.8 ± 0.3 (n=6) 4.1 ± 1.6 (n=7) 
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6.4.2 Long term body weight measurements and fat mass measure during 
fructose feeding in pregnancy in males 
There were no observational differences in birth weight between the groups 
with 3 and 6 month body weight (3 month body weight p value =  0.0174, 6 
month body weight p value =  0.0403) showing statistical difference in weight 
gain since birth. Results presented no other significant change in relation to fat 
mass apart from a significant increase of retroperitoneal fat at 3 and 6 months 
in the fructose fed group (3 month fat mass p value =  0.0174, 6 month fat mass 
p value = 0.0403). 
Table 10: Measurements of body weight and adipose weight of the FR CHOW 
group (fed 10% fructose water, n=18) and H2O CHOW group (fed water, 
n=17) were taken during the study in males, values are in mean ± SEM; 
statistical differences are donated by * =  p<0.05 (unpaired t-test). 
Characteristic FR CHOW H2O CHOW 
Weaning Weight (g) 87.88 ± 4.1 (n=9) 81.96 ± 3.0 (n=12) 
3 Month Body Weight (g) 506.7 ± 13.4* (n=9) 469.3 ± 7.4 (n=12) 
6 Month Body Weight (g) 687.6 ± 17.8* (n=5) 631.9 ± 15.3 (n=8) 
9 Month Body Weight (g) 752.5 ± 2.5 (n=2) 682.8 ± 26.0 (n=4) 
 
  
3 Month Retroperitoneal Fat (g) 10.9 ± 1.5* (n=4) 6.3 ± 0.7 (n=4) 
6 Month Retroperitoneal Fat (g) 15.1 ± 1.3* (n=3) 11.0 ± 0.9 (n=4) 
9 Month Retroperitoneal Fat (g) 25.2 ± 5.5 (n=2) 16.9 ± 2.3 (n=4) 
   
3 Month Epididymal Fat (g) 9.5 ± 1.9 (n=4) 6.9 ± 0.9 (n=4) 
6 Month Epididymal Fat (g) 12.9 ± 1.2 (n=3) 9.9 ± 0.2 (n=4) 
9 Month Epididymal Fat (g) 15.5 ± 1.9 (n=2) 12.4 ± 0.4 (n=4) 
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6.4.3 Measurement of food and water intake during pregnancy 
Overall, energy intake was not significantly greater in the FR group compared 
to the Control group on the 2 days measured but did not differ significantly 
over time within each diet group. 
Food and water intake during gestation for mothers 
Table 11: Measurements food and water intake along with body weight and 
total Kcal intake of the FR group (fed 10% fructose water, n=18) and CNTL 
group (fed water, n=17) in mothers during pregnancy, values are in mean ± 
SEM; statistical differences are donated by * =  p<0.05 (unpaired t-test). 
Characteristic FR CHOW (n=4) H2O CHOW (n=4) 
Total Food Intake (g) 
  
Premating Intake 11.73 ± 1.9* 21.63 ± 0.8 
7 Day Intake 12.17 ± 0.9* 24.33 ± 0.8 
14 Day Intake 18.35 ± 1.7* 27.17 ± 1.2 
 
  
Total 10% Fructose/Water Intake (ml) 
  
Premating Intake 118.8 ± 9.3* 37.50 ± 1.4 
Gestation Day 7 Intake 160.0 ± 23.0* 55.00 ± 2.8 
Gestation Day 14 Intake 141.7 ± 21.6* 55.00 ± 3.5 
 
  
Total Kcal Intake 
  
Premating Intake 86.2 ± 8.2 77.86 ± 2.8 
Gestation Day 7 Intake 102.0 ± 16.5 87.58 ± 2.8 
Gestation Day 14 Intake 112 ± 14.3 97.81 ± 4.3 
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6.4.4 The effect of fructose intake during pregnancy on expression of 
inflammatory markers on 3 month old offspring 
To determine the adipose metabolite genotype, mRNA gene expression 
analysis was performed on several key genes implicated in obesity regulated 
metabolic markers as previously discussed in the introduction chapter.  
6.4.5 Gene expression of inflammatory markers on reproductive adipose 
tissue 
No additional statistical differences were observed in gene expression of any 
inflammation markers in reproductive adipose tissue. Table 12. 
Table 12: mRNA gene expression values of inflammatory and metabolic 
markers on FR CHOW (fed 10% fructose water, n=7) compared to H2O 
CHOW group (fed water, n=9) in reproductive adipose tissue at 3 months of 
age, Values are in mean ± SEM; NS = no significant difference.  
Group FR CHOW (n=7) H2O CHOW (n=9) 
p value 
Adiponectin 0.02 ± 0.01 0.03 ± 0.01 ns 
Chop 1.2e-006 ± 3.7e-007 1.0e-006 ± 2.3e-007 ns 
FTO 8.3e-006 ± 2.9e-006 8.3e-006 ± 2.8e-006 ns 
GRP78 0.02 ± 0.01 0.03 ± 0.01 ns 
IL-6 3.1e-008 ± 1.4e-008 2.4e-008 ± 1.3e-008 ns 
IL-18 2.9e-006 ± 1.5e-006 1.6e-006 ± 7.2e-007 ns 
Leptin 1.7e-004 ± 5.8e-005 1.9e-004 ± 9.0e-005 ns 
MCP-1 1.1e-006 ± 4.1e-007 1.5e-006 ± 8.8e-007 ns 
TNF-Į 0.0002325 ± 6.5e-005 0.0001909 ± 2.9e-005 ns 
NF-kB 9.5e-006 ± 3.1e-006 1.0e-005 ± 3.8e-006 ns 
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6.4.6 Gene expression of inflammatory markers on retroperitoneal 
adipose tissue 
No additional statistical differences were observed in gene expression of 
adiponectin; chop, GRP78, IL-6, IL-18, TNF-Į 
Table 13: mRNA gene expression values of inflammatory and metabolic 
markers on FR CHOW (fed 10% fructose water, n=7) compared to H2O 
CHOW group (fed water, n=9) in retroperitoneal adipose tissue at 3 months of 
age, Values are in mean ± SEM; NS = no significant difference. S 
=significance (p=<0.05, unpaired t-test) 
Group FR CHOW (n=7) H2O CHOW (n=9) 
p value 
Adiponectin 0.01664 ± 0.002 0.01026 ± 0.001 ns 
Chop 4.3e-007 ± 8.1e-008 8.5e-007 ± 1.9e-007 ns 
FTO 1.3e-004 ± 1.5e-005 8.2e-005 ± 9.2e-006 S 
GRP78 0.0023 ± 0.0004394 0.0013 ± 0.0002975 ns 
IL-6 1.4e-007 ± 1.3e-008 1.5e-007 ± 4.4e-008 ns 
IL-18 8.4e-005 ± 1.3e-005 7.0e-005 ± 2.6e-005 ns 
Leptin 0.0004 ± 5.2e-005 0.0002 ± 2.7e-005 S 
MCP-1 1.2e-005 ± 1.1e-006 6.2e-006 ± 1.1e-006 S 
TNF-Į 1.5e-006 ± 2.7e-007 9.8e-007 ± 1.4e-007 ns 
NF-kB 2.6e-005 ± 3.8e-006 1.4e-005 ± 8.3e-007 S 
 
  
216 
 
6.4.7 Gene expression of inflammatory markers on retroperitoneal 
adipose tissue 
Metabolic and inflammatory marker analysis showed a statistically significant 
up-regulation in leptin, MCP-1, FTO, NF-Kb gene expression of fructose fed 
group compared to the control group (p<0.05) at 3 months of age.  
Figure 6.2 Up-regulation of Leptin, MCP-1, FTO, NF-Kb gene expression 
 
Figure 43.2 - An up-regulation of Leptin, MCP-1, FTO, and NF-kB mRNA 
expression values of FR group offspring (n=8) compared to H2O group 
offspring (n=9) in retroperitoneal adipose tissue at 3 months of age. Values 
are in mean ± SEM; statistical differences are donated by * =  p<0.05 
(unpaired t-test).  
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6.4.8 The effect of fructose intake during pregnancy on expression of 
inflammatory markers on 6 month old offspring 
To determine the adipose metabolite genotype, mRNA gene expression 
analysis was performed on several key genes implicated in obesity regulated 
metabolic markers as previously discussed. 
Gene expression of inflammatory markers on reproductive adipose tissue 
No additional statistical differences were observed in gene expression of 
adiponectin, chop, FTO, GRP78, IL-1B, IL-18, leptin, MCP-1, TNF-Į1)-kB 
and TLR-4. Table 6.6 
Table 14: mRNA gene expression values of inflammatory and metabolic 
markers on FR CHOW (fed 10% fructose water, n=7) compared to H2O 
CHOW group (fed water, n=9) in reproductive adipose tissue at 6 months of 
age, Values are in mean ± SEM; NS = no significant difference. S 
=significance (p=<0.05, unpaired t-test) 
Group FR CHOW (n=7) H2O CHOW (n=8) p value 
Adiponectin 1.9e-006 ± 5.2e-007 1.6e-006 ± 3.1e-007 ns 
Chop 1.4e-007 ± 4.9e-008 1.4e-007 ± 4.3e-008 ns 
FTO 0.00014 ± 3.3e-005 0.00024 ± 7.3e-005 ns 
GRP78 0.00026 ± 8.7e-005 0.00022 ± 8.8e-005 ns 
IL-1B 4.8e-007 ± 1.7e-007 5.1e-007 ± 7.9e-008 ns 
IL-6 6.5e-007 ± 1.1e-007 1.9e-007 ± 7.3e-008 S 
IL-18 1.9e-006 ± 9.3e-007 3.7e-006 ± 1.2e-006 ns 
Leptin 0.00021 ± 0.0001 0.00024 ± 6.8e-005 ns 
MCP-1 4.2e-006 ± 1.7e-006 2.8e-006 ± 9.9e-007 ns 
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TNF-Į 1.8e-006 ± 5.9e-007 4.5e-007 ± 1.4e-007 ns 
NF-Kb 5.9e-006 ± 1.5e-006 7.6e-006 ± 2.5e-006 ns 
TLR4 9.2e-006 ± 2.8e-006 1.9e-005 ± 5.9e-006 ns 
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6.4.9 Gene expression of inflammatory markers on retroperitoneal 
adipose tissue 
No additional statistical differences were observed in gene expression of FTO, 
GRP78, TNF-ĮDQGOHSWLQ7DEOH 
Table 15: mRNA gene expression values of inflammatory and metabolic 
markers on FR CHOW (fed 10% fructose water, n=7) compared to H2O 
CHOW group (fed water, n=9) in retroperitoneal adipose tissue at 6 months of 
age, Values are in mean ± SEM; NS = no significant difference. S 
=significance (p=<0.05, unpaired t-test) 
Group FR CHOW (n=7) H2O CHOW (n=8) 
p value 
Adiponectin 0.0074 ± 0.002 0.019 ± 0.004 S 
Chop 3.3e-005 ± 7.4e-006 8.6e-006 ± 3.9e-006 S 
FTO 8.5e-005 ± 1.5e-005 9.4e-005 ± 2.8e-005 ns 
GRP78 8.5e-006 ± 3.0e-006 1.9e-006 ± 6.4e-007 ns 
IL-1B 0.0028 ± 0.00083 0.00083 ± 0.00028 S 
IL-6 8.5e-006 ± 1.3e-006 3.6e-006 ± 8.1e-007 S 
IL-18 5.2e-005 ± 1.2e-005 1.9e-005 ± 5.5e-006 S 
Leptin 0.00087 ± 0.00021 0.00047 ± 0.00016 ns 
MCP-1 5.2e-005 ± 1.3e-005 1.6e-005 ± 6.2e-006 S 
TNF-Į 1.7e-005 ± 4.0e-006 9.5e-006 ± 3.3e-006 ns 
NF-Kb 8.0e-005 ± 1.9e-005 2.8e-005 ± 5.7e-006 S 
TLR4 0.00065 ± 0.00013 0.00023 ± 8.3e-005 S 
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6.4.10 Gene expression of inflammatory markers on retroperitoneal 
adipose tissue 
Metabolic marker analysis showed a statistically significant up-regulation in 
adiponectin, CHOP, IL-1B, IL-18, IL-6, MCP-1, NF-kB and TLR4 gene 
expression of fructose fed group compared to the control group (p<0.05). See 
Figure 6.2. 
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Figure 44.2 - An up-regulation of CHOP, IL-1B, IL-18, IL-6, MCP-1, NF-kB 
and TLR4 mRNA expression values of FR group offspring (n=8) compared to 
H2O group offspring (n=9) in retroperitoneal adipose tissue at 6 months of 
age. Values are in mean ± SEM; statistical differences are donated by * =  
p<0.05 (unpaired t-test). 
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6.4.11 The effect of fructose intake during pregnancy on expression of 
inflammatory markers on 9 month old offspring 
To determine the adipose metabolite genotype, mRNA gene expression 
analysis was performed on several key genes implicated in obesity regulated 
metabolic markers as previously discussed. 
Gene expression of inflammatory markers on reproductive adipose tissue 
No additional statistical differences were observed in gene expression of any 
inflammation markers in reproductive adipose tissue. Table 16. 
Table 16: mRNA gene expression values of inflammatory and metabolic 
markers on FR CHOW (fed 10% fructose water, n=7) compared to H2O 
CHOW group (fed water, n=9) in reproductive adipose tissue at 9 months of 
age, Values are in mean ± SEM; NS = no significant difference. S 
=significance (p=<0.05, unpaired t-test) 
Group FR CHOW (n=6) H2O CHOW (n=7) 
p value 
Adiponectin 0.001 ± 0.0002 0.002 ± 0.0003 ns 
Chop 2.4e-008 ± 3.7e-009 3.4e-008 ± 6.9e-009 ns 
FTO 2.1e-006 ± 3.7e-007 2.8e-006 ± 4.9e-007  ns 
GRP78 3.4e-008 ± 2.5e-008 2.3e-008 ± 4.9e-009 ns 
IL-1B 6.3e-005 ± 1.0e-005 5.7e-005 ± 1.6e-005 ns 
IL-6 9.9e-008 ± 2.3e-008 1.4e-007 ± 4.7e-008 ns 
IL-18 3.8e-006 ± 7.2e-007 3.4e-006 ± 6.8e-007 ns 
Leptin 8.8e-006 ± 2.0e-006 1.5e-005 ± 3.7e-006 ns 
MCP-1 3.7e-007 ± 1.0e-007 2.2e-007 ± 6.7e-008 ns 
TNF-Į 7.9e-008 ± 1.1e-008 9.7e-008 ± 2.1e-008 ns 
223 
 
NF-Kb 1.2e-006 ± 2.1e-007 1.9e-006 ± 2.8e-007 ns 
TLR4 1.0e-007 ± 1.4e-008 1.6e-007 ± 2.8e-008 ns 
 
6.4.12 Gene expression of inflammatory markers on retroperitoneal 
adipose tissue 
No additional statistical differences were observed in gene expression of 
adiponectin, CHOP, FTO, GRP78, IL-1B, IL-6, IL-18, leptin, MCP-1, TNF-Į
NF-kB, TLR4.  
Table 17: mRNA gene expression values of inflammatory and metabolic 
markers on FR CHOW (fed 10% fructose water, n=7) compared to H2O 
CHOW group (fed water, n=9) in retroperitoneal adipose tissue at 9 months of 
age, Values are in mean ± SEM; NS = no significant difference. S 
=significance (p=<0.05, unpaired t-test) 
Group FR CHOW (n=6) H2O CHOW (n=7) 
p value 
Adiponectin 0.00089 ± 0.0001 0.00073 ± 0.0001 ns 
Chop 1.0e-005 ± 2.4e-006 4.0e-006 ± 2.4e-006 ns 
FTO 9.9e-006 ± 2.0e-006 7.1e-006 ± 1.1e-006 ns 
GRP78 6.4e-006 ± 1.9e-006 6.5e-006 ± 5.5e-007 ns 
IL-1B 0.00029 ± 9.6e-005 4.9e-005 ± 1.2e-005 ns 
IL-6 3.3e-006 ± 1.0e-006 1.2e-006 ± 3.9e-007  ns 
IL-18 1.8e-006 ± 7.0e-007 1.1e-006 ± 7.3e-007 ns 
Leptin 2.3e-005 ± 5.7e-006 1.2e-005 ± 2.2e-006 ns 
MCP-1 1.4e-005 ± 3.4e-006 2.7e-006 ± 4.2e-007 S 
TNF-Į 5.1e-006 ± 7.5e-007 1.1e-006 ± 2.3e-007 S 
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NF-Kb 2.0e-005 ± 4.1e-006 1.5e-005 ± 2.3e-006 ns 
TLR4 1.5e-006 ± 3.8e-007 1.1e-006 ± 2.6e-007 ns 
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6.5 Electrochemiluminescence protein results on 3 months and 9 months 
offspring of gestational fructose feeding on retroperitoneal adipose tissue 
MSD multiplex array plates were processed for the detection and 
quantification of cytokine concentration present in retroperitoneal adipose 
tissue. Plates were run for 3 months and 9 months, results for 6 months were 
omitted as due a technical error with the SECTOR instrument at the point of 
analysis.  
6.5.1 3 Month Retroperitoneal MSD multiplex arrays 
Inflammatory marker analysis showed a statistically significant up-regulation 
in IL-1B, protein expression of fructose fed group compared to the control 
group (p<0.05), see Figure 6.3. 
 
 
 
 
 
 
 
 
Figure 45.3 - An up-regulation of IL-1B protein expression values of FR group 
offspring (n=8) compared to H2O group offspring (n=9) in retroperitoneal 
adipose tissue at 3 months of age. Values are in mean ± SEM; statistical 
differences are donated by * =  p<0.05 (unpaired t-test). 
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Inflammatory marker analysis showed no statistically significant up-regulation 
in IL-6, protein expression of fructose fed group compared to the control 
group.  
 
Figure 46.4 - IL-6 protein expression values of FR group offspring (n=8) 
compared to H2O group offspring (n=9) in retroperitoneal adipose tissue at 3 
months of age. Values are in mean ± SEM; no statistical differences were 
observed (unpaired t-test). 
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Inflammatory marker analysis showed no statistically significant up-regulation 
in MCP-1, protein expression of fructose fed group compared to the control 
group.  
 
 
Figure 47.5 ± MCP-1 protein expression values of FR group offspring (n=8) 
compared to H2O group offspring (n=9) in retroperitoneal adipose tissue at 3 
months of age. Values are in mean ± SEM; no statistical differences were 
observed (unpaired t-test). 
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Inflammatory marker analysis showed no statistically significant up-regulation 
in TNF-Į SURWHLQ expression of fructose fed group compared to the control 
group.  
 
Figure 48.6 ± TNF-Į protein expression values of FR group offspring (n=8) 
compared to H2O group offspring (n=9) in retroperitoneal adipose tissue at 3 
months of age. Values are in mean ± SEM; no statistical differences were 
observed (unpaired t-test). 
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6.5.2 9 Month Retroperitoneal MSD multiplex arrays 
Inflammatory marker analysis showed a statistically significant up-regulation 
in IL-1B, protein expression of fructose fed group compared to the control 
group (p<0.05).  
 
Figure 49.7 ± An up-regulation of IL-1B protein expression values of FR 
group offspring (n=6) compared to H2O group offspring (n=7) in 
retroperitoneal adipose tissue at 3 months of age. Values are in mean ± SEM; 
statistical differences are donated by * =  p<0.05 (unpaired t-test). 
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Inflammatory marker analysis showed a statistically significant up-regulation 
in IL-6, protein expression of fructose fed group compared to the control group 
(p<0.05).  
 
Figure 50.8 ± An up-regulation of IL-6 protein expression values of FR group 
offspring (n=6) compared to H2O group offspring (n=7) in retroperitoneal 
adipose tissue at 3 months of age. Values are in mean ± SEM; statistical 
differences are donated by * =  p<0.05 (unpaired t-test). 
 
 
 
 
 
 
231 
 
Inflammatory marker analysis showed a statistically significant up-regulation 
in MCP-1, protein expression of fructose fed group compared to the control 
group (p<0.05).  
 
Figure 51.9 ± An up-regulation of MCP-1 protein expression values of FR 
group offspring (n=6) compared to H2O group offspring (n=7) in 
retroperitoneal adipose tissue at 3 months of age. Values are in mean ± SEM; 
statistical differences are donated by * =  p<0.05 (unpaired t-test). 
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Inflammatory marker analysis showed a statistically significant up-regulation 
in TNF-Į SURWHLQ expression of fructose fed group compared to the control 
group (p<0.05).  
 
Figure 52.10 ± An up-regulation of TNF-Į protein expression values of FR 
group offspring (n=6) compared to H2O group offspring (n=7) in 
retroperitoneal adipose tissue at 3 months of age. Values are in mean ± SEM; 
statistical differences are donated by * =  p<0.05 (unpaired t-test). 
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6.6 Triglyceride concentration, insulin plasma and glucose levels 
measured in gestational fructose fed offspring compared to the control 
group 
We observed no statistical differences in the triglyceride, insulin or glucose 
levels of either group during the 9 months of this study.  
Table 18: Measurements of triglyceride concentrations, insulin plasma, and 
glucose levels for the FR CHOW group (fed 10% fructose water) and H2O 
CHOW group (fed water) were taken during the study, values are in mean ± 
SEM; NS = no significant difference. S =significance (p=<0.05, unpaired t-
test). 
Group FR CHOW H2O CHOW  p value 
3 month insulin 0.56 ± 0.07 (n=21) 0.73 ± 0.08 (n=24) ns 
6 month insulin 0.66 ± 0.12 (n=13) 0.97 ± 0.25 (n=15) ns 
9 month insulin 2.0 ± 0.38 (n=6) 1.6 ± 0.21 (n=7) ns 
3 month glucose 167.9 ± 13.74 (n=21) 182.7 ± 12.56 (n=24) ns 
6 month glucose 155.8 ± 15.81 (n=13) 133.6 ± 10.99 (n=15) ns 
9 month glucose 191.9 ± 26.58 (n=6) 149.7 ± 13.02 (n=7) ns 
3 month triglycerides 106.1 ± 12.58 (n=21) 119.0 ± 13.16 (n=24) ns 
6 month triglycerides 91.97 ± 12.73 (n=13) 76.34 ± 10.16 (n=15) ns 
9 month triglycerides 102.4 ± 8.50 (n=6) 134.2 ± 13.31 (n=7) ns 
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6.7 Discussion 
The main focus of my study was to investigate the effect of fructose intake 
during pregnancy and its effects on the long term health of the offspring 
exposed to this nutrient manipulation during pregnancy.  
From my previous chapter it was evident that raiesed fructose intake (10%) 
during pregnancy was able to show a change in body composition with 
increased fat mass of the adipose depot and significant changes in the mRNA 
expression of metabolic markers, inflammatory markers and triglyceride 
concentrations. Therefore it was crucial to investigate the longer term effects  
on the offspring and the metabolic adaptations they might occur later in life. 
Studies involving nutrient manipulation during pregnancy affecting the 
offspring in later life have already been conducted in humans and 
animals181,157.  However there has not been a study involving fructose feeding 
and its impact on offspring over a long period.  
My study design was based on the set up as in chapter 5 but in this instance the 
offspring were allowed to be born and kept for periods of 3, 6 and 9 months. 
Rats reach puberty at 6 weeks of ages, at 6 months they have reached social 
maturity. equivaleny to ~18 years of age in human years and at 9 months they 
are close to reaching 25 years in human terms386. This long term process 
DOORZHG WKHVWXG\ WR LQYHVWLJDWH WKHRIIVSULQJ¶V IXOOGHYHORSPHQW IURP\RXQJ
infancy to full grown maturity386.  
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6.7.1 Body weight and fat mass measurements 
Body weight measurements recorded throughout the experiment were analysed 
separately as the huge weight differences became apparent once the rat 
offspring reached puberty, females grew to approximately maximum weight of 
~300 grams with males reaching ~750 grams. My study showed that weaning 
weights were not statistically different between groups  in both males and 
females. Body weights at 3 months showed a significant increase in the 
fructose fed group for both male and females. This pattern did not carry on for 
the females at 6 months, whereas the males still showed signs of increased 
body weight. Both groups showed no statistically difference at 9 months 
between fructose fed and control groups. This change in body weight could be 
a possible plateau reached in maximum growth for each gender. Females 
reached a plateau at around 300 grams which is first seen at 3 months in the 
fructose fed group, the control group reaches that threshold at 6 months, much 
later than the fructose fed group. The same was seen for males at 9 months. A 
possible explanation could be fructose feeding during pregnancy allows leads 
to increased weight gain during the postnatal growth period. This has 
previously been described in chapter 5 and documents a Swedish cohort study 
investigating the long effects of weight gain during both early infancy and 
early childhood on fat mass at adolescent359. The study concluded that rapid 
weight gain during infancy was solely responsible for an increase in metabolic 
risk at 17 years of age. The study was able to show that this change was 
independent from a number of factors such gestational age, current height, 
rapid weight gain in childhood, birth weight and maternal fat mass along with 
socioeconomic status197. These findings are also in unison with studies in 
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murine studies360 and infants born preterm361,362,362 all concluding that rapid 
weight gain during early postnatal life could lead to increased risk in long term 
metabolic health outcomes363.  
When observing the weight measurements of adipose tissue depots in males, 
we can see a significant increase of retroperitoneal adipose tissue weight in the 
fructose fed group for 3 and 6 months age, once again coinciding with the 
same pattern of increase in body weight. No measureable difference was seen 
in epididymal adipose tissue. Females, however, only demonstrate an increase 
in uterine adipose tissue weight at 3 months in the fructose fed group. This also 
coincides with body weight increase, however no significant increase was 
observed with any retroperitoneal adipose tissue weight. A possible 
explanation for uterine fat increase could be the linked to the reproductive 
status of the female, as they fully developed and attained sexual maturity.  
During measurements of food and fructose/water intake the study shows that 
pregnancy leads to increased quantities of fructose intake compared to water in 
correlation with decreased chow intake in the fructose group. However, overall 
energy intake was not statistically greater in the fructose fed group compared 
to controls, a similar result to that presented in chapter 5. The increased 
fructose intake could be a possible explanation to increased adiposity in 3 and 
6 months of males and 3 months in females. Studies have shown that ad 
libitum consumption of fructose sweetened beverages was significantly 
increased in comparison to water and also affect food intake during this period 
for the control group387. However this increased consumption of fructose did 
not affect the body weight gain of rats, this was further supported by other 
studies reporting the same effect388.  
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It has been well established that children from mothers who are overweight, 
obese or have gestational diabetes mellitus have a higher chance of developing 
childhood metabolic syndrome features such as hypertension, glucose 
intolerance, insulin resistance and uncharacteristic lipid profiles389. As 
previously described, excess or high fructose diets have been associated with 
obesity and increased weight gain and with studies linking maternal obesity to 
the development of metabolic disease in offspring. It is therefore clinically 
significant to examine the effects of a high fructose-based diet during different 
gestational periods to investigate any changes in maternal and offspring 
metabolic phenotype.  
An important finding from the study was the non-significant increase of 
triglyceride, insulin or glucose levels in the offspring from fructose fed 
mothers. Our previous study was able to show signs of hypertriglyceridemia in 
mothers, but none of these metabolic alterations have seemed to be present in 
the offspring of this study. However, there are only a limited number of studies 
in the current scientific domain that relate to maternal fructose intake. Studies 
using fructose solid diets of 78% and 50% during certain periods of pregnancy 
have demonstrated changes in offspring metabolism and also altered maternal 
hypertriglyceridemia286,287.  
The studies listed above used fructose solid diets of high concentrations; this is 
very unlikely to be seen even in a western diet, a more common strategy is 
using low fructose concentrations288. Our study as described in chapter 5 was 
able to show hypertriglyceridemia during the late gestation which was not 
present in previous fructose intake studies, displaying instead 
hypotriglyceridemia in late gestation287. Mainly studies involving fructose 
238 
 
intake combined with a high fat diet, which eliminates the contribution of 
fructose during this approach to the metabolic phenotype. Therefore fructose 
intake studies investigating long terms in offspring are not well known289. A 
possible explanation for the non-significant increase of triglyceride, insulin or 
glucose levels in the offspring could be due to the low fructose levels used 
(10% fructose used in study), studies using elevated levels of fructose as 
described above have shown significant changes.   
  
239 
 
6.7.2 Gene expression of inflammatory markers at 3, 6 and 9 months 
My study was able to demonstrate that reproductive adipose tissue was not 
different in any of the inflammatory markers that were tested between groups. 
However this is completely the opposite effect seen in retroperitoneal adipose 
tissue, metabolic and inflammatory marker analysis showed a statistically 
significant up-regulation in leptin, MCP-1, FTO, NF-Kb gene expression of 
fructose fed group compared to controls.  
Furthermore at 6 month of age, metabolic and inflammatory marker analysis 
showed a statistically significant up-regulation in CHOP, IL-1B, IL-18, IL-6, 
MCP-1, NF-kB, TLR4 and decrease in adiponectin gene expression of fructose 
fed group in retroperitoneal adipose tissue. Only IL-6 was up-regulated in the 
reproductive adipose tissue, no other inflammatory or metabolic marker 
showed a significant increase.  
A possible explanation for this increase in inflammatory response from the 
retroperitoneal adipose tissue and muted response from the reproductive fat is 
that retroperitoneal adipose tissue is a more metabolically active endocrine 
tissue. As previously described in chapter 4, subcutaneous adipose tissue is 
often seen as energy sink and when it undergoes metabolic dysregulation, it 
leads to increased cytokine production and greater  fat mass accumulation in 
undesired locations. This could possibly be the case of retroperitoneal adipose 
tissue as its high specificity for raised expression of so many inflammatory 
genes could be a signal of dysregulation.   
The cascade of inflammatory markers showing an increase in gene expression 
during 3 and 6 months could be a possible correlation to the increase in weight 
240 
 
gain seen male and females during that time period. As gene expression at 9 
months in retroperitoneal adipose tissue is only raised for MCP-1 and TNF-Į
and reproductive adipose tissue is not significant in any inflammatory markers. 
Studies have shown that the expression of MCP-1 in various cell types is also 
induced through fructose intake283,280.  
This weight gain seen at 3 and 6 months from the fructose fed groups would go 
to demonstrate that not only does fructose cause long term health implications 
such as weight gain during early post natal growth but also elicit and 
underlying chronic inflammatory response in offspring of fructose fed mothers 
during pregnancy.  
One highlighted cytokine was MCP-1 which was statistically significant in all 
three time periods of the study. Due to the weight gain over a long period, 
MCP-1 is activated to recruit more macrophages to infiltrate cells of stress and 
increases the chances of metabolic characteristics such as insulin resistance 
and metabolic syndrome. The increased fat mass from fructose intake leads to 
reduced adiponectin secretion in adipocytes and further stimulates the release 
of TNF-Į DQG ,/-6, due to the removal of any inhibitory controls138. These 
conditions lead to a possible elevated inflammatory response, in particular 
MCP-1 that as previously described, stimulates the recruitment of other 
monocytes and macrophages to the adipocyte of target285.  
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6.8 Protein expression of inflammatory markers at 3, and 9 months  
In addition to gene expression, I also conducted protein expression through the 
ECL method. I observed an increase in protein expression from the fructose 
fed group in 3 months and 9 months for proteins such as IL-1B at 3 months 
and IL-1B, MCP-1, TNF- ĮDQG,/-6 protein expression at 9 months from the 
retroperitoneal adipose tissue. The raised abundance o of these proteins 
expressed from the fructose fed group at 9 months was accompanied  with 
enhanced MCP-1 and TNF-Į JHQH H[SUHVVLRQ 7KLV JHQH-protein interaction 
gives more evidence to the theory that offspring from fructose fed mothers 
undergo chronic inflammation during early and later stages of life.  
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6.9 Conclusion 
My study was able to show that individuals whose mothers underwent fructose 
feeding during pregnancy are more than likely to develop chronic 
inflammation in retroperitoneal adipose tissue from early infancy to later adult 
life. The possible mechanisms for this process are still unknown and will 
require further investigative research.  
As hypothesised earlier in the chapter, fructose intake during pregnancy will 
lead to an increase inflammatory response during early postnatal growth along 
with increased fat mass in the fructose fed group compared to the control. This 
will be evident in both adipose tissue depots with increased triglyceride 
concentrations and insulin levels calumniating from fructose feeding in 
pregnancy. However, this was not evident from all the findings and I 
concluded that only retroperitoneal adipose tissue was affected sufficiently to 
produce an inflammatory response to the fructose intake during pregnancy. 
Also triglyceride, insulin or glucose levels were not elevated in the fructose fed 
group. A possible explanation for this occurrence is that there was no 
activation of de novo lipogenesis pathway to inhibit triglyceride clearance.  
  
243 
 
Chapter 7 Ȃ Conclusions 
 
7.1 Conclusion 
7.1.1 General aims 
My study was structured to investigate the effects of maternal nutrient 
manipulation on adipose tissue induced inflammation and its contribution 
towards metabolic disease in later adult life. I achieved this by analysing and 
reviewing the metabolic homeostasis of male and female sheep exposed to 
nutrient restricted environment and varying postnatal conditions. I also studied 
the rat model and analysed and reviewed the effect of nutritional uptake during 
pregnancy and the possible implications on inflammatory processes on the 
adipose tissue. This chapter summary shows the key findings determined 
throughout the thesis.  
7.1.2 Impact of gestational nutrient restriction on the sheep model 
From reviewing the literature it was suggested that for the development and 
growth of the offspring, the intrauterine environment plays a critical role. The 
frequency of adult disease increases in infants who have a suboptimal growth 
in utero181,182.  When looking at the effects of early life nutrition on growth 
DQGGHYHORSPHQW³SURJUDPPLQJ´ZDVGHILQHGDVWKHODVWLQJFRQVHTXHQFHVRID
stimulus or insult during a sensitive period in early life183. It is now well 
recognised that either throughout or at specific stages of pregnancy, changes in 
the macronutrient or micronutrient composition of the maternal diet can have 
significant effects on the fetus171. My study highlights distinct nutritional 
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scenarios in young adult offspring, a 40% reduction in maternal nutrition 
uptake during late gestation (110 days to term), proceeded by environments 
that challenge their potential for post-natal growth. These changes are 
predicted to be damaging and increasing the risk for detrimental metabolic 
results at the time of birth and throughout adult life, concluding in a 
predisposition for the onset of metabolic diseases. In conclusion, my study was 
able to demonstrate that subcutaneous adipose tissue gene expression after 
nutritional manipulation during late gestation suffers limited alterations. In 
contrast exposure to maternal nutrient restriction at the time of organogenesis 
resulted in raised markers of inflammation within pericardial adipose tissue 
despite a reduction in total fat mass. 
 
7.1.3 Impact of gestational nutrient manipulation on the rat model 
The focus of first study was to investigate the effect of raised fructose 
consumption during pregnancy and its effect on fat mass and inflammatory 
markers. Despite the large amounts of evidence of increased fructose 
consumption, there have not been enough studies extensively looking into 
fructose consumption during pregnancy and its potential role with 
inflammatory markers. The second study was designed to examine the 
metabolic effects on the offspring that occurs from early to later life following 
fructose intake in pregnancy. It has been well known that nutritional 
manipulation during various periods of pregnancy in animal and human 
models have shown increased risk of adverse effects on the offspring in later 
adult life170. My study was able to show that individuals whose mothers 
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underwent fructose feeding during pregnancy are more than likely to develop 
chronic inflammation in retroperitoneal adipose tissue from early infancy to 
later adult life.  
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7.2 Study limitations 
7.2.1 Sheep model 
Using the sheep as a model for the nutrient restriction during pregnancy for 
translation research to humans does have some limitations. The sheep genome 
is still not fully encoded. This has a huge impact on the limitation of genes 
available and published for the analysis of mRNA expression in my study. An 
example at the time of the study was adiponectin receptor, a key receptor in the 
translation of adiponectin activity during weight gain/loss and inflammatory 
processes, yet many attempts to design primers based on limited genome code 
meant analysis was completed. The same limitations apply to NF-kB that is a 
key regulator of inflammatory pathways and transcribing their genes390.  
 
 
7.2.2 Rat model 
The rat model has been widely used for experiments in a range of fields. 
Limitations for this model also rise in the form of short gestational period that  
LV RQO\  ZHHNV FRPSDUHG WR WKH VKHHS¶V  ZHHNV FORVHU WR KXPDQV
therefore selected periods of gestation are not readily available in the rat. Pups 
are born in large litters that can play a major role in lactation as there is more 
competition for milk and growth. Rat models are also distinctly different in 
maturity compared to sheep; they are fully sexually mature at 6 weeks. Tissue 
size is incredibly small compared to sheep, requiring no margin for error or 
even repeated experiments with the same tissue to verify results. Advantages 
such as handling size and cost efficiency per rat compared to sheep is 
affordable along full genome encoding allows for correct primer design. 
247 
 
7.3 Future work and perspectives 
In order to validate the findings of the studies conducted, it would be essential 
to complete further investigations into the rat model for a clearer understanding 
into fructose and inflammation during pregnancy. Suggestions are discussed 
below. 
 
7.3.1 Non-pregnant group 
During the study in chapter 5 and 6, it would have been useful to have a non-
pregnant group undergoing fructose intake for the same length of time. This 
could provide a clearer picture to the effects of fructose feeding during 
pregnancy. It would determine if the inflammatory response seen in chapter 5 
is really down to fructose or homeorhesis in pregnancy.  
 
7.3.2 Other adipose depots 
A possible analysis of other fat depots if possible might help explain the reason 
why reproductive fat was inhibited in response to increased weight gain and 
subsequent inflammatory response in chapter 6.  
 
7.3.3 Further protein work 
The cost of MSD protein plates did restrict the amount of protein work I could 
carry out in the limited time I had in Canada. A full range of metabolic and 
protein array multiplex plates would help further understand the inflammatory 
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process caused by fructose intake in pregnancy.  Other methods for protein 
expression such as western blotting in addition to MSD protein plates could 
have been a beneficial advantage to this experiment and added more weight to 
the evidence provided.  
 
7.3.4 Final Remarks 
Final Remarks 
This study highlighted that nutrient manipulation during different stages of 
gestation followed by obesity or postnatal activity contributes to the alterations 
of adipose tissue function and physiology in relation to inflammatory gene and 
protein responses. The research conducted in this study could play a role in 
help understanding the mechanisms and pathways that are involved in the 
inflammatory response during such situations.   
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